Cohort 2 (colorectal cohort) \r\n* Ability to undergo a fresh tumor biopsy for the purpose of screening for this clinical trial (including able and willing to give valid written consent) to ability or to provide an available archival tumor sample taken less than 3 months prior to study enrollment if a fresh tumor biopsy is not feasible with an acceptable clinical risk; tumor lesions used for fresh biopsies should be the same lesions to be irradiated when possible and should not be the same lesions used as RECIST target lesions, unless there are no other lesions accessible \r\n* Microsatellite stable (MSS) tumor as documented by either: \r\n** Immunohistochemistry (IHC) testing that does not suggest loss of MLH-1, MSH-2, PMS2 or MSH6 \r\n** Polymerase chain reaction (PCR) testing that does not suggest microsatellite instability (MSI)Xx_NEWLINE_xXTumor verified by a thoracic surgeon to be in a location that will permit sublobar resectionXx_NEWLINE_xXTumor located peripherally within the lung; NOTE: peripheral is defined as not touching any surface within 2 cm of the proximal bronchial tree in all directions; patients with non-peripheral (central) tumors are NOT eligibleXx_NEWLINE_xXPatients must not have received previous irradiation for head and neck tumor, skull base, or brain tumorsXx_NEWLINE_xXThe participant has a primary brain tumorXx_NEWLINE_xXChildren with definitive confirmatory eligible histologic or cytological diagnosis of eligible CNS tumor within the brain or spinal cord, who have not previously received either irradiation or chemotherapy (except corticosteroids) will be eligible for study entryXx_NEWLINE_xXHave a histopathological diagnosis (fresh or banked tumor biopsy sample, preferably collected within the last 3 years) of nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation, or ablative therapies.Xx_NEWLINE_xXDirect tumor extension into the stomach, duodenum, small bowel or large bowelXx_NEWLINE_xXInclusion criteria:\n\n        Subjects must satisfy all the following inclusion criteria to be enrolled in the study:\n\n          1. Signed, written Institutional Review Board/Ethics Committee-approved Informed Consent\n             Form(s).\n\n          2. Stage IV pancreatic ductal adenocarcinoma (PDA) with histological or cytological\n             confirmation of PDA.\n\n          3. Subjects must be determined to be HA-high based on archived or fresh tumor core biopsy\n             or sample obtained after the subject has documented metastatic disease.\n             Biopsies/samples must meet the following requirements:\n\n               1. Pancreas tumor biopsies/samples obtained on or after the date that metastatic\n                  disease is documented or tumor biopsies/samples from a metastatic lesion are\n                  acceptable.\n\n               2. Tumor biopsies or samples must meet the requirements provided in the Study\n                  Laboratory Manual with regard to tumor tissue architecture. Note: cytology\n                  samples from fine needle aspirates without maintained tissue architecture or\n                  brushing biopsies are not acceptable.\n\n               3. Tumor tissue (formalin-fixed paraffin-embedded [FFPE] block preferred) must\n                  include enough tumor to make a minimum of 5-10 unstained, consecutive FFPE slides\n                  (10 slides are preferred) of 1 archival block that meet specific tissue sample\n                  requirements (see Study Laboratory Manual).\n\n          4. Radiographic confirmation of Stage IV PDA with at least 1 tumor metastasis measurable\n             on computed tomography (CT) scan and/or magnetic resonance imaging (MRI) per Response\n             Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, excluding the\n             primary pancreatic lesion.\n\n          5. If a subject has had adjuvant/neoadjuvant therapy and/or therapy for locally advanced\n             disease (chemotherapy for non-metastatic pancreatic cancer in combination with or\n             without radiation therapy), tumor recurrence or disease progression must have occurred\n             no sooner than 6 months after completing the last dose of the aforementioned\n             therapies, provided all toxicities have returned to baseline or ? Grade 1.\n\n          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n\n          7. Life expectancy ?3 months.\n\n          8. Age ?18 years.\n\n          9. A negative urine or serum pregnancy test within 7 days before Cycle 1, Day 1 (C1D1;\n             first dose of study medication) if female subject is of childbearing potential.\n\n         10. Screening clinical laboratory values as follows:\n\n               1. Total bilirubin ?1.5 times upper limit of normal (ULN) (subjects with Gilbert\n                  syndrome are eligible independent of bilirubin levels).\n\n               2. Aspartate aminotransferase (serum glutamic oxaloacetic transaminase) and alanine\n                  aminotransferase (serum glutamic pyruvate transaminase) ?2.5 times ULN, (if liver\n                  metastases are present, then ?5 times ULN is allowed).\n\n               3. Serum creatinine ?2.0 mg/dL or calculated creatinine clearance ?40 mL/min.\n\n               4. Serum albumin ?2.5 g/dL.\n\n               5. Prothrombin time or international normalized ratio (INR) within normal limits\n                  (±15%), unless subject takes warfarin, in which case prothrombin time or INR\n                  result must be within therapeutic range.\n\n               6. Partial thromboplastin time (PTT) within normal limits (±15%).\n\n               7. Hemoglobin ?9 g/dL (transfusion and erythropoietic agents allowed).\n\n               8. Absolute neutrophil count ?1,500 cells/mm3.\n\n               9. Platelet count ?100,000/mm3.\n\n         11. For women of childbearing potential (WOCBP) and for men, agreement to use a highly\n             effective contraceptive method from the time of screening throughout the study until 1\n             month (WOCBP) or 6 months (men) after administration of the last dose of any study\n             medication. Highly effective contraceptive methods consist of prior sterilization,\n             intrauterine device (IUD), intrauterine hormone-releasing system (IUS), oral or\n             injectable contraceptives, barrier methods, and/or true sexual abstinence.\n\n        Exclusion criteria:\n\n        Subjects are ineligible for enrollment if they meet any of the following exclusion\n        criteria:\n\n          1. Clinical evidence of deep vein thrombosis (DVT), pulmonary embolism (PE) or other\n             known TE event present during the screening period.\n\n               1. Subjects with superficial vein thrombosis are eligible.\n\n               2. Subjects with visceral/splanchnic vein thrombosis are still eligible if, in the\n                  opinion of the Investigator, the visceral/splanchnic vein thrombosis is primarily\n                  associated with the anatomic location of the underlying disease of metastatic\n                  pancreatic cancer.\n\n          2. Previous radiotherapy, surgery, chemotherapy, or investigational therapy for the\n             treatment of metastatic disease.\n\n             a. Palliative radiotherapy for pain control of metastatic bone lesions is allowed.\n\n          3. Known central nervous system involvement or brain metastases.\n\n          4. New York Heart Association Class III or IV cardiac disease (Appendix C) or myocardial\n             infarction within the past 12 months.\n\n          5. History of cerebrovascular accident or transient ischemic attack.\n\n          6. Clinically significant pre-existing carotid artery disease.\n\n          7. Known infection with human immunodeficiency virus, or active infection with hepatitis\n             B or hepatitis C within the past 12 months.\n\n          8. Known allergy to hyaluronidase.\n\n          9. Current use of megestrol acetate or megestrol acetate-containing drugs (use within 10\n             days of Day 1).\n\n         10. Contraindication to heparin as per institutional guidelines.\n\n         11. Women currently pregnant or breastfeeding.\n\n         12. Intolerance to dexamethasone.\n\n         13. History of another primary cancer within the last 3 years with the exception of\n             non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical\n             carcinoma in-situ.\n\n         14. Any other disease, active, uncontrolled bacterial, viral or fungal infection requiring\n             systemic therapy, metabolic dysfunction, physical examination finding or clinical\n             laboratory finding that leads to reasonable suspicion of a disease or condition that\n             contraindicates the use of an investigational drug, or that may affect the\n             interpretation of the results, or that may render the subject at high risk for\n             treatment complications.\n\n         15. Immunization with a live vaccine up to 2 weeks prior to Day 1.\n\n         16. Hypersensitivity to the active substance or ingredients of PEGPH20, gemcitabine, and\n             nab-paclitaxel.\n\n         17. Inability to comply with study and follow-up procedures as judged by the Investigator.Xx_NEWLINE_xXIDH mutation status of the primary tumor must be available or tumor samples must be available for pre randomization testingXx_NEWLINE_xXA contrast enhancing brain tumor that is any of the following:Xx_NEWLINE_xXRectal tumor at baseline which would be considered to require complete TMEXx_NEWLINE_xXPrimary unresectable rectal cancer; a tumor is considered unresectable when invading adjacent organs and an en bloc resection will not achieve negative marginsXx_NEWLINE_xXElevation in tumor markers without radiographic evidence of disease progression is not satisfactory for progression on previous treatmentXx_NEWLINE_xXAngiosarcoma tumor specimen, if availableXx_NEWLINE_xXPresence of tumor(s) invading into the heart or great vessels (including carotid artery) or another location where bleeding is associated with high morbidity including patients with primary cardiac or great vessel angiosarcomaXx_NEWLINE_xXAt least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXMedulloblastoma or medulloblastoma variants including posterior fossa primitive neuroectodermal tumor (PNET) as documented by an institutional pathologistXx_NEWLINE_xXCentral nervous system (CNS) embryonal tumor other than medulloblastoma or PNET in the posterior fossa, for example, patients with diagnosis of atypical teratoid/rhabdoid tumor (ATRT), supratentorial PNET, pineoblastoma, ependymoblastoma, embryonal tumor with abundant neuropil and true Rosettes (ETANTR) are excludedXx_NEWLINE_xXTumor size > 3.5 cmXx_NEWLINE_xXUncontrolled tumor-related pain or impending spinal cord compression.Xx_NEWLINE_xXTumor assessment for FGF/FGFR gene alteration status.Xx_NEWLINE_xXAll of the following staging criteria (according to the 7th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:\r\n* By pathologic evaluation, primary tumor must be pT1-3\r\n* By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b\r\n* If pN0, pathological tumor must be >= 3.0 cmXx_NEWLINE_xXFor patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist; if pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins; if tumor is still present at the resected margin after re-excision(s), the patient must undergo mastectomy to be eligible; (patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection)Xx_NEWLINE_xXFor patients who undergo mastectomy, the margins must be free of residual gross tumor; (patients with microscopic positive margins are eligible as long as post-mastectomy radiation therapy [RT] of the chest wall will be administered)Xx_NEWLINE_xXEvidence that tumor is adherent to or invading the mesorectal fascia on imaging studies such that the surgeon would not be able to perform an R0 resection (one with negative margins)Xx_NEWLINE_xXTumor is causing symptomatic bowel obstruction (patients who have had a temporary diverting ostomy are eligible)Xx_NEWLINE_xXPatients must have tumor slides available for submission for HER-2 testing; HER-2 testing must be completed by the central lab prior to step 2 randomizationXx_NEWLINE_xXFor patients who undergo lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS as determined by the local pathologist; additional operative procedures may be performed to obtain clear margins; if tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible; (patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection)Xx_NEWLINE_xXFor patients who undergo mastectomy, the margins must be histologically free of residual (microscopic or gross) tumorXx_NEWLINE_xXPatients must not be planning to require any additional form of systemic anti-tumor therapy while on protocol treatmentXx_NEWLINE_xXPatients must not have cavitating pulmonary lesions; patients must not have tumor invading the gastrointestinal (GI) tract or evidence of endotracheal or endobronchial tumor within 28 days prior to registrationXx_NEWLINE_xXPatient’s baseline imaging must not indicate the presence of tumor invading or encasing any major blood vesselsXx_NEWLINE_xXTumors must be tested and known negative for EGFR tyrosine kinase inhibitor (TKI) sensitizing mutations (EGFR exon 19 deletions, L858R, L861Q, G719X) and ALK gene rearrangements by routine Clinical Laboratory Improvement Act (CLIA)-certified clinical testing methods; negative circulating tumor DNA results alone are not acceptable; prior testing for tumor PD-L1 status is not requiredXx_NEWLINE_xXNo history of the following:\r\n* Clinically-significant gastrointestinal bleeding within 6 months prior to registration\r\n* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months prior to registration\r\n* Drug induced pneumonitis within 3 months prior to registration\r\n* Signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\r\n* Radiographic evidence of cavitating pulmonary lesion(s)\r\n* Tumor invading any major blood vessels\r\n* Evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or mainstem endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXEntire tumor must be in the colon (rectal involvement is an exclusion); surgeon confirmation that entire tumor was located in the colon is required only in cases where it is important to establish if the tumor is a colon versus (vs.) rectal primaryXx_NEWLINE_xXNewly diagnosed patients must have histologic verification of a primary extracranial germ cell tumor in any of the categories outlined; elevation of serum tumor markers without histologic confirmation is not sufficient for entry on the trial\r\n* NOTE: for low risk patients, materials for rapid surgical central review must be sent within 7 days of study enrollmentXx_NEWLINE_xXFor oropharynx primary tumors, the patient must have negative human papillomavirus (HPV) status of the tumor as determined by p16 protein expression using immunohistochemistry (IHC)Xx_NEWLINE_xXPatients with, per the operative and/or pathology report, positive margin(s) (tumor present at the cut or inked edge of the tumor) which is not superceded by an additional margin of tumor-negative tissue, nodal extracapsular extension, and/or gross residual disease after surgery are not eligibleXx_NEWLINE_xXPer the operative report, the gross total resection of the primary tumor with curative intent was completed within 8 weeks prior to randomizationXx_NEWLINE_xXPatients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):            \r\n* Positive capillary-lymphovascular space involvement and one of the following:                \r\n** Deep third penetration\r\n** Middle third penetration, clinical tumor >= 2 cm\r\n** Superficial third penetration, clinical tumor >= 5 cm\r\n* Negative capillary-lymphatic space involvement                \r\n** Middle or deep third penetration, clinical tumor >= 4 cmXx_NEWLINE_xXPatients with any size of grade 2 or 3 of the following “intermediate (rarely metastasizing)” or “malignant” tumors, as defined in the WHO classification of soft tissue tumors for which we have consensus data of chemotherapy-resistance are eligible only for the non-chemotherapy cohort:\r\n* So-called fibrohistiocytic tumors - plexiform fibrohistiocytic tumor, giant cell tumor of soft tissues\r\n* Fibroblastic/myofibroblastic tumors - solitary fibrous tumor, malignant solitary fibrous tumor, inflammatory myofibroblastic tumor, low grade myofibroblastic sarcoma, myxoinflammatory fibroblastic sarcoma, atypical myxoinflammatory fibroblastic tumor, myxofibrosarcoma, low grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma\r\n* Tumors of uncertain differentiation - epithelioid sarcoma, alveolar soft part sarcoma, clear cell sarcoma of soft tissue, angiomatoid fibrous histiocytoma, ossifying fibromyxoid tumor, myoepithelioma, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, neoplasms with perivascular epithelioid cell differentiation (PEComa), intimal sarcoma, atypical fibroxanthoma, mixed tumor NOS, phosphaturic mesenchymal tumor, malignant ossifying fibromyxoid tumor, malignant mixed tumor, malignant phosphaturic mesenchymal tumor\r\n* Chondro-osseous tumors - extraskeletal osteosarcoma\r\n* Pericytic (perivascular) tumors - malignant glomus tumor\r\n* Nerve sheath tumors - malignant peripheral nerve sheath tumor, malignant granular cell tumor, epithelioid malignant peripheral nerve sheath tumor, malignant Triton tumor\r\n* Undifferentiated sarcomas (with a specific pathologic category in the WHO classification) - undifferentiated round cell sarcoma, undifferentiated epithelioid sarcoma, undifferentiated spindle cell sarcomaXx_NEWLINE_xXPatients with gross total resection of the primary tumor prior to enrollment on ARST1321 are NOT eligible; patients who have experienced tumor recurrence after a gross total tumor resection are NOT eligibleXx_NEWLINE_xXPatients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if excision was attempted or accomplished as long as adequate anatomic imaging (MRI for most primary tumor sites) was obtained prior to surgeryXx_NEWLINE_xXGroup A: patients < 12 months (< 365 days) of age with newly diagnosed INRG stage L1 neuroblastoma/ganglioneuroblastoma who meet the following criteria:\r\n* Greatest tumor diameter < 5 cm of adrenal or non-adrenal origin\r\n* Patients with non-adrenal primaries are eligible, but must have positive uptake on metaiodobenzylguanidine (MIBG) scan or elevated catecholamine metabolites (urine or serum) to support the diagnosis of neuroblastoma\r\n* No prior tumor resection or biopsyXx_NEWLINE_xXGroup A will be further split into two subsets, which are mutually exclusive, for statistical purposes\r\n* Group A1:\r\n** > 6 months and < 12 months of age with an adrenal primary tumor < 5 cm in greatest diameter OR\r\n** Patients less than 6 months of age with an adrenal primary tumor > 3.1 and < 5 cm in greatest diameter OR\r\n** < 12 months of age with a non-adrenal primary site < 5 cm in greatest diameter\r\n* Group A2: =< 6 months of age with an adrenal primary site and tumor =< 3.1 cm in greatest diameter.Xx_NEWLINE_xXGroup B: patients < 18 months (< 547 days) of age with newly diagnosed INRG stage L2 neuroblastoma/ganglioneuroblastoma who meet the following criteria:\r\n* No life threatening symptoms or no impending neurologic or other organ function compromise (e.g. epidural or intraspinal tumors with existing or impending neurologic impairment, periorbital or calvarial-based lesions with existing or impending cranial nerve impairment, anatomic or mechanical compromise of critical organ function by tumor [abdominal compartment syndrome, urinary obstruction, etc.]); horner syndrome is not considered neurologic compromise\r\n* No prior tumor resection, tumor biopsy ONLY\r\n* Only patients with both favorable histology and favorable genomic features will remain on study as part of Group B; the institution will be notified of histologic and genomic results within 3 weeks of specimen submission on ANBL00B1 or APEC14B1Xx_NEWLINE_xXGroup A and C patients, not required to undergo tumor biopsy, who do not enroll on ANBL1232 within 4 weeks of confirmatory imaging studyXx_NEWLINE_xXThere is no minimum performance level; children with ependymoma may suffer neurologic sequelae as a result of their tumor or surgical measures taken to establish a diagnosis and resect the tumor; in the majority of cases, there is neurologic recovery; neurologic recovery is not likely to be impeded by protocol therapyXx_NEWLINE_xXThe tumor must be located in the supratentorial compartment only (any component involving the brain stem or cerebellum is not allowed)Xx_NEWLINE_xXPostoperative tumor plus surgical bed size exceeds 5 cm in maximum diameterXx_NEWLINE_xXPathologic evidence of active primary disease or local/regional breast tumor recurrence at the time of registration;Xx_NEWLINE_xXPatients must have had all visible tumor resected completely within 60 days prior to registration; CIS disease is not expected to be completely excised; all patients must have tumor tissue from the histologic diagnosis of recurrence available for central pathology review submission; failure to submit these materials will make the patient ineligible for this studyXx_NEWLINE_xXPatients must have had cystoscopy confirming no visible papillary tumor within 21 days prior to registration; (CIS disease is not expected to have been completely excised)Xx_NEWLINE_xXPatients with histologically confirmed ovarian stromal tumor [granulosa cell tumor, ganulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord-stromal tumor, sex cord tumor with annular tubules]Xx_NEWLINE_xXConfirmation of GCT histology (both seminoma and nonseminoma) on pathologic review at the center of enrollment; tumor may have originated in any primary site\r\n* NOTE: in rare circumstances, patients will be allowed to enroll even if a pathologic diagnosis may not have been established; this would require a clinical situation consistent with the diagnosis of GCT (testicular, peritoneal, retroperitoneal or mediastinal mass, elevated tumor marker levels [HCG >= 500; AFP >= 500] and typical pattern of metastases)Xx_NEWLINE_xXPatient has had previous treatment with the study drug or other Wilms' tumor 1 (WT1)-related immune therapyXx_NEWLINE_xXHistologically confirmed diagnosis of inoperable PVNS/ dt-TGCT or potentially resectable tumor that would result in unacceptable functional loss or morbidity as determined by a qualified surgeon or multi-disciplinary tumor board (must be documented in the CRF during screening)Xx_NEWLINE_xXGerm cell tumor (GCTs), excluding immature teratoma, or teratoma with malignant transformation.Xx_NEWLINE_xXFor Phase 2, must have one of the following tumor types: recurrent or refractory NSCLC (any histology), or HCC with elevated alpha-fetoprotein (AFP) ?200 nanogram/milliliter (ng/mL).Xx_NEWLINE_xXFor Phase 2 only, more than 1 prior line of therapy for their tumor type.Xx_NEWLINE_xXPatients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. Patient must be willing to undergo a new tumor biopsy at baseline or at molecular pre-screening if applicable, and during therapy on this study. For patients in the phase II part of the study, exceptions may be granted after documented discussion with Novartis. After a sufficient number of paired biopsies are collected, the decision may be taken to stop the collection of biopsies.Xx_NEWLINE_xXPatients with ? 3 visceral metastases (excluding pulmonary lesions), with no lesions >3.0 cm. Patients with substantial tumor burden of non-measurable disease may not be good candidates for an immunotherapy and should be discussed with the Medical Monitor.Xx_NEWLINE_xXGreatest tumor dimension of all sites must be =< 5.0 cm or < 250 cm^3Xx_NEWLINE_xXWomen with histologically proven invasive breast cancer without distant metastases; a clinical tumor classification of tumor size must be at least 1 cm with or without clinical pathologic evidence of positive nodesXx_NEWLINE_xXKnown endobronchial lesions and/or lesions infiltrating major pulmonary vessels (Note: tumor abutting the vessel is acceptable, but contiguous tumor and vessel is not; CT with contrast is strongly recommended to evaluate such lesions)Xx_NEWLINE_xXCNS GCT including pure germinoma and MMGCT; patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor will be eligible for the study; patients with mature/immature teratoma who have tumor marker elevations are eligible on this study; patient with ONLY mature and/or immature teratoma are ineligible in the absence of the tumor marker elevationsXx_NEWLINE_xXPatients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the studyXx_NEWLINE_xXSubjects with histopathologic confirmation of intermediate or high-grade primary central nervous system lymphoma (PCNSL) as documented by brain biopsy, or cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy), and cluster of differentiation 20 (CD20) positive; whenever possible, the tumor should be characterized by immunophenotypeXx_NEWLINE_xXPresence of greater than 1 cm x 1 cm residual tumor enhancement on postoperative MRI;Xx_NEWLINE_xXPatients with a histologically confirmed diagnosis of high-grade glioma (HGG), medulloblastoma, CNS embryonal tumor (not otherwise specified [NOS]), ependymoma, or atypical teratoid rhabdoid tumor (ATRT) that is recurrent, progressive or refractoryXx_NEWLINE_xXPHASE I (STRATUM 1): Patients with a histologically confirmed diagnosis of a primary CNS tumor that is recurrent, progressive, or refractory; all tumors must have histologic verification of HGG, medulloblastoma, CNS embryonal tumor (NOS), ependymoma, or ATRT; patients with low-grade gliomas are excludedXx_NEWLINE_xXPHASE I (STRATUM 1): Patients with progressive DIPG, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since last treatment, OR the appearance of a new tumor lesion since diagnosis \r\n* Please note:\r\n** Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation\r\n** Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma WHO II-IV. These patients must have radiographic evidence of progressionXx_NEWLINE_xXSURGICAL STUDY (STRATUM 2): Patients must have recurrent or refractory disease with a histological diagnosis at either the time of diagnosis or at the time of recurrence of one of the following: \r\n* HGG\r\n* Medulloblastoma, \r\n* CNS embryonal tumor (NOS), \r\n* Ependymoma, or \r\n* ATRTXx_NEWLINE_xXAny evidence of tumor metastasis or co-existing malignant diseaseXx_NEWLINE_xXSolid tumor treated curatively more than 5 years previously without evidence of recurrenceXx_NEWLINE_xXWillingness to undergo serial tumor biopsies before and on treatmentXx_NEWLINE_xXParticipants enrolled must have disease that is accessible for tumor biopsies and must agree to a pre-treatment tumor biopsyXx_NEWLINE_xXResection of at least 80% of the volume of the tumor is feasible; resectability will be determined by the surgeon and radiologist after discussion among the multidisciplinary teamXx_NEWLINE_xXTumor lesion accessible for biopsy after the start of treatment. (Note: this lesion should be separate from measurable lesions that will be used for response assessment.)Xx_NEWLINE_xXPatients must have had histologic verification of one of the malignancies listed below at original diagnosis or at time of relapse\r\n* Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)\r\n* Osteosarcoma\r\n* Rhabdomyosarcoma\r\n* Non-rhabdomyosarcoma soft tissue sarcoma \r\n* Desmoplastic small round cell tumor\r\nNote: Patients with known involvement of the central nervous system (CNS) by malignancy will be included if there is no evidence of active bleeding or intratumoral hemorrhage on radiographic imagingXx_NEWLINE_xXAt least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXPatients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocolXx_NEWLINE_xXPatients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excludedXx_NEWLINE_xXThe maximum radiation target volume for GTV3 is 65 cc (per NRG Oncology guide); patient may be excluded after the first sMRI scan if the GTV3 volume is greater than 65 cc (we anticipate that contrast-enhancing tumor volume [residual tumor volume following tumor resection] would be less than 20 cc)Xx_NEWLINE_xXAvailability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL or DLBCLXx_NEWLINE_xXSubjects enrolling to the phase 1 portion of the trial who have received a prior RET TKI must be able and willing to undergo a pre-treatment fresh tumor biopsyXx_NEWLINE_xXSubjects enrolling to cohort B or C of the phase 2 portion of the trial who have received a prior RET TKI must be able and willing to undergo a pre-treatment fresh tumor biopsyXx_NEWLINE_xXPatients are required to have an activating ALK aberration in their tumor detected by certified assay (i.e. CLIA in the US.) prior to registration. The report from this test is required to be submitted for eligibility. Patients with at least one of the following genetic features in their tumor will be considered to have an activating ALK aberration:Xx_NEWLINE_xXTo be enrolled in the dose escalation or in the MTD expansion, Subject must have a locally confirmed diagnosis of either of the following tumor types:Xx_NEWLINE_xXUpon the identification of an MTD or RP2D, the Sponsor, in consultation with the study investigators, may open the enrollment of two of the following nonrandomized tumor specific extension cohorts:Xx_NEWLINE_xXFor the MTD expansion cohort, Subject must have an accessible tumor lesion(s) and consent to tumor biopsy of such a lesion(s) during screening and after starting KO-947 treatment.Xx_NEWLINE_xXThe tumor must have been determined to be microsatellite stable (MSS).Xx_NEWLINE_xXThe Sponsor may decide to limit the specific tumor types selected or treatment settings for specific arms based on evidence gathered.Xx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Tumor deposits that are clearly accessible for serial tumor biopsies - a patient’s biopsied lesion must be at least 1 cm in diameter (in at least one dimension)Xx_NEWLINE_xXBe willing and able to undergo a core or excisional tumor biopsy according to institutional standards (guided visually or by computed tomography [CT] or ultrasound), paracentesis, or thoracentesis for tumor cells \r\n* Note: This is to be done prior to treatment at C1D1 and post-treatment (cycle 2 day 8), if this is clinically and safely feasible to do so; this will allow the use of this freshly obtained tissue for correlative analyses in the studyXx_NEWLINE_xXPatient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at baseline, and again during therapy on this study.Xx_NEWLINE_xXAvailable tumor sample for testingXx_NEWLINE_xXEpidural tumor < 2 mm from spinal cordXx_NEWLINE_xXPatient is willing to undergo a fresh tumor biopsy (core or excisional) for correlative analyses (ie. PD-L1 expression)Xx_NEWLINE_xXPrior ACT therapy should be completed, and residual disease documented by either radiographic progression or active disease observed on biopsy (i.e. hematologic or solid tumor malignancy must be deemed active by the treating investigator); the investigator may deem that the disease is active on the basis of a pre-treatment biopsy demonstrating viable tumor cells or clinical progression of disease (i.e. RECIST progression is not required)Xx_NEWLINE_xXRadiographic evidence of measurable disease tumor lesion (? 1cm in greatest dimension) or nodal disease (>1.5cm in greatest dimension)Xx_NEWLINE_xXHistopathologically confirmed melanoma, Merkel cell carcinoma or other solid tumor malignancyXx_NEWLINE_xXConfirmed availability of representative tumor specimensXx_NEWLINE_xXSubjects must agree to undergo tumor biopsies until biopsies have been obtained from 20 subjects (i.e., biopsies are required in at least the first 20 enrolled subjects, or until a goal of 20 study biopsies are obtained); subjects in whom a biopsy is technically not feasible or in whom would result in unacceptable risk in the opinion of the investigator, may be exempted from the biopsy requirement with discussion with the principal investigatorXx_NEWLINE_xXThe size of the Grade IV glioma tumor is multi-focal and > 30mm in size, as assessed at the baseline (pre-study) MRI evaluation.Xx_NEWLINE_xXPatients with histologically or serologically confirmed relapsed/refractory nonseminoma germ cell tumor, (i.e., embryonal carcinoma, choriocarcinoma, or yolk sac tumors) including female germ cell tumors (GCT) and primary mediastinal NSGCTXx_NEWLINE_xXPatients must have evidence of recurrent or metastatic carcinoma by one or more of the following:\r\n* The appearance of metastatic disease by standard imaging techniques\r\n* The appearance of rising serum tumor marker, AFP or beta-hCG\r\n* NOTE: If a rising tumor marker is the only evidence of progressive disease, at least 2 consecutive rising values at least one week apart are needed; patients with only evidence of disease is rising tumor marker AFP and beta-hCG will be provided alternate causes of increased serum levels of these markers are not present, such as cross reaction with luteinizing hormone (LH) (that can be tested if needed by testosterone suppression of LH), hepatitis, use of marijuana or second primary tumor, etcXx_NEWLINE_xXGroup A: Subjects with any solid tumor (including lymphomas).Xx_NEWLINE_xXPatients must have archival tumor tissue or agree to a tumor biopsy for mutation and biomarkers analysis unless previously discussed with sponsor's medical monitor or its designee (fresh tumor biopsies are recommended at baseline in patients with readily accessible tumor lesions and who consent to the biopsies). Patients with ovarian, fallopian tube, primary peritoneal, or breast cancer in Part A and all patients enrolled in Part B must also agree to provide fresh blood sample at the baseline for the evaluation of BRCA mutations and/or confirmation of prior BRCA results or other homologous reconstitution deficiency mutation even if it was previously tested.Xx_NEWLINE_xXPatients must have radiologic evidence of recurrent, refractory or progressive malignant central nervous system (WHO grade III or IV) or solid tumor; for patients with radiologic features of DIPG histologic confirmation of diagnosis is not required though biopsy is suggested if clinically indicatedXx_NEWLINE_xXDiagnosis of metastatic or advanced CRC, UCC, SCCHN, salivary gland cancer or NSCLC with tumor accessible for biopsyXx_NEWLINE_xXWilling to consent to tumor biopsies during the studyXx_NEWLINE_xXFor Part A exclusively (RO6874281 monotherapy), confirmed advanced and/or metastatic solid tumor, with at least one tumor lesion of location accessible to biopsy per clinical judgment of the treating physician, and confirmed progression at baseline; for whom no standard therapy that would confer clinical benefit to the participant existsXx_NEWLINE_xXFor phase 2 specifically, agree to pre- and on-treatment tumor biopsiesXx_NEWLINE_xXDiagnosis of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid)Xx_NEWLINE_xXMolecular testing results from Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories used for patient eligibility should be obtained from the most recent tumor biopsy (baseline tumor biopsies and on-progression tumor biopsies are optional)Xx_NEWLINE_xXImmunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXPrimary breast tumor size at least 2 centimeter (cm) in one dimension by clinical or radiographic exam; patients who have multicentric breast cancer are eligible if each lesion is ER-negative and HER2-negative; in that case, one lesion needs to be identified as the index lesion to be followed for clinical response; the index lesion must also be the lesion from which core biopsies are obtainedXx_NEWLINE_xXFor patients enrolled on Phase 2 of study at UCSF, tumor biopsy is required in the subset of patients who have a metastatic lesion amenable to biopsy in the judgment of study investigator and Interventional RadiologyXx_NEWLINE_xXHas documented evidence of an activating EGFR mutation in the tumor tissue determined by either sequencing or PCR-based technique (Part 1).Xx_NEWLINE_xXPrimary spine tumorXx_NEWLINE_xXBRAF mutation in loci other than V600 (BRAF nonV600 MUT) or BRAF fusion detected by genetic testing of the primary tumor or regional/distant metastasisXx_NEWLINE_xXSubjects must provide either a fresh or archived tumor sample for correlative study analysesXx_NEWLINE_xXExtradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon spinal cordXx_NEWLINE_xXThe subject has tumor in contact with, invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXTumor size ?1.5 cm in greatest diameter in the axis parallel to the treatment probe AND ?1.5 cm in the axis anti-parallel to the treatment probe AND ?1.5 cm in Anterior/ Posterior dimension. Tumor size ?1.5 cm in greatest diameter as measured by breast ultrasound, mammogram and/or MRI. The largest dimension measured will be used to determine eligibility.Xx_NEWLINE_xXHistory of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor.Xx_NEWLINE_xXAll patients must have had an MRI of the brain and spine that has measurable tumor (not only diffuse leptomeningeal tumor) within two weeks prior to study enrollment; Note: central review of MRIs is required, but may be completed concurrently with patient registration; completion of central review is not required prior to starting treatmentXx_NEWLINE_xXEvidence of hormone sensitive, ER rich primary tumor defined by an Allred score of >= 6Xx_NEWLINE_xXMacrovascular tumor invasion.Xx_NEWLINE_xXIs willing to provide and there is confirmed availability of pre-existing diagnostic or resected tumor samples, such as paraffin-embedded sections. Providing fresh tumor biopsy is optional for subjects in Dose Escalation cohorts.Xx_NEWLINE_xXHas a tumor that contains a nonsynonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening.Xx_NEWLINE_xXPoorly differentiated carcinoma, high grade neuroendocrine tumor or small cell carcinomas are excluded from this studyXx_NEWLINE_xXPIK3CA MUTANT COHORT (closed 03/17/2016): Tumor PIK3CA mutation presentXx_NEWLINE_xXPatients with biopsy proven low grade glioma or astrocytoma, ependymoma, craniopharyngioma, meningioma, neurocytoma, medulloblastoma or gangliogliomas or other rare tumor requiring tumor bed or tumor irradiation; patients with a presumed diagnosis of optic glioma or gliomas based on imaging and clinical characteristics will also be allowed on this trial as it may be against the standard of care to biopsy some of these individuals (for example, a patient with neurofibromatosis [NF]-1 and an optic glioma will not require a biopsy for diagnosis)Xx_NEWLINE_xXMust have biopsy-proven desmoid tumor (or aggressive fibromatosis). For patients with recurrent disease, a biopsy is not required at the time of recurrenceXx_NEWLINE_xXthe desmoid tumor has already recurred after a prior surgery orXx_NEWLINE_xXUse of steroids for non-tumor indications (for example: asthma or severe allergic reaction) is permittedXx_NEWLINE_xXDental braces or prosthesis that interferes with tumor imagingXx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXThe subject has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of clinically significant bleeding from tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXFor Arm A, patients must have disease that is amenable to biopsy and must be willing to provide consent for a tumor biopsy at baseline (within 30 days of beginning ONC201) and at least 1 on-treatment tumor biopsy.Xx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXPHASE II: Patients for whom tumor biopsy and/or resection is clinically indicated and who are eligible for and enrolled on the phase II component (any stratum) will also be eligible for the optional target validation stratumXx_NEWLINE_xXPHASE II: Tumor must be measurable in at least two dimensions on imagingXx_NEWLINE_xXHas one of the following tumor locations/types:1) NSCLC involving the superior sulcus; 2) Large cell neuro-endocrine cancer (LCNEC); or 3) Sarcomatoid tumor.Xx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at restXx_NEWLINE_xXHER2-positive (immunohistochemistry score 3+) or ERBB2- amplification (ratio ERBB2/centromeres >= 2.0 or mean gene copy number >= 6) on primary tumor or of metastatic or unresectable loco-regional biopsy.Xx_NEWLINE_xXMust be able and willing to undergo mandatory tumor biopsy.Xx_NEWLINE_xXAny hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to study entry.Xx_NEWLINE_xXLimited disturbance of tumor during biopsy.Xx_NEWLINE_xXTumor Treatment Field (TT Fields) therapy allowed.Xx_NEWLINE_xXKnown to be T790M+ (on pre-treatment tumor or plasma) or known germline T790MXx_NEWLINE_xXParticipants must have a biopsy-proven tumor consistent with small cell lung cancer and intracranial lesions radiographically consistent with or pathologically proven to be brain metastases; patients who have undergone prior systemic therapy are eligibleXx_NEWLINE_xXParticipants with a maximum tumor diameter exceeding 5 cm (if not resected)Xx_NEWLINE_xXHas an evaluable baseline tumor sample to submit for analysis.Xx_NEWLINE_xXPrimary tumor size > 1 cmXx_NEWLINE_xXFor endometrial carcinoma patients, a diagnosis of epithelial endometrial carcinoma is required. Stromal tumors and carcinosarcoma (mixed malignant Mullerian tumor) are excluded.Xx_NEWLINE_xXPart A: subjects must have a FFPE tumor sample available (e.g., from their prior surgery) that is suitable for the next generation sequencing (NGS) required for this studyXx_NEWLINE_xXPart B: subjects must have at least 1 lesion amenable to the mandatory fresh tumor biopsy at study entry and provide a biopsy suitable for the NGS required for this study.Xx_NEWLINE_xXAble to provide a sufficient amount of representative tumor specimen for central laboratory testing of RAS mutation status and microsatellite stable (MSS).Xx_NEWLINE_xXAvailability to provide a representative tumor specimen biopsyXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXParticipant must be willing to undergo tumor biopsies prior to treatment and on Cycle 2 Day 1. In the Phase 2 part of the trial, participants with bone-only disease, or participants for whom a biopsy is contra-indicated, may opt out of providing tumor biopsies. Note: A subset of participants in Phase 2 will be required to provide tumor tissue until tumor pairs have been collected from at least 15 ER?WT and 15 ER?mut (determined by sponsor-designated central laboratory test).Xx_NEWLINE_xXConfirmed tumor programmed death?ligand 1 (PD-L1) evaluation as documented through central testing of a representative tumor tissue specimenXx_NEWLINE_xXPrimary breast tumor size of greater than (>) 2 centimeters (cm) by at least one radiographic or clinical measurementXx_NEWLINE_xXBiopsy proven neuroendocrine tumor, which is somatostatin receptor positive as demonstrated on somatostatin receptor PET\r\n* All sites or origin are eligible\r\n* Functional and nonfunctional tumors are allowedXx_NEWLINE_xXAny patient with suspected brain tumor on diagnostic MR imaging who will undergo a resectionXx_NEWLINE_xXBleeding or thrombotic disorders or participants at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels (eg, carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy.Xx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: MTD expansion: Patients must be willing to undergo pre- and on-treatment tumor biopsies; patients are exempt from this requirement if, in the opinion of the investigator, the biopsy procedure would pose a significant risk or if they have only pulmonary metastatic diseaseXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: MTD expansion: Patients currently taking anticoagulants and who cannot safely hold the medication to facilitate pre and on-treatment tumor biopsies are excluded from participationXx_NEWLINE_xXParticipants with tumor =< 1 cm proximity to the ventricles will be allowed to enroll; however the study agent (rQNestin34.5v.2) may not be injected in any area that is within 1 cm of the ventricle regardless of where the tumor is locatedXx_NEWLINE_xXPresence of tumor cells in the brain or spinal cord which are symptomatic or require treatmentXx_NEWLINE_xXTumor accessible for biopsies and agreement to conduct pre-dose and post-dose fresh tumor biopsies.Xx_NEWLINE_xXKnown to be T790M+ (on pre-treatment tumor or plasma) or known germline T790MXx_NEWLINE_xXFor Ph1a monotherapy and combination cohorts, histologic or cytologic confirmation of advanced solid tumor.Xx_NEWLINE_xXTumor accessible for unrestricted illumination for photodynamic therapy (PDT) (accessibility as determined by the physician)Xx_NEWLINE_xXPrevious treatment in the target tumor areaXx_NEWLINE_xXGreater than 50% tumor burden in the liver by imaging.Xx_NEWLINE_xXEXCLUSION - TREATMENT: Tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXParticipants with a maximum tumor diameter exceeding 5 cm (if not resected)Xx_NEWLINE_xXAt least one tumor lesion with location accessible to biopsy per clinical judgment of the treating physicianXx_NEWLINE_xXPlatelets ?70x103/?L (? 70 x 10^9/L) (superficial tumor dosing only)Xx_NEWLINE_xXFor deep tumor cohorts, patients who require uninterrupted anticoagulants of any type, on daily aspirin therapy, or NSAIAs.Xx_NEWLINE_xXPatients must be able to undergo appropriate imaging studies to monitor tumor responseXx_NEWLINE_xXRadiographic evidence of leptomeningeal dissemination, gliomatosis cerebri, infratentorial tumor, or disease at sites remote from the supratentorial brain.Xx_NEWLINE_xXPatients with pure WDLS, myxoid/round cell or pleomorphic tumor histologic subtypes.Xx_NEWLINE_xXlargest tumor volume < 10 ccXx_NEWLINE_xXlongest tumor diameter < 3 cmXx_NEWLINE_xXPatients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse - a) Rhabdomyosarcoma, b) Non-rhabdomyosarcomatous Soft Tissue Sarcoma (including desmoplastic small round cell tumor), c) Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor (PNET), d) Osteosarcoma, e) Neuroblastoma (Measurable), f) Neuroblastoma (Evaluable), g) Hepatoblastoma.Xx_NEWLINE_xXThe participant has a primary brain tumorXx_NEWLINE_xXThe participant has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXPatients must have received no previous therapy for the tumor with the exception of corticosteroids and surgery; patients with a gross total resection will not be eligibleXx_NEWLINE_xXPatients with histologically confirmed diagnosis of a primary central nervous system tumor will be eligible; patient tumors must test positive for the BRAFV600E or the BRAF Ins T mutation at a Clinical Laboratory Improvement Act (CLIA)-approved laboratory; if either mutation cannot be confirmed from a prior test and archival tumor is not available to confirm presence of either mutation, patients must have tumor biopsy to collect tumor sample for mutation confirmationXx_NEWLINE_xXAvailable biopsy of primary tumor with adequate samplesXx_NEWLINE_xXAny advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H)Xx_NEWLINE_xXProgression of tumor or intolerance to therapies known to provide clinical benefit. There is no limit to the number of prior treatment regimensXx_NEWLINE_xXCan supply tumor tissue for study analyses (dependent on tumor type)Xx_NEWLINE_xXTumor(s) involving the brain stemXx_NEWLINE_xXMetastatic or unresectable solid tumor malignancyXx_NEWLINE_xXAgree to provide archival tumor material for researchXx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at restXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Tumor tissue or circulating tumor deoxyribonucleic acid (DNA) tested positive for HER2 mutation; mutations outside the list will be assessed on a case-by-case basis by the study team to determine eligibilityXx_NEWLINE_xXCohort C: Patients in this cohort only will require a single tumor biopsy 48-72H after the first administration of IMGN853 and gemcitabine on day 1, cycle 1 of treatment, providing it is safe/feasible and confers non-significant risk to patientXx_NEWLINE_xXFor the dose expansion and extension cohorts, patients also must have confirmation of tumor T790M+ mutation status from a biopsy sample taken after disease progression on the most recent treatment regimen with an EGFR TKI. Prior to entry, a result from the central analysis of the patient's T790M mutation status must be obtained.Xx_NEWLINE_xXINCLUSION - PROCUREMENT: EBV positive tumor (can be pending)Xx_NEWLINE_xXINCLUSION - INFUSION: EBV positive tumorXx_NEWLINE_xXPatient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/ baseline or at molecular pre-screening if applicable, and during therapy on this study.Xx_NEWLINE_xXPathological diagnosis for the resected tumor demonstrates transformation to higher grade (i.e. WHO grade III or IV) gliomas; if a patient is diagnosed as high-grade glioma (HGG) upon resection after receiving the pre-surgical treatment, the patient will be withdrawn from the study and considered for therapeutic options for HGG (trials for HGG or standard of care); the tumor tissue of such a case would be brought to the lab before the pathological diagnosis is made? and thus would be processed before the lab is informed of the final HGG diagnosis; will evaluate the tumor tissue to help us develop future approaches for HGGXx_NEWLINE_xXPathologically confirmed squamous cell carcinoma of the oral cavity; clinical stage >= T2 (primary tumor greater than 2 cm in size) and/or evidence of regional nodal involvement by clinical exam or imagingXx_NEWLINE_xXPROCUREMENT INCLUSION: CD30 positive tumor as assayed in a Clinical Laboratory Improvement Act (CLIA) certified pathology laboratory (result can be pending at this time)Xx_NEWLINE_xXTREATMENT INCLUSION: CD30-positive tumor as assayed in a CLIA certified pathology laboratoryXx_NEWLINE_xXTREATMENT EXCLUSION: Tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXSolid tumor located in central lungXx_NEWLINE_xXTumor invades a major blood vesselXx_NEWLINE_xXSubmission of research blood draw and/or tumor sampleXx_NEWLINE_xXFor Parts 1 and 3, eligibility may be based on local read of fresh or archived tumor biopsy. Archived or fresh FFPE biopsy must be provided for retrospective centralized review.Xx_NEWLINE_xXPatients must have stage cT2-T4a N0 M0 disease; clinical T stage is based on the transurethral resection of the bladder tumor (TURBT) sample, exam under anesthesia and cross-sectional imaging studies; patients must undergo cystoscopy and TURBT as part of the staging procedure within 120 days prior to registration; to exclude non-bulky/low-risk tumors, subjects must have documented muscle invasion with at least one of the following:\r\n* Disease measuring at least 10 mm on cross-sectional imaging; bladder thickening on imaging, by itself, is not adequate\r\n* The presence of tumor-associated hydronephrosisXx_NEWLINE_xXParticipant’s core biopsy slides suggest that later re-sectioning will not contain sufficient tumor to allow for an adequate evaluation of Ki67 and TUNEL assays, at a minimumXx_NEWLINE_xXUncontrolled tumor painXx_NEWLINE_xXParticipants enrolling to the HR or replicative stress cohorts during stage 1 must have disease that is amenable to biopsy and be willing to undergo a pre-treatment tumor biopsy.Xx_NEWLINE_xXParticipants enrolling to the HR or replicative stress cohort during stage 1 may not be on anticoagulant therapy unless the treating investigator has deemed it safe to temporarily hold to facilitate the pre-treatment tumor biopsy.Xx_NEWLINE_xXThe tumor must not have an infratentorial component;Xx_NEWLINE_xXUnresectable HCC, defined by imaging criteria or cytohistologic assessment; TACE as a preferred method of treatment is determined by a multidisciplinary Brigham and Women’s Hospital (BWH)/Dana Farber Cancer Institute (DFCI) Liver Tumor BoardXx_NEWLINE_xXMain tumor size > 1 cmXx_NEWLINE_xXA hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced than the non-tumorous liver parenchyma on arterial phase computed tomography scans)Xx_NEWLINE_xXMust have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy, and be willing to undergo tumor biopsy during treatmentXx_NEWLINE_xXTumor positive for EBV encoded RNA (EBER) based on report from certified laboratory.Xx_NEWLINE_xXPatients with T1 primary tumor or T4 large volume tumor that has resulted in larynx dysfunction at baseline (for example tumor largely penetrating into base of tongue and resulting in inability to swallow at baseline)Xx_NEWLINE_xXFor other immune checkpoint naïve tumor cohort all of the following must apply:Xx_NEWLINE_xXPart A and Part B: Must be willing to undergo pretreatment and on-treatment core needle or excisional tumor biopsies.Xx_NEWLINE_xXPatients must have received pre-study nivolumab for up to 12 months and have 2 consecutive tumor assessments confirming Complete response (CR), Partial response (PR), or Stable disease (SD)Xx_NEWLINE_xXRAS wild-type; both KRAS and NRAS testing are necessary; the presence of pathogenic mutations in KRAS or NRAS is exclusionary; primary tumor or metastatic tumor may be testedXx_NEWLINE_xXPresence of >= 1 tumor lesion not included as a RECIST 1.1 target lesion which is assessed by investigator and/or radiologist as likely to be amenable to percutaneous biopsy by punch, computed tomography (CT)-, or ultrasound-guided core needle biopsy for serial sampling on treatmentXx_NEWLINE_xXNo contraindication to tumor biopsy at time of study enrollmentXx_NEWLINE_xXPatients must have documented histological or cytological evidence of tumor(s) of the prostate.Xx_NEWLINE_xXApproximately 1 cm3 preferred but 1 mg minimum of accessible and dispensable tumor (minimum of 3 passes with a core needle)Xx_NEWLINE_xXInsufficient tumor available to produce vaccineXx_NEWLINE_xXImmunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines.Xx_NEWLINE_xXExpansion phase: Tumor-specific cohort(s) at the RD:Xx_NEWLINE_xXHistologically proven T1-3N0M0 NSCLC =< 5 cm diameter (patients with tumor size up to 7 cm are allowed if radiation dose/volume histogram constraints for normal tissues can be met); T3 patients with chest wall invasion or 2 nodules within the same lobe are eligibleXx_NEWLINE_xXOne or more high-risk features identified:\r\n* Tumor diameter >= 1 cm (phase I component) or >= 2 cm (phase II component)\r\n* Tumor standardized uptake value maximum (SUVmax) >= 6.2\r\n* Moderately, poorly differentiated or undifferentiated histologyXx_NEWLINE_xXPathological diagnosis for the resected tumor demonstrates transformation to higher grade (i.e. WHO grade III or IV) gliomas; if a patient who received neoadjuvant vaccines is diagnosed as high grade glioma (HGG), the patient will be withdrawn from the study and considered for therapeutic options for HGG (trials for HGG or standard of care); the tumor tissue of such a case would be brought to the lab before the pathological diagnosis is made; and thus would be processed before the lab is informed of the final HGG diagnosis; because HGG tissue may still reflect the vaccine effects, we will evaluate the tumor tissue to help us develop future approaches for HGGXx_NEWLINE_xXPatients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study; if the patient is not eligible for surgical resection, the primary tumor must be amenable to SBRT or request for applications (RFA); generally, this will be defined as a primary tumor < 10 cm in size or a primary lesion which can be treated to a dose of >= 8 Gy x 5 without excessive perceived risk of toxicityXx_NEWLINE_xXPatients must have evaluable tissue/blood for testing as specified by the concurrent FoundationOne criteria; this will be obtained during the standard of care tumor diagnosis and tumor staging evaluationXx_NEWLINE_xXCOHORT II: Pathologically proven solid tumor in the head and neck that are amenable to palliative treatmentXx_NEWLINE_xXPHASE I: In order to perform a retrospective biomarker analysis with the next generation gene sequencing UW-OncoPlex assay; fresh tumor biopsies from metastatic or primary tumor lesion will be done if considered safe and feasible by treating physician and radiologist; Patients who already have OncoPlex or other equivalent gene sequencing assay (eg Foundation One, Perthera, Caris etc) test results available from prior tumor biopsy are eligible to participate, without the needed of a repeat tumor biopsy, but the test results need to be provided to the study principal investigatorXx_NEWLINE_xXPHASE IB: Fresh tumor biopsies from metastatic or primary tumor lesions will be done only if considered safe and feasible by treating physician and radiologist; patients who already have OncoPlex or other equivalent gene sequencing assay (eg Foundation One, Perthera, Caris etc) test results available from prior tumor biopsy are eligible to participate, without the needed of a repeat tumor biopsy, but the test results need to be available to the study principal investigatorXx_NEWLINE_xXIn the opinion of the local PI: Head and neck cancer patients with airway tumor recurrence that may compromise breathing or swallowing if inflammation or edema is transiently aggravated by Hiltonol injection. Head and neck cancer patients with tumor invading major blood vessels for whom there may be a risk of blockage or bleeding if inflammation or edema is transiently increased by Hiltonol injections.Xx_NEWLINE_xXPatients must have a PN amenable to a percutaneous biopsy to participate in the biopsy portion of this study, and must be willing to undergo pre-, and on treatment tumor biopsies; there should be no contraindication for serial biopsies; NOTE: up to 10 patients who meet all criteria, but have PN which cannot be biopsied safely, will be eligible for the treatment portion of the studyXx_NEWLINE_xXMay not have a NF1 related tumor such as optic pathway glioma or malignant peripheral nerve sheath tumor, which requires treatment with chemotherapy or surgeryXx_NEWLINE_xXTumor size (based on evaluation of images or pathology if patient in the post-pathology cohort) must be less than or equal to 3 cmXx_NEWLINE_xXTumor suspected or known to invade the esophagusXx_NEWLINE_xXDocumented pCAD expressing tumor cells with the exception of HNSCC and ESCC. An archived tumor sample collected within 36 months prior to baseline if available, or a new tumor biopsy sample must be available for molecular pre-screening.Xx_NEWLINE_xXConsent for a tumor biopsy at screeningXx_NEWLINE_xXHigh grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden.Xx_NEWLINE_xXTumor: patient must have one of the following diagnoses to be eligible:Xx_NEWLINE_xXPatient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollmentXx_NEWLINE_xXPatients with bulky tumor on imaging are ineligible; treating physicians are encouraged to contact the study chair to request a rapid central imaging review to confirm fulfilment of these eligibility criteria, if they have concerns\r\nBulk tumor is defined as:\r\n* Tumor with evidence of clinically significant uncal herniation or midline shift\r\n* Tumor with diameter of > 5 cm in one dimension on T2/fluid attenuated inversion recovery (FLAIR)\r\n* Tumor that in the opinion of the site investigator, shows significant mass effect in either the brain or spine\r\n* Multi-focal/ metastatic disease: \r\nNote: A second focus of enhancement in a single FLAIR abnormality is permissible and will not exclude the subject\r\n** Patients with multi-focal parenchymal disease are ineligible\r\n** Patients with leptomeningeal metastatic disease are eligible\r\n* Strata B, D and E – patients whose tumor has a significant component involving the brainstem or with significant fourth ventricular compression are ineligibleXx_NEWLINE_xXEXCLUSION CRITERIA FOR STRATUM C: Patients with bulky tumor on imaging are ineligible; treating physicians are encouraged to contact the study chair to request a rapid central imaging review to confirm fulfilment of these eligibility criteria, if they have concerns; bulky tumor is defined as:\r\n* Tumor with any evidence of uncal herniation or midline shift\r\n* Tumor with diameter of > 5 cm in one dimension on T2/FLAIR\r\n* Tumor that in the opinion of the site investigator, shows significant mass effect\r\n* Metastatic disease: Patients with =< 5 separate foci of metastatic disease not causing mass effect on adjacent parenchyma and each measuring less than 0.5 cm in maximum diameter will be eligible for this arm of the study; patients with diffuse linear leptomeningeal spread are not eligible for this arm of the study\r\n* Multi-focal disease: Patients with multi-focal parenchymal disease will be eligible for stratum C if the sum of the product of the maximum perpendicular diameters of all measurable non-contiguous lesions is less than 16 cm^2; in such cases, a minimum of 2 and a maximum of 5 “target” non-contiguous lesions will be selected; the lower size limit of the target lesion(s) should be at least twice the thickness of the slices showing the tumor to decrease the partial volume effect (e.g., 8 mm lesion for a 4 mm slice)Xx_NEWLINE_xXConfirmed locally advanced and/or metastatic solid tumor, with at least one tumor lesion of non-critical location accessible to biopsy (with exception of non-small cell lung cancer [NSCLC] participants), and with confirmed progression at baseline that has progressed on, or participant is intolerant to, the standard of care therapyXx_NEWLINE_xXLow tumor burden as defined by Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria (2):\r\n* No tumor mass (nodal or extranodal) >= 7 cm in one dimension on computed tomography (CT)\r\n* Fewer than 3 (2 or less) nodal masses > 3 cm\r\n* No systemic or B symptoms\r\n* No splenomegaly greater than 16 cm by CT scan\r\n* No risk of organ compression – ureteral, orbital, neurological, gastrointestinal\r\n* No leukemic phase (> 5.0 x 10^9/L circulating FL cells in the blood as detected by complete blood count [CBC] with differential and smear)\r\n* No cytopenias – absolute neutrophil count (ANC) < 1000 or platelets < 100,000Xx_NEWLINE_xXUnequivocal evidence of tumor progression as documented by biopsy or brain MRI scan per Revised Assessment in Neuro-Oncology (RANO) criteriaXx_NEWLINE_xXPhase II: if surgical resection/debulking prior to MLA is not indicated, a biopsy of the tumor will be done at the same time of MLA to obtain tumor tissue for both diagnostic purposes and immune monitoringXx_NEWLINE_xXELIGIBILITY FOR SCREENING: EBV positive tumor (can be pending)Xx_NEWLINE_xXAt least one endoscopically measurable tumor 6 - 10mm in diameterXx_NEWLINE_xX-  Confirmed diagnosis of HCC > 10 mm with a characteristic 4-phase CT or dynamic\n             contrast enhanced MRI finding showing intense arterial uptake followed by \washout\ of\n             contrast in the venous-delayed phases per American Association for the Study of Liver\n             Disease (AASLD) criteria.\n\n          -  Patients between ages 20 and 80\n\n          -  Patients with single or multiple (2-4 nodules) HCC who are unsuitable or unwilling for\n             surgical resection or RFA. The largest tumor nodule should be less than 10 cm in the\n             largest diameter. The total volume of tumor cannot exceed 50% of liver; or patients\n             with liver metastatic gastrointestinal cancer, including neuroendocrine tumor\n\n          -  Patients are candidates for TAE or Transarterial ChemoEmbolization (TACE). No tumor\n             invasion to portal vein or thrombosis in portal vein.\n\n          -  ECOG score 0-1 with no known cardiac, pulmonary or renal dysfunction\n\n          -  Child-Pugh score group A or B7 liver functional score\n\n          -  Prior local therapies such as surgical resection, radiofrequency ablation, or alcohol\n             injection are allowed as long as tumor progresses from the prior treatment and the\n             patients are still candidates for TAE. All prior therapy must be at least 4 weeks\n             prior to enrollment and free from treatment-related toxicity.\n\n          -  No TAE/TACE in the past\n\n          -  Patients have normal organ function: ANC ? 1000 /µL, Hemoglobin ? 9 gm/dL, Platelets ?\n             50,000 /µL, Creatinine ? 2 mg/dL, AST and ALT < 5 X upper normal limit of the current\n             institution; bilirubin ? 3.0 mg/dL, PT prolongation no more than 4 sec above upper\n             limit of normal.\n\n        For the expansion cohort of neuroendocrine tumor or metastatic gastrointestinal cancer\n\n          -  Unresectable, locally advanced or metastatic, well differentiated (low or intermediate\n             grade), neuroendocrine tumors (NET).\n\n          -  Liver metastatic gastrointestinal cancer.Xx_NEWLINE_xXTumor expression of NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) and/or reverse transcriptase polymerase chain reaction (RTPCR)Xx_NEWLINE_xXPatients with a histologic diagnosis of malignant pleural mesothelioma (MPM), epithelioid subtype, who in the opinion of the attending thoracic surgeon can receive a macroscopically complete resection of tumorXx_NEWLINE_xXPatients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocolXx_NEWLINE_xXPatients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excludedXx_NEWLINE_xXPatients with residual enhancing tumor that lies completely within 1-2 cm of the inner table of the skullXx_NEWLINE_xXPatients must be untreated with curative-intent surgery for current diagnosis of stage III, IVa, or IVb disease; diagnostic biopsy of primary tumor and/or nodal sites is permitted.  \r\n* Diagnostic simple tonsillectomy is permitted, provided patient has Response Evaluation Criteria in Solid Tumors (RECIST)-measurable residual tumor and/or nodal disease\r\n* Patients with a second HNSCC primary tumor are eligible for this study, provided more than 2 years have elapsed since the first diagnosis of HNSCC, the original tumor was managed with surgery only (no adjuvant chemotherapy/radiotherapy), and has not recurredXx_NEWLINE_xXRadiographic evidence of regional or distant metastases with suspected tumor in an area that is safe to biopsyXx_NEWLINE_xXWillingness to undergo a tumor biopsy at baseline and at disease progressionXx_NEWLINE_xXMedical contraindications to stopping aspirin, Coumadin or other anticoagulants prior to image-guided tumor biopsies; follow institutional guidelines when determining drugs to avoid and length of washoutXx_NEWLINE_xXCryoablation can be performed near vessels of the head and neck, and if deemed necessary tumor may be displaced using a saline injection (hydrodisplacement); tumor displacement from nerves may be required and will be performed as deemed appropriate to avoid nerve injuryXx_NEWLINE_xXTumor size not measurableXx_NEWLINE_xXEBV (+) nasopharyngeal carcinoma in the protocol treated tumorXx_NEWLINE_xXFor dose escalation: Subjects with any type of solid tumor (all comer) will be eligible for dose escalation and dose expansion at MTD in Part 1; Subjects enrolled for dose expansion (MTD expansion cohort \all comer\) will be stratified according to high fibroblast growth factor receptor (FGFR) expression levels / FGFR mutation using archival or fresh tumor biopsy materialXx_NEWLINE_xXINCLUSION - PROCUREMENT: Diagnosis of refractory or metastatic GD2-positive sarcoma not responsive to standard treatment; (patients with osteosarcoma do not require GD2 testing of their tumor)Xx_NEWLINE_xXInfra-tentorial tumorXx_NEWLINE_xXThe tumor must carry a genetic alteration of ALKXx_NEWLINE_xXPatient must have an original diagnosis, benefited by autologous transplantation, confirmed by biopsy* of solid tumor, including but not limited to: high-grade glial tumor, low-grade glial tumor, ependymoma, medulloblastoma, primitive neuro-ectodermal tumor (PNET), Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, retinoblastoma, or miscellaneous poor-prognosis solid tumors; lymphomas and other lymphoid malignancies will not be studied in this protocol\r\n* Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation; brain stem gliomas are defined as intrinsic tumors of the pons causing diffuse enlargement; these patients are diagnosed on clinical and radiographic appearance of the lesion and the biopsy requirement will be waived for this groupXx_NEWLINE_xXPatient must agree, as part of the informed consent, to provide blood and archived tumor samples for molecular correlates, pharmacokinetics and pharmacodynamics; patients in the expansion cohort A must have tumor sites that are accessible for tumor biopsy and must agree to undergo a pre-treatment and post-treatment biopsy; patients in cohort B group 3 and 4 must have tumor sites that are accessible for tumor biopsy and must agree to undergo a pre-treatment and post-treatment biopsy; this requirement may be waived after discussion with the principal investigator as long as a minimum of 5 patients in cohort B group 3 and 10 patients in cohort B group 4 are able to undergo the required biopsiesXx_NEWLINE_xXCOHORT A: Patients must have accessible tumor sites for biopsy and must agree to pre-treatment and post-treatment biopsiesXx_NEWLINE_xXCOHORT B, GROUP 4: HEAD AND NECK SQUAMOUS CELL CARCINOMA: Patients must not have evidence of major vessel involvement or encasement by tumor; a tumor abutting a major blood vessel may be allowed after review of scans with the radiologist and discussions with the principal investigator (PI)Xx_NEWLINE_xXContraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapyXx_NEWLINE_xXPatients enrolled at Dose Level 6 or higher in the phase I portion of the trial must have at least one tumor mass suitable and easily accessible for excisional biopsy, or alternatively, accessible for CT or ultrasound guided core needle biopsy. The procedure must be able to be performed with minimum morbidity.Xx_NEWLINE_xXPresence of known or suspected ongoing ischemia of non-tumor tissues includingXx_NEWLINE_xXPatients must have an accessible primary tumor or metastasis, and be willing to have a pre-treatment and post-treatment tumor biopsy (at 6 to 8 weeks after beginning)Xx_NEWLINE_xXNote: Patients may be enrolled more than once (e.g., for a new tumor)Xx_NEWLINE_xXSubjects must have demonstrated either tumor progression or recurrence by any of the radiographic criteria and/or clinical criteria as defined below:\r\n* Subjects with progressive non-resectable disease regardless of location in the brain or spine are eligible for this study; patients with evidence of leptomeningeal dissemination are eligible for this study; patients do not require biopsy/histologic confirmation at the time of progression or relapse\r\n* Radiographic progression is defined as > 40% increase in the product of the three perpendicular diameters of current tumor relative to the baseline measurement (defined as either the initial scan or scan at start of a previous therapy): length (L) x width (W) x transverse (T) (current scan) > 1.4 x L x W x T (baseline scan), or the development of any new sites of disease independent of the response of the initial tumor\r\n* Post radiation changes are often seen on post-treatment imaging studies, so that classification of a patient as having progressive disease may require several serial magnetic resonance imaging (MRI)’s if the child has received radiation within the preceding 12 months\r\n* Tumor volume includes the entire tumor volume seen on gadolinium enhanced T1 magnetic resonance (MR) imaging plus non-enhancing abnormality seen on T2 or fluid attenuated inversion recovery (FLAIR); coronal and axial images will be evaluated\r\n* All tumor cysts will be included in the tumor volume\r\n* Clinical progression without radiographic progression includes children with optic pathway gliomas who demonstrate sustained decrease in visual fields and/or acuity in three serial vision examinations; each of the vision examinations must be performed > 2 weeks apart\r\n* Children with previously negative cerebrospinal fluid (CSF) cytology who show evidence of tumor cells in fluid obtained by lumbar puncture can be designated as having progressive disease in the absence of radiographic evidence of progressionXx_NEWLINE_xXSubjects must be diagnosed with CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) based on the standard histologic and immunophenotypic criteria described in the World Health Organization (WHO) classification of lymphoid malignancies, including immunophenotypic confirmation that the tumor cells co-express B cell antigens cluster of differentiation (CD)19/20 and CD5; mantle cell lymphoma should be excluded based on positive staining of the tumor cells for CD23, or the absence of staining of the tumor cells for cyclin D1 or the absence of t(11;14); this diagnosis should be confirmed at a Dana-Farber Harvard Cancer Center institution (Dana-Farber Cancer Institute [DFCI], Brigham and Women's Hospital [BWH], Massachusetts General Hospital [MGH], Beth Israel Deaconess Medical Center [BIDMC]) within approximately one month after the subject is registered; any question on histology confirmation should be brought to the attention of the Principal InvestigatorXx_NEWLINE_xXEndometrial cancer\r\n* Patients at a higher risk of recurrence (because of either grade, myometrial invasion, lymphatic vascular space invasion, tumor size, lymph node status, tumor extension, presence or absence of surgical staging)\r\n* Patients who have suffered a recurrence at the vaginal cuff\r\n* Patients who are unable to undergo surgery and must have treatment for an inoperable primary endometrial cancerXx_NEWLINE_xXCriteria only for the randomized phase 2 part: mesothelin screen positive determined from archival tumor tissue and to be performed centrally. MSLN-positive is defined as >= 30% of tumor cells with membrane staining intensities >= 2+\r\n* For the run-in-phase 1, patients will not be selected based on the mesothelin expressionXx_NEWLINE_xXNSCLC patients with radiographic evidence of major airway or blood vessel invasion by cancer, radiographic evidence of intra-tumor cavitation, or gross hemoptysis (>= one teaspoon) within the preceding 2 months.Xx_NEWLINE_xXPatients with tumor morphology that predicts poor coverage of the majority of the tumor including bilateral thalamic involvement, or cysts that represent > 50% of cross-sectional areas of the pons. These subjects should be discussed with the study chairs.Xx_NEWLINE_xXSubjects with tumor amenable to potentially curative therapy per principal investigator (PI)Xx_NEWLINE_xXParticipants must be willing to undergo one mandatory on-study tumor biopsy following a 4 week, single cycle induction treatment of olaparib. A second on-study biopsy at time of disease progression is optional, but not mandatory.Xx_NEWLINE_xXLargest tumor =< 4 cm.Xx_NEWLINE_xXMalignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.Xx_NEWLINE_xXPatients with gastrointestinal stromal tumor (GIST) tumors and Kaposi’s sarcoma are excludedXx_NEWLINE_xXINCLUSION - TREATMENT: Pathologic review shows no evidence of residual disease in the tumor bed (to also include no evidence of residual ductal carcinoma in situ [DCIS])Xx_NEWLINE_xXINCLUSION - TREATMENT: Tumor bed should be no larger than 5 cm in size on pathologic reviewXx_NEWLINE_xXHas greater than 75% liver parenchyma replacement by tumorXx_NEWLINE_xXWillingness and ability to undergo mandatory tumor biopsy at baselineXx_NEWLINE_xXPatients are excluded if they had undergone tumor-­directed therapy within 3 monthsXx_NEWLINE_xXSubjects must have an area of tumor amenable to excisional biopsy for the generation of TIL separate from, and in addition to, a target lesion to be used for response assessment.Xx_NEWLINE_xXHER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testingXx_NEWLINE_xXHER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central) laboratory testingXx_NEWLINE_xXConfirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity ORXx_NEWLINE_xXDose Expansion cohort(s): subjects in the dose expansion cohorts must also have confirmation of tumor T790M mutation status (confirmed positive) by cobas® EGFR Mutation Test v2 from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) plasma sample taken after disease progression on the most recent treatment regimen (EGFR TKI or chemotherapy or other therapy).Xx_NEWLINE_xXHave at least 2 tumor lesions accessible for biopsyXx_NEWLINE_xXTarget tumor in region not in previously irradiated fieldXx_NEWLINE_xXSubjects must have at least one extra-central nervous system (CNS), non-bone tumor lesion amenable for IT injection ? 1.5 cm and that is not in close proximity or encasing crucial structures such as major blood vessels, trachea, nerve bundles etc.Xx_NEWLINE_xXThe primary tumor must be considered resectable by RP with gross negative margins as determined by a urologist. (Applicable to cohorts A and B1 only)Xx_NEWLINE_xXConfirmation of: a) Cohort A: MSI-H CRC either by immunohistochemistry (IHC) for loss of protein expression in one of 4 mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) or by detection of microsatellites within the tumor DNA as per institutional practices; b) Cohort B: CMS4 CRC classification on pretreatment primary tumor; c) Cohort C: MSI-H non-CRC solid tumor either by IHC for loss of protein expression in one of 4 mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) or by detection of microsatellites within the tumor DNA as per institutional practices.Xx_NEWLINE_xXSTRATUM C: Participants with recurrent, progressive, or refractory SHH Medulloblastoma and presence of either a or b as confirmed by central pathology review of the tumor specimen: a) copy number loss of 9q b) PTCH1 mutationXx_NEWLINE_xXDocumented activating EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples by Food and Drug Administration (FDA)-approved testXx_NEWLINE_xXWillingness to have 2 tumor biopsies; the first before and the second while on therapy (optional for all patients and may become mandatory in order to ensure 15 patients at maximum tolerated dose [MTD] have paired biopsies).Xx_NEWLINE_xXPatients who require immediate cytoreduction due to high risk of tumor lysis syndrome (ie, absolute lymphocyte count greater than 100k/uL)Xx_NEWLINE_xXMaximal tumor resection has been performed as feasibleXx_NEWLINE_xXAll subjects must agree to pre-treatment tumor biopsy; subjects in whom biopsy is technically not feasible or in whom would result in unacceptable risk, in the opinion of the investigator, may be exempted from the biopsy requirement with discussion with the principal investigatorXx_NEWLINE_xXHistological variants in the primary tumor, other than adenocarcinoma; for example: neuroendocrine tumor, small cell or sarcomatoidXx_NEWLINE_xXPatients must be willing to have archived tumor specimens utilized for correlative studies if availableXx_NEWLINE_xXHas at least 1 measurable solid RCC tumor and no RCC tumor that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Patients may have VHL disease-associated tumors in other organ systemsXx_NEWLINE_xXSubject provides consent for fresh paired tumor biopsy samples to be obtained at screening and after 4 weeks of treatment (not required for run-in cohort or expansion of run-in cohort).Xx_NEWLINE_xXSTUDY TREATMENT: An adequate pre-treatment tumor biopsy is required to confirm histologic diagnosis. Acceptable options include laparoscopic biopsy or image-guided core needle biopsy (minimum of two cores). Fine needle aspiration (FNA) biopsy or cytology from ascites is not adequate.Xx_NEWLINE_xXCity of Hope (COH) Clinical Pathology confirms HER2+ tumor expression by immunohistochemistry (>= 20%, 1+)Xx_NEWLINE_xXPatient has at least one (1) measurable papillary LG tumor, evaluated visually, ? 15 mm. The largest lesion should not exceed 15mm.Xx_NEWLINE_xXPatient should have at least one remaining papillary LG tumor evaluated visually with a diameter of at least 5 mm.Xx_NEWLINE_xXThe participant is diagnosed with gastrointestinal stromal tumor (GIST) or Kaposi sarcoma.Xx_NEWLINE_xXDose Escalation, Renal insufficiency, NSCLC and CPI-Treated Expansion Cohorts: For subjects with urothelial cancer and NSCLC: Subjects must submit a tumor tissue for Nectin-4 expression. Enrollment for these subjects is not dependent on the immunohistochemistry using the H-Score (IHC H-Score).Xx_NEWLINE_xXDocumentation of BRAFV600 wild-type status in melanoma tumor tissue through use of a clinical mutation test approved by the local health authorityXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXHas intermediate-high risk, high risk, or M1 NED RCC as defined by the following pathological tumor-node-metastasis and Fuhrman grading status:Xx_NEWLINE_xXM1 NED RCC participants who present not only with the primary kidney tumor but also solid, isolated, soft tissue metastases that can be completely resected at one of the following: the time of nephrectomy (synchronous) or, ?1 year from nephrectomy (metachronous).Xx_NEWLINE_xXNewly diagnosed brain cancer or tumor called glioblastoma or GBMXx_NEWLINE_xXTumor test result shows MGMT methylated or indeterminate tumor subtypeXx_NEWLINE_xXBiopsy-only of GBM with less than 20% of tumor removedXx_NEWLINE_xXAny known tumor outside of the brainXx_NEWLINE_xXNewly-diagnosed brain cancer or tumor called glioblastoma or GBMXx_NEWLINE_xXTumor test result shows MGMT unmethylated typeXx_NEWLINE_xXAny known tumor outside of the brainXx_NEWLINE_xXBiopsy with less than 20% of tumor removedXx_NEWLINE_xXPHASE I: Patients with recurrent, refractory, or progressive non-hematologic malignancies (central nervous system [CNS] or solid tumors) associated with activation of the RAS/RAF/ERK pathway, including any LGG, any tumor in a patient with NF1, or any tumor with a documented activating BRAF, NRAS, or KRAS mutation, will be eligible; LGG is defined as any World Health Organization (WHO) grade I or II (or equivalent) astrocytic, oligodendroglial, and/or glioneuronal tumorXx_NEWLINE_xXPHASE II: Patients with recurrent or progressive disease, as defined in the following three strata below, will be eligible; for eligibility determination, tumor imaging from at least two time-points must be available to document radiographic progression or recurrence; patients with non-progressive refractory tumors will not be eligible \r\n* Stratum 1: patients with LGG with a BRAF truncated fusion that is measurable in at least two dimensions on imaging\r\n* Stratum 2: patients with NF1 and LGG that is measurable in at least two dimensions on imaging\r\n* Stratum 3: pediatric patients with a recurrent or progressive tumor thought to involve the Ras/Raf/ERK pathway but not included in strata 1 or 2 that is measurable in at least two dimensions on imaging; this includes any LGG not included in strata 1 or 2 (i.e., any LGG without a BRAF truncated fusion in a patient without NF1), any tumor other than LGG in a patient with NF1, and any other tumor with a documented activating BRAF, NRAS, or KRAS mutation\r\n* Stratum 4 (surgical arm, target validation): patients who meet criteria for stratum 1, 2, or 3 for whom tumor biopsy and/or resection is clinically indicatedXx_NEWLINE_xXPHASE II: At least 3 months must have elapsed since the last dose of irradiation to the target tumor(s) at the time of enrollmentXx_NEWLINE_xXParticipant is willing to sign a screening consent and provide pre-trial tumor material for BRAF testing (both for BRAF V^600E mutation and BRAF KIAA1549 fusion assessments)\r\n* All patients who are candidates for enrollment in stratum 5 based on their tumor histology must be pre-screened\r\n* Screening may be applied to potential stratum 1 and 2 patientsXx_NEWLINE_xXPatients whose prior BRAF testing was performed at another lab (Clinical Laboratory Improvement Amendments [CLIA]/College of American Pathologist [CAP] certified or otherwise) must send additional tumor material to Brigham and Women's Hospital (BWH) for confirmation; however, to preserve available tumor material, patients whose tumor material has previously undergone BRAF analysis at the Lindeman and Ligon Labs at Brigham and Women’s Hospital using the same procedures as described in this protocol, will not be required to submit additional tumor material for analysis; these patients must have both the BRAFV600E mutation and BRAF KIAA1549 fusion assessments done and if only one test was previously conducted; additional tissue will be required for the second testXx_NEWLINE_xXNF-1 patients with radiographic evidence of a progressive, recurrent or refractory low grade glioma, with or without pre-treatment tumor tissueXx_NEWLINE_xXPatients will be assigned to one of 6 strata prior to enrollment; all BRAF assessments used for stratification below must be done at the Lindeman and Ligon Labs at Brigham and Women’s Hospital using the same procedures as described in this protocol; assessments for both BRAF V^600E mutation and BRAF KIAA1549 fusion are required for patients who will enroll on strata 1, 2 and 5 \r\n* Stratum 1: patients with non NF-1 associated progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAFV^600E mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively; patients with optic pathway glioma are excluded\r\n* Stratum 2: patients with non NF-1 associated progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and without a BRAF aberration i.e. BRAF^V600E mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively; patients with optic pathway glioma are excluded\r\n* Stratum 3: patients with neuro-fibromatosis 1 (NF-1) associated progressive, recurrent or refractory low grade glioma (World Health Organization [WHO] grade I & II), with or without tissue\r\n* Stratum 4*: patients with non-NF1 associated progressive, recurrent or refractory optic pathway glioma with or without tissue available for BRAF evaluation\r\n* Stratum 5: patients with non NF-1 associated progressive, recurrent or refractory low grade glioma other than pilocytic astrocytoma or optic pathway glioma with a documented BRAF aberration identified in pre-trial tumor material\r\n* Stratum 6: patients with non-NF-1 associated progressive, recurrent or refractory low grade glioma (other than optic pathway glioma [OPG]) with tissue available for BRAF analyses who cannot be classified into stratum 1, 2 or 5 due to inadequate tissue quality, assay failure, etc\r\n**Clarification: Stratum 4 was specifically designed for patients with hypothalamic/optic pathway gliomas; the intent is that if there is any optic chiasm invasion regardless of where the tumor is originating from (chiasm vs. hypothalamus vs. other location), the patient should be enrolled on Stratum 4, regardless of whether the tumor has been biopsied or not; obviously, there are some tumors that include part of the hypothalamus and clearly do NOT include the chiasm at all; in these situations, and if the tumor is a biopsy proven pilocytic astrocytoma, these patients should be enrolled on Stratum 1 or 2 (depending upon BRAF status)Xx_NEWLINE_xXPatients must have recurrence or progression of their low-grade glioma after coming off treatment with AZD6244 on PBTC-029 or PBTC-029B, with or without having received additional anti-tumor therapy following discontinuation of AZD6244; the progression must be unequivocal and sufficient to warrant re-treatment in the opinion of the investigator; progression will be defined as either progressive disease (PD) that meets the study definitions of progressive disease by MRI or vision deterioration thought to be related to tumor in patients with optic pathway tumorsXx_NEWLINE_xXAny tumor ER/PgR status, any HER-2/neu status as measured by local hospital pathology laboratory and meets any tumor assay profile described in protocol section 4.1.2FXx_NEWLINE_xXDocumentation of Disease:\r\n* Histologic Documentation: Well- or moderately-differentiated neuroendocrine tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local pathology\r\n** The pathology report must state ONE of the following: 1) well- or moderately-differentiated neuroendocrine tumor, 2) low- or intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical carcinoid tumor; documentation of histology from a primary or metastatic site is allowed\r\n** Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible\r\n* Stage: Locally advanced/unresectable or metastatic disease\r\n* Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic, gastrointestinal (GI), lung, or unknown primary site; GI, lung, and unknown primary NETs will enroll in the carcinoid tumor cohort of the study\r\n** Functional (associated with a clinical hormone syndrome) or nonfunctional tumors are allowed\r\n* Radiologic Evaluation: Target lesions must have shown evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating growth of existing lesions, development of new lesions, or treatment changes must be submittedXx_NEWLINE_xXEvidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib, or the subject with radiographic evidence of cavitating pulmonary lesion(s); or subjects with tumor invading or encasing any major blood vessels.Xx_NEWLINE_xXTumor MGMT promoter deoxyribonucleic acid (DNA) not methylated (i.e., unmethylated) by central testingXx_NEWLINE_xXMaximal tumor diameter of 6.6 cm or less; patients with multifocal tumors are allowed if the sum of the maximal tumor diameters does not exceed 6.6 cm; note, the maximal tumor diameter for the first 3 subjects enrolled will be 5 cmXx_NEWLINE_xXKnown mutation of the IDH1 or IDH2 genes in the tumor\r\n* Documentation that no IDH1 or IDH2 mutations are present in the tumor by a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory is required prior to initiation of study treatmentXx_NEWLINE_xXInfra-tentorial tumorXx_NEWLINE_xXTumor sample must be available for HPV p16 and PD-L1 testing and if oropharyngeal, must be tested for HPV p16Xx_NEWLINE_xXHas a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the patient has undergone potentially curative therapy with no evidence of that disease for five yearsXx_NEWLINE_xXPancreatic tumor size ? 5cmXx_NEWLINE_xXDirect invasion of the duodenum by the primary tumorXx_NEWLINE_xXTumor > 2.0 cm, nodal involvement, or metastatic involvementXx_NEWLINE_xXThe tumor must be at least 5 cm in maximum dimensionXx_NEWLINE_xXTumor accessible for biopsyXx_NEWLINE_xXNo individual tumor size is >50 mm3Xx_NEWLINE_xXTumor is not impinging on Middle Cerebral Artery/speech-motor stripXx_NEWLINE_xXSubjects with EGFR or ALK genomic tumor aberrations should have documented disease progression on FDA-approved therapy for these aberrations; subjects with EGFR or ALK genomic tumor aberrations who develop isolated brain metastases with good response outside the central nervous system (CNS) while on FDA-approved therapy for these aberrations may be included at the discretion of the treating oncologistXx_NEWLINE_xXIf tumor demonstrates EGFR or ALK genomic tumor aberrations, subject should have documented disease progression on FDA-approved therapy for these aberrationsXx_NEWLINE_xXTumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ? 50% of tumor cells (tumor proportion score [TPS] ? 50%) as assessed by immunohistochemistry at a central laboratory.Xx_NEWLINE_xXAdvanced solid tumor malignancy without curative optionsXx_NEWLINE_xXThe participant has tumor in contact with, invading, or encasing major blood vessels or radiographic evidence of significant cavitary pulmonary lesionsXx_NEWLINE_xXThe subject has pathologic evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXBaseline archival tumor specimen available or willingness to undergo a pretreatment tumor biopsy to obtain the specimen.Xx_NEWLINE_xXMalignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.Xx_NEWLINE_xXPatients must have at least one tumor amenable to serial biopsy in clinic or be willing to undergo serial biopsies through image-guided procedures during the neoadjuvant phase of the protocol. Patients must be willing to provide tumor samples at the time points.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed A) low lying (i.e. =< 6 cm from the anal verge) rectal adenocarcinoma eligible for concurrent chemoradiation therapy to rectal tumor, B) if the treatment is palliative in the metastatic setting, no additional requirements for tumor size or nodal involvement is needed; C) if the treatment is in the neoadjuvant setting, the tumor must ALSO be high-risk locally advanced rectal cancer defined as T3-4, N+, and/or at risk for a positive radial margin (as determined by the surgeon)Xx_NEWLINE_xXLocally advanced/borderline resectable HCC as defined by:\r\n* Solitary tumor > 5 cm OR\r\n* Unilobar multifocal disease either with > 3 tumors or one tumor > 3 cm OR\r\n* Bilobar disease with adequate future liver remnant, still technically resectable OR\r\n* High risk disease features (alpha-fetoprotein [AFP] > 200, or tumor > 3 cm with macrovascular invasion)\r\n* No extrahepatic spread, no nodal disease, and no bilateral left and right branch portal vein involvementXx_NEWLINE_xXRadiology evidence of reMB or recurrent grade III and IV glioma; patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologistXx_NEWLINE_xXHistologically confirmed diagnosis of high-grade glioma (any histology, including but not limited to glioblastoma, astrocytoma, and oligodendroglioma) in any tumor sample and presence of histone H3 K27M mutation by a Clinical Laboratory Improvement Act (CLIA)-approved immunohistochemistry or deoxyribonucleic acid (DNA) sequencing test on any glioma tumor sampleXx_NEWLINE_xXMaximum postoperative dimension of cavity plus residual contrast enhancing tumor of < 6 cm; if a patient is found on the radiation planning scan to have a tumor target larger than this size, the patient will be removed from the studyXx_NEWLINE_xXPatients must have a wild type or mutated RAS tumor status known prior to enrollmentXx_NEWLINE_xXMust have a growing tumor amenable to percutaneous image-guided cryoablation based on routine Interventional Radiology criteriaXx_NEWLINE_xXMetastatic poorly differentiated and/or high-grade neuroendocrine tumor/carcinoma originating outside of the lung (including unknown primary)Xx_NEWLINE_xXPatient has symptoms related to hormone production from tumor (i.e. functional tumor)Xx_NEWLINE_xXAny hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registrationXx_NEWLINE_xXBiopsy-proven benign or malignant brain tumor requiring tumor bed or tumor irradiation; this may include, but is not limited to, low-grade or favorable high-grade glioma, pituitary adenoma, vestibular schwannoma (acoustic neuroma), and meningioma as the most common diagnoses; other tumor types that require irradiation and are deemed appropriate for proton radiation therapy are also eligible; patients with a presumed diagnosis based on imaging and clinical characteristics will be permitted on this trial without pathological diagnostic confirmation if it is within standard of care to offer radiation therapy without a biopsyXx_NEWLINE_xXPatients must agree to consent for their tumor samples to be used for generation of cellular research tools such as organoidsXx_NEWLINE_xXAre diagnosed with gastrointestinal stromal tumor or Kaposi sarcoma.Xx_NEWLINE_xXEGFRvIII, the target antigen, must be identified on tumor tissue by immunohistochemistry (IHC) or polymerase chain reaction (PCR), i.e. EGFRvIII positive via pathology reportXx_NEWLINE_xXPatients with evidence of tumor in the brainstem, cerebellum, optic apparatus, or spinal cord, radiological evidence of actively growing multifocal disease, or leptomeningeal diseaseXx_NEWLINE_xXHistologically proven malignancy necessitating cranio-spinal irradiation; this will include patients with a diagnosis of medulloblastoma, supratentorial primitive neuroectodermal tumor (SPNET), disseminated ependymoma, embryonal tumor with abundant neuropil and true rosettes (ETANTR), atypical teratoid/rhabdoid tumor (ATRT), and disseminated low-grade glioma (LGG) or histologically confirmed germ cell tumor or elevated alpha-fetoprotein (AFP) (serum > 10 IU/L or cerebrospinal fluid [CSF] > than institutional norm) or B-HCG (serum or CSF > than institutional norm) in the setting of radiographic disease consistent with a germ cell tumor necessitating cranio-spinal irradiationXx_NEWLINE_xXPatients must have a tumor or plaque that is refractory to conventional treatment including but not limited to one of the following (up to 4 lesions in a single field of PDT or RT will be considered for treatment):\r\n* Plaque stage disease that has failed at least 2 skin directed therapies (including topical steroids) or refractory plaques despite at least one systemic therapy or plaques with evidence of folliculotropism\r\n* The presence of a tumor of MFXx_NEWLINE_xXEvidence of CD20 expression by immunohistochemistry or flow cytometry on the tumor specimen obtained with the biopsy performed with screeningXx_NEWLINE_xXThe tumor must be confined to the supratentorial compartmentXx_NEWLINE_xXThe patient must have completed chemoradiation with radiation therapy and temozolomide of the primary tumor according to standards of careXx_NEWLINE_xXTumor diameter in the plane perpendicular to LITT trajectory must be =< 3.5 cm in diameterXx_NEWLINE_xXIt must be the surgeon’s expectation that >= 90 of the tumor can be treated with LITT to the yellow TdT line (i.e. 43 degrees for 2 min)Xx_NEWLINE_xXTumor must be unifocal & unilateralXx_NEWLINE_xXPatients will be eligible regardless of whether they have had prior nephrectomy or still have their primary tumor in-situ.Xx_NEWLINE_xXParticipation in Iowa Neuroendocrine Tumor RegistryXx_NEWLINE_xXWilling to undergo the intra-tumoral (IT) injection of the poly-ICLC into the prostatic tumor as per the protocolXx_NEWLINE_xXFor disease-specific cohort participants: Must have an archival (banked) tumor sample or agree to have a new (fresh) tumor biopsy during the screening period. If a new tumor sample is needed, the disease should be accessible for a nonsignificant risk biopsy procedure (those occurring outside the brain, lung/mediastinum, and pancreas, or obtained with endoscopic procedures not extending beyond the stomach or bowel). For participants in the Western safety cohort, this biopsy is optional.Xx_NEWLINE_xXPatients with at least two liver tumor lesions with at least one with a diameter of 2 cm or bigger, which is amendable for (super-)selective TATE as the target lesion. Alternatively, patients with one intra-hepatic lesion of 2 cm or bigger and exhapetic lesion(s) are also acceptable.Xx_NEWLINE_xXSubjects without baseline tumor imagingXx_NEWLINE_xXNo suitable artery with a diameter greater than 4mm in proximity of at least one side of the tumor as determined by CT or MRIXx_NEWLINE_xXHas any evidence of small cell histology, or combined small cell and non-small cell histology, in original tumor biopsy or in screening biopsy performed since progression.Xx_NEWLINE_xXWillingness to undergo a fresh tumor biopsy pre-treatment and on treatment, if deemed safe and feasible by treating oncologist.Xx_NEWLINE_xXPatients who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy or paracentesis for tumor cells before therapy (at baseline) and after initiation of treatment (before cycle 2) for all subjects if this is clinically and safely feasible to do soXx_NEWLINE_xXPatients with anticipated contraindications to interval tumor reductive surgeryXx_NEWLINE_xXMust not have received immunotherapy, eg, tumor vaccines, within 42 days.Xx_NEWLINE_xXSubjects must have at least one target lesion in breast/chest wall/axilla which is amenable to application of high intensity focused ultrasound:\r\n* The distance from the skin: A targetable portion of the tumor must be ? 5 mm from the skin\r\n* The rib cage should not be in the prefocal ultrasound path or behind the target area of the lesion (minimum distance from the posterior aspect of the target area to rib cage must be at least 10 mm)\r\n* Subject’s tumor must be larger than 9 mm in the anterior-posterior dimension (measured by ultrasound)\r\n* Subject’s tumor must be greater than or equal to 0.3 cubic centimetersXx_NEWLINE_xXDocumented non-synonymous somatic mutation in NF1 in any tumor specimen or cell-free DNA assay by Clinical Laboratory Improvement Act (CLIA)-approved laboratoryXx_NEWLINE_xXThe subject has biopsy accessible tumor and is willing to undergo biopsy prior to planned protocol treatmentXx_NEWLINE_xXPatient has a tumor in the bladder diverticulumXx_NEWLINE_xXEvidence of active tumor lysis syndrome based on laboratory assessmentXx_NEWLINE_xXPathologically-proven diagnosis of a solid tumor malignancyXx_NEWLINE_xXPrevious tumor response to PD-1 or PD-L1 inhibiting therapy\r\n* Note: Tumor response is defined as complete response (CR), partial response (PR), or stable disease (SD) that is durable for at least 16 weeksXx_NEWLINE_xXFor Arms A-F, subjects must have biopsiable disease. For Arms A, B, and C, subjects must have at least two lesions amenable to biopsy and response evaluation. For Arms D, E, and F, subjects must have at least three lesions amenable to biopsy, response evaluation, and radiation. Tumor lesions used for biopsy should not be lesions used as RECIST target lesions.Xx_NEWLINE_xXTumor deemed accessible by metastatectomy (TIL harvest) which expects to yield > 1.5 cm^3 of resectable tumor amountXx_NEWLINE_xXSimultaneous primary cancers or separate bilateral primary tumor sitesXx_NEWLINE_xXPatients must agree to undergo two research biopsies of (a) malignant lesion(s); the investigator must also judge that the patient has tumor(s) safely accessible for biopsy; patients may be exempt from the second biopsy if after the performance of the first biopsy it is felt that a second biopsy would be unsafe for the patient; if the patient has only one Response Evaluation Criteria in Solid Tumors (RECIST) measurable target lesion for response assessment, research biopsies must not be performed on that target lesionXx_NEWLINE_xXThe subject must have EGFR and c-Met overexpressed in tumor as determined by immunohistochemistry (IHC) test score of 2+ for both markersXx_NEWLINE_xXThe subject has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXThe target tumor is limited to neuroblastoma; patients must have had histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines at the time of initial diagnosisXx_NEWLINE_xXAdvanced, solid tumor malignancy that is amenable to biopsy; patient must consent to 4 mandatory biopsies during studyXx_NEWLINE_xXPatients with tumor(s) invading a major vascular structure (e.g. carotid artery) or other key anatomical structure (e.g. pulmonary airway) in the event of post treatment tumor swelling and/or necrosis (hepatic and portal vein involvement allowed)Xx_NEWLINE_xXIntrahepatic lesion amenable to pre and post SBRT biopsies, unless the investigator determines that the tumor biopsies would be unsafeXx_NEWLINE_xXThe subject has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXTumor deemed amenable to biopsy by core for metastatic site or endoscopic biopsy for primary tumor (for both before and on-treatment biopsies)Xx_NEWLINE_xXMeasurable metastatic or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: reverse transcriptase-polymerase chain reaction (RT-PCR) on tumor tissue, tumor deoxyribonucleic acid (DNA) sequencing or any other Clinical Laboratory Improvement Act (CLIA) certified laboratory test on resected tissue; patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligibleXx_NEWLINE_xXPathological or clinical (i.e., by imaging) diagnosis of brain metastatic tumor lesionsXx_NEWLINE_xXPresence of inoperable tumor lesion/s from histologically confirmed solid tumors or lymphomas, in patients with at least one lesion ? 1 cm and suitable for intra-lesional injection, who have disease progression after treatment with available therapies, or who are intolerant to such treatmentsXx_NEWLINE_xXTotal tumor burden requiring ? 75 mL AvidinOX injectionXx_NEWLINE_xXPresence of unreachable (e.g. located in a region that cannot be reached by needle) or untreatable tumor lesions so that the benefit from the treatment of the treatable lesions does not justify patient's inclusionXx_NEWLINE_xXProgrammed death ligand 1 (PD-L1) expression on ? 1% of tumor cells by validated immunohistochemistry assayXx_NEWLINE_xXNeuroendocrine-like prostate cancer, based on histology OR based on clinical presentation as defined by meeting one of the two below criteria; all subjects must submit their primary tumor or metastatic biopsy pathology specimens to the Duke Cancer Institute where they will be centrally reviewed by Duke Pathology (Dr. Jiaoti Huang); central Duke pathologic review is not required for screening but rather for confirmation of histologic subtype; local pathologic review is sufficient for eligibility determination\r\n* Criterion 1: presence of 1 of 3 histologically proven diagnoses:\r\n** Primary small cell carcinoma of the prostate, defined by classic histologic features such as small tumor cells with scanty cytoplasm, darkly stained nuclei with homogeneous chromatin pattern; the tumor cells do not form glandular structure but grow as solid sheets with frequent mitotic figures and necrosis\r\n** Intermediate atypical carcinoma of the prostate, which has histologic features distinct from small cell carcinoma or adenocarcinoma; the tumor grows as solid sheets or vague glandular structures; the tumor cells have moderate amounts of cytoplasm and centrally located, round and regular nuclei with fine, granular and homogeneous chromatin; mitosis and necrosis are absent\r\n** Mixed histology tumors of the prostate, containing both adenocarcinoma and neuroendocrine or small cell components\r\n* Criterion 2: presence of histologically proven adenocarcinoma of the prostate without any sign of neuroendocrine or small cell histology that is radiographically progressing despite castrate levels of testosterone (< 50 ng/mL) with the following poor risk features:\r\n** Prior progression despite therapy with either abiraterone acetate and/or enzalutamide\r\n** At least one of the following:\r\n*** Liver metastases\r\n*** Bulky radiographic progression (>= 2 cm short axis lymph nodes or >= 1 cm long axis visceral metastases) combined with low serum PSA (< 10 ng/mL)\r\n*** High serum LDH (> 1 X upper limit of normal)Xx_NEWLINE_xXLymphoma that is amenable to safe pre-treatment and post-treatment biopsy; the safety of the procedures will be determined by the treating physician and the surgeon or other proceduralist, in consultation with the principal investigator (PI), and in accordance with standard clinical practice; acceptable sites of disease include, for example: (1) palpable tumor mass that is accessible under direct visualization or sonogram, (2) non-palpable tumor tissue that is accessible for biopsy under computed tomography (CT) or sonogram guidance, (3) bone marrowXx_NEWLINE_xXPatients who are currently undergoing other anti-tumor therapies or have concurrent active cancerXx_NEWLINE_xXHas at least one extracranial tumor safely treatable with radical-dose radiation therapyXx_NEWLINE_xX(Bevacizumab-related exclusion) History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor typeXx_NEWLINE_xXThe patient has a pathologic diagnosis of tumor biopsy or fine needle aspiration (FNA) of esophageal or gastric cancer of adenocarcinoma histologyXx_NEWLINE_xXUncontrolled tumor related painXx_NEWLINE_xXPatients who have previously received systemic topotecan for their tumorXx_NEWLINE_xXHistologically or cytologically confirmed, primary or recurrent, head and neck squamous cell carcinoma, including variants; patients must have at least one measurable lesion in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (tumor diameter >= 1 cm; short-axis lymph node diameter >= 1.5 cm) OR by caliper measurement (tumor diameter >= 1 cm); any diagnostic pretreatment biopsy sample is acceptable including fine needle aspiration (FNA)Xx_NEWLINE_xXParticipants must have disease amenable to and be willing to undergo serial core or excisional biopsies of a tumor lesion(s)Xx_NEWLINE_xXPrimary tumor not amenable to TORSXx_NEWLINE_xXMust have marker clip indicating location of target tumor in breastXx_NEWLINE_xXSubjects must not have an MRI defined target tumor that is within 10 mm of skin (defined as volume encompassing first 3 mm from skin surface)Xx_NEWLINE_xXSubject is HLA-A*02 positive and subject's tumor shows expression of the MAGE-A4 RNA or protein.Xx_NEWLINE_xXEither the primary tumor and/or the metastatic tumor must be RB positive as defined below:\r\n* RB status: the invasive tumor must have greater than 50% of tumor cells staining positive for RBXx_NEWLINE_xXConsent for tumor biopsies (for patients enrolled in stage 1 only) and blood draws for research purposes (for all patients)Xx_NEWLINE_xXEvidence of tumor expression of CA19-9 based on IHC performed on tumor samples or elevated serum levels (?1.5 x ULN) of CA19-9 considered secondary to tumorXx_NEWLINE_xXAny tumor mass greater than 10 cm in longest diameterXx_NEWLINE_xXPatients with a biopsy-proven adult-type high-risk soft tissue sarcoma (STS) in the trunk (non-retroperitoneal) or extremities. Histologies will include the most common adult-type STS such as undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, fibrosarcoma, synovial sarcoma, angiosarcoma, epithelioid sarcoma and malignant peripheral nerve sheath tumor. STS considered high-risk as defined below:\r\n* Tumors greater than or equal to 5 cm, intermediate or high grade according to French Federation of Comprehensive Cancer Centers (FNCLCC) criteria, and a location deep or superficial to fascia\r\n* Intermediate or high-grade tumors that are locally recurrent, metastatic or have had prior inadequate resections \r\n* Intermediate and high grade tumors shall be grade 2 or 3 based on FNCLCC parameters (Trojani et al, 1984; Coindre 2006)\r\n** Tumor differentiation\r\n*** Score 1 (sarcomas closely resembling normal adult mesenchymal tissue)\r\n*** Score 2 (sarcomas for which histological typing is certain)\r\n*** Score 3 (embryonal and undifferentiated sarcomas)\r\n** Mitotic count (HPF – high power field – 0.17 mm squared)\r\n*** Score 1 (0-9 mitoses per 10 HPF)\r\n*** Score 2 (10-19 mitoses per 10 HPF)\r\n*** Score 3 (greater than or equal to 20 mitoses per 10 HPF)\r\n** Tumor necrosis\r\n*** Score 0 (no necrosis)\r\n*** Score 1 (less than 50% tumor necrosis)\r\n*** Score 2 (greater than or equal to 50% tumor necrosis)\r\n** Histological grade\r\n*** Grade 1 – total score 2 or 3\r\n*** Grade 2 – total score 4 or 5\r\n*** Grade 3 – total score 6, 7 or 8Xx_NEWLINE_xXPatients with multiple primary lung tumors (defined below) are eligible:\r\n* Synchronous tumors (diagnosed within 6 months [mo]),\r\n** Different histology, \r\n** Same histology,\r\n** Second tumor in different lobed or lung;\r\n* Metachronous tumors (diagnosed > 6 mo apart),\r\n** Different histology,\r\n** Same histology,\r\n** Second tumor in different lobe or lung,\r\n** Tumor-free interval of at least 4 years (y)Xx_NEWLINE_xXPatients will be eligible if tumor is metastatic, unresectable, progressive, or if complete tumor resection is not considered to be feasible without substantial risk or morbidityXx_NEWLINE_xXThere will be no limit to number of prior myelosuppressive regimen for GIST or other tumor manifestations associated with NF1Xx_NEWLINE_xXMain portal vein tumor thrombusXx_NEWLINE_xXPatients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) N2-N3 nodal disease or T3-T4 primary tumorXx_NEWLINE_xXPrior surgical therapy other than incisional/excisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors; residual measurable tumor is required for enrollment on study as outlined aboveXx_NEWLINE_xX(For Cohort A) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST). (For cohort B) Clinical or radiologic primary tumor size of at least 1.5 cm prior to enrollment onto protocol 2014-0185 (ARTEMIS). Primary tumor of at least 1.0 cm or evidence of continued lymph node involvement by imaging (ultrasound or magnetic resonance imaging [MRI]) after adriamycin-based neoadjuvant therapyXx_NEWLINE_xX(For cohort B): Primary tumor sample collected before NACT started (on ARTEMIS) and underwent molecular testing for integral biomarkers including immunohistochemical assessment of FRalphaXx_NEWLINE_xXEvidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen or high likelihood of CD19 expression based on disease histologyXx_NEWLINE_xXDocumented HER2 overexpression or gene-amplified tumor by a validated approved methodXx_NEWLINE_xXMetastatic or unresectable AR+ triple-negative breast cancer (TNBC); AR positivity assessed centrally and defined as immunohistochemical (IHC) staining of >0% of tumor nuclei.Xx_NEWLINE_xXPatients are eligible if they undergo a targeted treatment recommended by the Molecular Tumor Board, excluding clinical trialsXx_NEWLINE_xXHistologic or cytologic diagnosis of NSCLC who have received previous intrathoracic radiation therapy with definitive intent and have a tumor recurrence in or near the prior irradiation fields; re-biopsy of the recurrence is not required and is left to the discretion of the treating physician, although every effort should be made to confirm recurrence pathologicallyXx_NEWLINE_xXDocumented ALK-rearrangement (or ROS1 rearrangement for phase I only) break-apart fluorescence in situ hybridization (FISH) (in >= 15% or tumor cells), or next generation sequencing assay performed on tumor sample or cell-­free DNA in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratoryXx_NEWLINE_xXPancreatitis that is active or within the preceding 3 months which in the judgment of the endoscopist would make tumor injection likely to trigger severe recurrent pancreatitisXx_NEWLINE_xXPrior therapy with tumor vaccineXx_NEWLINE_xXPatients with tumor morphology that predicts poor coverage of the majority of the tumor; this will be determined by the study chairs; patients with evidence of cystic changes greater than 1 cm in diameter will be excluded; these subjects should be discussed with the study chairsXx_NEWLINE_xXHas a diagnosis of low grade (G1 or G2), uni- or multifocal papillary appearing bladder tumor, stage Ta.Xx_NEWLINE_xXHas or has ever had: upper tract TCC; urethral tumor (prostatic urethra included); any invasive bladder tumor known to be other than tumor Ta, low-grade (G1-G2); any evidence of lymph node or distant metastasis; any bladder tumor with histology other than TCC; or carcinoma in situ (CIS).Xx_NEWLINE_xXHas a tumor in a bladder diverticulumXx_NEWLINE_xXFor subjects with recurrent tumor, the subject had at least a 6-month cystoscopically confirmed tumor-free interval between the last tumor recurrence and screening cystoscopic examination.Xx_NEWLINE_xXOriginal diagnosis has been confirmed through a histopathologic review of the primary tumor slides by an expert pathologist at the Principal Investigator's institutionXx_NEWLINE_xXSubjects that do not have a baseline tumor specimen/biopsy prior to starting study medications\r\n* Tumor specimens do not need to be at Jefferson at time of eligibility determination; tumor specimens held at outside institutions should be requested for analysis of pre-treatment tumor vs post-treatment tumorXx_NEWLINE_xXPancreatic target tumor diameter of ? 2.0 cm (shortest axis) to ? 6.0 cm (longest axis) and a minimum tumor volume of 14.0 cc as qualified by the central reading centerXx_NEWLINE_xXThe tumor must be accessible for injectionXx_NEWLINE_xXTumor which invades the ventricular system or located in the brain stemXx_NEWLINE_xXSubjects must have measurable disease (at least one target lesion) as defined by RECIST 1.1; target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollmentXx_NEWLINE_xXPrior therapy with talimogene laherparepvec, tumor vaccineXx_NEWLINE_xXNo individual tumor size is >50 mm3Xx_NEWLINE_xXTumor is not impinging on Middle Cerebral Artery/speech-motor stripXx_NEWLINE_xXPatients may be maintained on hormonal therapy provided there is clear evidence of tumor progressionXx_NEWLINE_xXIs not a candidate for local therapies, including liver transplantation, tumor ablation, transarterial embolization, or resectionXx_NEWLINE_xXPatient’s tumor(s) to be treated is(are) =< 5.0 cm or =< 250 cm^3Xx_NEWLINE_xXHistological confirmation of malignancy (primary tumor)Xx_NEWLINE_xXPatients that require urgent therapy due to tumor mass effects or spinal cord compressionXx_NEWLINE_xXA pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2); the primary tumor location should be known or believed to be midgutXx_NEWLINE_xXSomatostatin receptor (SSTR) positive sites as demonstrated by either SSTR2 positivity (2+ or 3+ intensity and greater than 10% tumor cell occupying the receptors) or a nuclear medicine scan utilizing 111In-DTPA-phe3-octreotide (Octreosca) or 68Ga-DOTA-tyr3-octreotide within 12 months prior to anticipated cycle 1 day 1 (C1D1) demonstrating SSTR positive tumor sitesXx_NEWLINE_xXSubjects must demonstrate at least one of the following:\r\n* One or more MIBG+ and DOTATOC- tumors in addition to one or more DOTATOC+ tumors\r\n* One or more tumor sites where the calculated \safe\ radiation tumor dose is higher by at least 25% with a combination of 131I-MIBG and 90Y-DOTATOC than it is with 90Y DOTATOC aloneXx_NEWLINE_xXTumor mitotic rate > 20/10 high-power field (hpf) and/or Ki67 index > 20% (if available)Xx_NEWLINE_xXAt the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysisXx_NEWLINE_xXAll patients must have histologic proof of solid tumor malignancy and radiographic evidence of spine metastasisXx_NEWLINE_xXPatients with greater than 50% liver tumor burdenXx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Histological documentation of overexpressing mesothelin at the moderate (2+) or stronger (3+) level in at least 30% of tumor cells as determined by immunohistochemistry (IHC)Xx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Extent of baseline tumor burden will not interfere with causal assessment of treatment-emergent hepatotoxicity, at the investigator’s discretionXx_NEWLINE_xXPatients must have histologically-proven, recurrent supratentorial grade IV glioblastoma (or grade III IDH-wildtype anaplastic astrocytoma), for which a complete surgical resection is unsafe due to location, shape, or size of the tumor. Diagnosis of recurrence will be established by biopsy and frozen section immediately prior to initiating LITT procedure. If findings on frozen section are not consistent with recurrence (glioblastoma or recurrent IDH-wildtype anaplastic astrocytoma), decision to proceed with LITT procedure will be at the discretion of the neurosurgeon (only patients with histologically-proven recurrent tumor will be evaluable for efficacy).Xx_NEWLINE_xXIn the context of this clinical trial, a lesion suitable for LITT is single, enhancing, supratentorial, at least 2 cm from inner table of skull over the hemispheric convexity, and > 1 cm, but < 4 cm in cross-sectional dimension, including thalamic tumor (=< 3 cm).Xx_NEWLINE_xXUnresectable primary tumor or regional disease or distant metastasesXx_NEWLINE_xXAnti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, andXx_NEWLINE_xXPrimary tumor excised by radical inguinal orchiectomy and pathology consistent with pure seminoma with negative surgical marginsXx_NEWLINE_xXSubjects must have measurable plexiform neurofibroma(s) amenable to volumetric MRI analysis; the target lesion must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumor of interest; tumors must be at least 3 milliliter (mL) in volume (most plexiform neurofibromas [PN] 3 cm in longest diameter will meet this criteria); if the tumor is < 3 cm in longest diameter, the patient may still be eligible; central review of the MRI of the target plexiform is required prior to enrollment to ensure that the tumor is measurable and amenable to volumetric analysisXx_NEWLINE_xXPatients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 monthsXx_NEWLINE_xXThe subject has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of XL184 (cabozantinib)Xx_NEWLINE_xXPatient must provide a tumor biopsy as the time of progression on Arm B; if a patient does not have a tumor lesion amenable of biopsy or it has been unsafe for a biopsy to be performed, cross-over will be allowedXx_NEWLINE_xXPatients who have noncanonical DNA repair defects and extensive visceral disease or symptomatic bone disease requiring urgent tumor responseXx_NEWLINE_xXHas tumor primarily localized to the brainstem or spinal cordXx_NEWLINE_xXTumor accessible and participant consents to undergo fresh tumor biopsies.Xx_NEWLINE_xXTumor type:Xx_NEWLINE_xXHas archive tumor tissue from primary tumor or metastatic site (excluding bone), for which the source and availability have been confirmed.Xx_NEWLINE_xXTumor must be supratentorial onlyXx_NEWLINE_xXStereotactic biopsy will not be allowed unless there is plans for second surgery to remove >= 80% of the tumorXx_NEWLINE_xXCELL PROCUREMENT: Subjects must not have tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXLYMPHODEPLETION: Subjects must not have tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXHistologic diagnosis for which single-agent doxorubicin is NOT appropriate therapy, including but not limited to:\r\n* Alveolar or embryonal rhabdomyosarcoma\r\n* Ewings sarcoma or primitive neuroectodermal tumor (PNET)\r\n* Osteosarcoma\r\n* Gastrointestinal stromal tumor (GIST)Xx_NEWLINE_xXPatients should have microsatellite stable (MSS) tumor by polymerase chain reaction (PCR) assay or mismatch repair protein proficient (MMRP) tumor by immunohistochemistry as confirmed by the presence of MLH1, MSH2, MSH6, and PMS2; the diagnosis of colorectal cancer should be confirmed by pathology either on the primary tumor or from a prior biopsy of a metastatic disease siteXx_NEWLINE_xXNo more than 42 days should elapse from the day study-specific tumor sample is taken at initial diagnosis (or subsequent procedure) to the time of the first intake of ODM-201.Xx_NEWLINE_xXSubject that underwent excisional biopsy of the primary tumor.Xx_NEWLINE_xXDirect tumor extension into the stomach, duodenum, small bowel or large bowelXx_NEWLINE_xXAt the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysisXx_NEWLINE_xXPatient must consent to two mandatory biopsies and have tumor amenable to biopsyXx_NEWLINE_xXWilling to undergo tumor biopsy at baseline and during treatment (during week 6 or 7); please note that tumor biopsy is not needed in subjects where the tumor is not accessible or if tumor biopsy is considered not in patient’s best interestXx_NEWLINE_xXLocally advanced breast cancer defined as any of the following per American Joint Committee on Cancer (AJCC) staging criteria:\r\nNote: imaging methods that may be used for tumor measurement to determine eligibility include breast ultrasound and breast magnetic resonance imaging (MRI); mammography may not be used\r\n* T2 based on tumor measurements by physical examination or imaging with clinically positive regional lymph nodes (cN1 or cN2), irrespective of hormone receptor status\r\n* Hormone receptor-negative patients with tumor size of 3-5 cm measured by physical examination or imaging with clinically negative regional lymph nodes (cN0)\r\n* Any T3 based on tumor measurements by physical examination or imaging, irrespective of hormone receptor status\r\n* Any T4 (including inflammatory breast cancer), irrespective of hormone receptor statusXx_NEWLINE_xXIs medically able and willing to undergo needle biopsy of a tumor lesion; PD-L1 expression is not required to enroll in the trialXx_NEWLINE_xXOligometastatic disease or unresectable primary abdominal malignancy with biopsy-proven primary disease histology of solid tumor categorization; patients with a diagnosis of hepatocellular carcinoma do not require a biopsyXx_NEWLINE_xXPatients must have recurrent disease, histologically proven or imaging suggestive of recurrent disease as determined by principal investigator (PI); prior implantation of Gliadel wafers is acceptable, if tumor recurrence is confirmed by histologic examination of the recurrent tumorXx_NEWLINE_xXPatients must agree to enroll on the Neuro-Oncology Branch (NOB) Natural History protocol to allow the assessment of molecular tumor markersXx_NEWLINE_xXHave histologically or cytologically documented HCC (documentation of original biopsy for diagnosis is acceptable if tumor tissue is unavailable) or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required; for subjects without cirrhosis histological confirmation is mandatoryXx_NEWLINE_xXTumor size less than 5 mmXx_NEWLINE_xXPathologic confirmation of solid tumor, including central nervous system tumor or lymphoma, or leukemiaXx_NEWLINE_xXPhase 2 patients are also excluded if they had prior treatment with CK-101 or other third generation TKIs that target EGFR T790M mutation-positive NSCLC, or have evidence that the tumor harbors an exon 20 insertion mutationXx_NEWLINE_xXPatients are excluded if they have liver tumor volume > 50%Xx_NEWLINE_xXSubjects who have undergone at least six months of chemotherapy without radiologic progression of the tumor burdenXx_NEWLINE_xXWillingness to provide consent for biopsy samples; tumor biopsies will be required for all subjects, tumor lesions used for biopsy should not be lesions used as RECIST target lesions, unless there are no other lesions suitable for biopsy; if a RECIST target lesion is used for biopsy the lesion must be >= 2 cm in longest diameterXx_NEWLINE_xXAn inadequate tumor specimen as defined by the local pathologistXx_NEWLINE_xXAt least one lesion (metastasis or primary tumor) being considered accessible by non-high-risk collection procedures for biopsy.Xx_NEWLINE_xXACTolog target expression as evaluated by the in vitro diagnostic device IMA_Detect: Patient's tumor must express at least one ACTolog target as assessed by quantitative PCR (qPCR) (to be assessed from a tumor biopsy to be performed if all other eligibility criteria are met).Xx_NEWLINE_xXSubjects that do not have a baseline tumor specimen/biopsy prior to starting study medications\r\n* Tumor specimens do not need to be at Jefferson at time of eligibility determination; tumor specimens held at outside institutions are not a reason for exclusion; samples from outside institutions should be requested for analysis of pre-treatment tumor versus (vs) post-treatment tumorXx_NEWLINE_xXPancreatic tumor size =< 5 cmXx_NEWLINE_xXInaccessible tumor or lack of consent for sequential biopsiesXx_NEWLINE_xXThe tumor must be supratentorialXx_NEWLINE_xXPHASE II: Patients must have measurable disease according to RECIST 1.1 criteria that is amenable to biopsy and be willing to undergo pre- and post-treatment tumor biopsies; lesions to be biopsied do not have to be those used for measurementXx_NEWLINE_xXSince selumetinib is not expected to cause substantial myelosuppression, there will be no limit to number of prior myelosuppressive regimens previously received for NF1 related; or other tumor manifestationsXx_NEWLINE_xXAt least 4 weeks must have elapsed since receiving medical therapy directed at NF1 related tumor manifestationsXx_NEWLINE_xXMay not have a NF1 related tumor such as optic pathway glioma or malignant peripheral nerve sheath tumor, which requires treatment with chemotherapy, radiation, or surgeryXx_NEWLINE_xXWilling to provide tumor tissue amenable to ultrasound or computed tomography (CT)-guided biopsy for biomarker analyses\r\n* Patients with malignant ascites are permitted to participate and provide ascites samples for biomarker analyses\r\n* Patents receiving radiation to a single metastatic site in which only the primary tumor is accessible for biopsy by endoscopy will also be eligibleXx_NEWLINE_xXPatients must have multiple tumor lesions (at least 2): one for the ablation procedure and another for evaluation located outside the proposal ablation zoneXx_NEWLINE_xXPrimary tumor >= 3 cm (for all stages entered) to increase the likelihood that excess tumor will be available after resectionXx_NEWLINE_xXConcurrent administration of any other anti-tumor therapyXx_NEWLINE_xXPrimary tumor of the nasopharynx (nasopharyngeal carcinoma)Xx_NEWLINE_xXSubjects must have at least 1 lesion that is measurable by irRECIST\r\n* A previously irradiated lesion can be considered a target lesion if the lesion is well defined, measurable per irRECIST, and has clearly progressed\r\n* Subjects undergoing fresh tumor biopsies must have additional non-target lesions that can be biopsied at acceptable risk as judged by the investigator or if no other lesion suitable for biopsy, then an irRECIST target lesion used for biopsy must be >= 2 cm in longest diameterXx_NEWLINE_xXAble and willing to give valid written consent for available archival tumor samples or fresh tumor biopsies/resectionsXx_NEWLINE_xXHistologically confirmed solid tumor malignancy for which no curative therapy exists with at least 25% of tumor cells expressing mesothelin as determined by NCI Laboratory of Pathology; determination can be made using archival tumor tissue or fresh biopsy; subjects with epithelioid mesothelioma and pancreatic adenocarcinoma are automatically eligible and are not required to have this testXx_NEWLINE_xXLow tumor burden according to GELF criteria defined as:Xx_NEWLINE_xXNo leukemic phase >5,000/µL circulating tumor cells.Xx_NEWLINE_xXMaximal contiguous volume of tumor based on high b-value diffusion MRI < 1/3 volume of brainXx_NEWLINE_xXRecurrent glioma, or tumor involving the brainstem or cerebellum; prior low-grade glioma without prior RT, now with malignant progression are eligibleXx_NEWLINE_xXBased on clinical and radiographic evidence the tumor needs to be deemed resectable preoperatively by the surgeon and when necessary (determined by the surgeon) tumor board reviewXx_NEWLINE_xXPatients deemed to have un-resectable disease by the treating surgeon or upon tumor board reviewXx_NEWLINE_xXPatients with unresectable tumorXx_NEWLINE_xXHistologic or cytologic confirmation of advanced solid tumor.Xx_NEWLINE_xXTumor amenable to biopsy will be mandatory for this studyXx_NEWLINE_xXPK/PD/biomarker/metabolite expansion cohort(s) only: Subjects must consent to pre- and post-dose tumor biopsies and additional sample collection procedures.Xx_NEWLINE_xXTumor size > 4cm in largest dimensionXx_NEWLINE_xXResectable primary tumor of the head, body or tail of the pancreas defined per National Comprehensive Cancer Network (NCCN) guidelines version 2.2015:\r\n* No extra-pancreatic disease, aside from lymphadenopathy\r\n* No arterial tumor contact (celiac axis, superior mesenteric artery, or common hepatic artery)\r\n* No tumor contact with the superior mesenteric vein or portal vein or =< 180 degree contact without vein contour irregularityXx_NEWLINE_xXRadio-opaque markers must be present within the tumor bed; in patients who have undergone surgical resection, radio-opaque surgical clips within the tumor bed can be used as fiducials; patients without surgical clips in the tumor bed must be able to have fiducials placed endoscopically, laparoscopically, or through a computed tomography (CT)- or ultrasound-guided technique; if not, the tumor must be posterior and adjacent to the aorta, and treatment will only be permitted at the discretion of the principal investigatorXx_NEWLINE_xXPatients with evidence of gross tumor invasion into the lumen of the stomach or small bowel are not eligible; if imaging suggests luminal invasion of tumor, this must be ruled out endoscopically before the patient can be enrolled on studyXx_NEWLINE_xXPatients must be untreated with curative-intent surgery for current diagnosis of stage III, IVa, or IVb disease; diagnostic biopsy of primary tumor and/or nodal sites is permitted\r\n* Diagnostic simple tonsillectomy is permitted, provided patient has Response Evaluation Criteria in Solid Tumors (RECIST)-measurable nodal disease\r\n* Patients with a second HNSCC primary tumor are eligible for this study, provided more than 2 years have elapsed since the first diagnosis of HNSCC, the original tumor was managed with surgery only (no adjuvant chemotherapy or radiotherapy), and has not recurredXx_NEWLINE_xXA minimum tissue requirement of >= 3 core biopsies with tumor involvement and at least 50% tumor involvement in one of the core biopsies is requiredXx_NEWLINE_xXCohort C – Renal cell carcinoma (> pT1b); must have radiologic suspicion or histological proof of clear cell renal cell carcinoma >= 4 cm with no evidence of metastatic disease; patient with any degree of tumor extension into the renal vein are not eligible; patients must be candidates for contrast-enhanced ultrasound (CEUS) imaging and agree to undergo this additional imaging techniqueXx_NEWLINE_xXCentral lung lesions involving major blood vessels (arteries or veins) or a tumor encasing major blood vessels (i.e. carotid artery)Xx_NEWLINE_xXPaired, pre- and post-treatment, tumor biopsy is optional for subjects enrolled in the Dose Escalation and Food-effect cohortsXx_NEWLINE_xXPaired tumor biopsy is mandatory for all subjects enrolled in the Expanded cohort; subjects should agree to and be eligible for paired tumor biopsyXx_NEWLINE_xXRelapsed, refractory, or recurrent malignancy; all solid tumor diagnoses will be eligibleXx_NEWLINE_xXWell-circumscribed, measurable intraparenchymal brain lesion(s) with maximum tumor diameter =< 3.0 cm; if multiple lesions are present, the other(s) must not exceed 3.0 cm in maximum diameter; at least one lesion must be >= 0.5 cm in maximum diameter to be considered measurable diseaseXx_NEWLINE_xXThe primary tumor in the colon or rectum may be intact or resectedXx_NEWLINE_xXTumor characteristics - any of the following are excluded:\r\n* Evidence of distant metastases\r\n* Tumors whose location is restricted to the tubular esophagus (i.e., without involvement of the GEJ or cardia)\r\n* Tumors whose proximal end are at the level of the carina or higher\r\n* Invasion of the tracheobronchial tree or presence of tracheoesophageal fistula\r\n* Palpable supraclavicular nodes, biopsy-proven involvement of supraclavicular nodes, or radiographically involved supraclavicular nodes (> 1.5 cm in greatest dimension)\r\n* T1N0M0, T4Nany, or in situ carcinoma\r\n* Tumor must not extend 5 or more cm into the stomachXx_NEWLINE_xXHave biopsiable disease; subjects must have at least one lesion amenable to biopsy; tumor lesions used for biopsy should not be lesions used as RECIST target lesions; in cohort 9: paraganglioma-pheochromocytoma or cohort 10, where there is prominent bony disease, biopsies may not be possible due to the nature of the diseaseXx_NEWLINE_xXDose Expansion Cohort Group 1 and 2: At least one tumor lesion amenable to repeat core needle biopsy or punch biopsy without unacceptable risk of a major procedural complicationXx_NEWLINE_xXPatients who do not have other options of treatment, based on consensus recommendation of the multidisciplinary SSRS tumor board; patients will have an appropriate medical oncologist for their diseaseXx_NEWLINE_xXPrior treatment with programmed cell death (PD)-1, PD-ligand (L)1, cytotoxic T lymphocyte-associated protein 4 (CTLA 4) targeted therapy, or tumor necrosis factor receptor superfamily (TNFRSF) agonists including CD134 (OX40), CD27, CD137 (4-1BB), and CD357 (glucocorticoid-induced tumor necrosis factor receptor family-related protein [GITR])Xx_NEWLINE_xXEvidence of CD19 expression on any prior or current tumor specimen or a high likelihood of CD19 expression based on disease histologyXx_NEWLINE_xXDocumentation of CD19 expression on any prior or current tumor biopsyXx_NEWLINE_xXEvidence of ROR1 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimenXx_NEWLINE_xXLow tumor burden with at least one lesion that is suitable for image-guided intratumoral injection and needle biopsy.Xx_NEWLINE_xXAllergy to lidocaine, fentanyl, midazolam, or propofol (may be used during tumor biopsy or injection)Xx_NEWLINE_xXPrevious pathologic confirmation of a tumor treated with radiation to the brain completed at least 6 months prior to the start of planned reirradiation, except for patients with tumors that are routinely diagnosed without biopsy, including germinoma and optic pathway glioma; patients with a history of cranial irradiation for leukemia are eligibleXx_NEWLINE_xXPRIOR TO CELL PROCUREMENT: Tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXPRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXGross disease within the breast must be unifocal; (patients with microscopic multifocality are eligible as long as the total extent of tumor, gross and microscopic, occupies a volume with greatest dimension 3 cm or less)Xx_NEWLINE_xXPathologically confirmed advanced solid tumor cancersXx_NEWLINE_xXThe presence of the target antigen, EGFRvIII, must be identified on tumor tissue by immunohistochemistry (IHC) or polymerase chain reaction (PCR)Xx_NEWLINE_xXUnequivocal evidence of tumor progression during prior bevacizumab treatment per RANO criteria.Xx_NEWLINE_xXTumor located entirely in the infratentorium.Xx_NEWLINE_xXPHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Patients must have completed standard radiation therapy with concurrent temozolomide (TMZ) within 5 (weeks) wks of enrollment and must not have evidence of progressive disease on post treatment imaging; progression can only be defined using diagnostic imaging if there is new enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line) or if there is unequivocal evidence of viable tumor on histopathologic sampling(e.g., solid tumor areas [i.e,> 70% tumor cell nuclei in areas], high or progressive increase in mindbomb homolog 1[MIB-1] proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor); Note: given the difficulty of differentiating true progression from pseudoprogression, clinical decline alone, in the absence of radiographic or histologic confirmation of progression, will not be sufficient for definition of progressive disease in the first 12 weeks after completion of concurrent chemoradiotherapyXx_NEWLINE_xXPHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Has tumor localized primarily to the posterior fossa, spinal cord, or an unresectable locationXx_NEWLINE_xXPHASE I: Tumor localized primarily to the posterior fossa or spinal cordXx_NEWLINE_xXPatients that require urgent therapy due to tumor mass effects or spinal cord compressionXx_NEWLINE_xXPatient must be willing to consent to MSKCC protocol 12-245 (“Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy”)Xx_NEWLINE_xXEvidence of > 1 area of CIS not associated with papillary tumor at this timeXx_NEWLINE_xXPrior treatment with radiotherapy or chemotherapy for a brain tumor, irrespective of the grade of the tumorXx_NEWLINE_xXPatients must be able to have fiducials placed; if not, the tumor must be posterior and adjacent to the aorta and treatment will only be permitted at the discretion of the principal investigatorXx_NEWLINE_xXPresence of duodenal or gastric invasion by the tumor as noted by esophagogastroduodenoscopy (EGD) at time of fiducial placementXx_NEWLINE_xXTumor =< 12 cm from anal verge as determined by MRI or endoscopyXx_NEWLINE_xXNo clinically detectable (MR, endoscopy or digital rectal examination [DRE]) tumor presentXx_NEWLINE_xXPatients with del(17p) by FISH (or known tumor protein p53 [TP53] mutation)Xx_NEWLINE_xXThere is no specific tumor size cut-off for this protocol; however, the radiation treatment plan must meet the protocol’s dose constraintsXx_NEWLINE_xXTumor size must be >= 2 cm in the longest dimensionXx_NEWLINE_xXPlease note that tumor samples for patients with MF or SS can be CD30 negative and do not have to be CD30 positive on either flow cytometry or immunohistochemistry for patients to be eligibleXx_NEWLINE_xXAn archival tumor specimen or newly obtained tumor sample may be submitted at screening/baseline (a fresh tumor sample is preferred), unless agreed differently between Novartis and the Investigator.Xx_NEWLINE_xXNo evidence of disease progression: defined as increase in tumor size of > 25% or new lesionsXx_NEWLINE_xXIf a primary tumor is in place, it must be asymptomaticXx_NEWLINE_xXTumor replacement =< 50% of total liver volumeXx_NEWLINE_xXSignificant extrahepatic disease\r\n* Symptomatic extrahepatic disease (including primary tumor, if unresected)\r\n* Greater than 10 pulmonary nodules (each =< 20 mm in diameter) or combined diameter of all pulmonary nodules > 15 cm\r\n* Peritoneal carcinomatosisXx_NEWLINE_xXJUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients must have either measurable disease per Response Criteria in Solid Tumors (RECIST) version (v)1.1 or evaluable disease defined as an elevated tumor biomarker (CA19-9, carcinoembryonic antigen [CEA] or circulating free deoxyribonucleic acid [cfDNA] mutation); pancreatic cancer patients with an elevated tumor marker following a primary pancreatic surgery would be eligibleXx_NEWLINE_xXEvidence of MCPyV TAg tumor expression by immunohistochemistry on any prior or current tumor specimen or viral oncoprotein antibody confirmation within 6 weeks of the start of study interventionXx_NEWLINE_xXHistologically confirmed grade 2 or 3 soft tissue sarcoma that is unresectable or metastatic; surgery for primary or metastatic disease after chemotherapy following a response is allowed; patients with the following tumor types are eligible:\r\n* Undifferentiated pleomorphic sarcoma\r\n* Leiomyosarcoma\r\n* Malignant fibrous histiocytoma\r\n* Liposarcoma (myxoid/round cell, pleomorphic or dedifferentiated)\r\n* Synovial sarcoma\r\n* Myxofibrosarcoma\r\n* Angiosarcoma\r\n* Fibrosarcoma\r\n* Malignant peripheral nerve sheath tumor\r\n* Epithelioid sarcoma\r\n* Unclassified high-grade sarcoma (not otherwise specified)\r\n* Soft tissue sarcoma for which treatment with an anthracycline is appropriate at the approval of the principal investigator (PI)Xx_NEWLINE_xXNewly diagnosed, histologically proven (or strongly suspected, see below) T1-T2aN0M0 (Stage IA-IB) non-small cell lung cancer (NSCLC), with maximum tumor diameter =< 5 cm under consideration for stereotactic ablative body radiotherapy (SABR) as definitive primary treatmentXx_NEWLINE_xXSubjects must be willing to undergo malignancy genotyping for tumor protein 53 (TP53) mutation, insertion, or deletion at screeningXx_NEWLINE_xXPatient has a tumor amenable to injection of Toca 511 (ie, ? 2 cm and not close to or invading major vessels).Xx_NEWLINE_xXPatients acceptance to have a tumor biopsyXx_NEWLINE_xXNeed for urgent or emergent nephrectomy to relieve symptoms relating to the primary tumorXx_NEWLINE_xXAt least one tumor must qualify to be an index lesion for modified WHO criteria.Xx_NEWLINE_xXSubjects with conditions that carry high anesthetic risk in the opinion of the treating anesthesiologist are not eligible (i.e. subjects with significant airway compression by tumor or craniofacial abnormalities).Xx_NEWLINE_xXTumor may not extend greater than 4 cm below the gastroesophageal junctionXx_NEWLINE_xXUnequivocal metastatic tumor at baselineXx_NEWLINE_xXContrast-enhancing tumor component crossing the midline, multi-focal tumor, or tumor dissemination (subependymal or leptomeningeal)Xx_NEWLINE_xXPatients considered for enrollment are strongly recommended to have been discussed at multidisciplinary tumor board with input from surgery, medical oncology and radiation oncology prior to enrollmentXx_NEWLINE_xXcPoP study: any tumor with at least 2 (sub)cutaneous tumor/metastases at least 2 cm apart which are RT naïve with an indication for high dose palliative RTXx_NEWLINE_xXWilling to have tumor biopsies collected in cPoPXx_NEWLINE_xXTumor PD-L1 status, with Immunohistochemical (IHC) assay confirmed by a reference laboratory, must be known prior to randomization.Xx_NEWLINE_xXPatients must have an extra-cranial primary tumor diagnosisXx_NEWLINE_xXAdjacent tumor location to optic apparatus or brainstem, precluding achievement of meaningful dose with SRSXx_NEWLINE_xXPrimary brain tumorXx_NEWLINE_xXA single liver lesion with tumor size >= 3 cmXx_NEWLINE_xXMaximum tumor size of 7 cmXx_NEWLINE_xXTumor for which adequate radiation dosage cannot be safely deliveredXx_NEWLINE_xXAbility to have a skin and tumor biopsy from any site; patients without accessible tumor for biopsy will be considered on a case by case basis\r\n* Patients who cannot be biopsied will not be replaced (although up to 5 ineligible/inevaluable patients can be replaced)\r\n* Patients without accessible tumor for biopsy must provide archived tumor from the most recent biopsy availableXx_NEWLINE_xXAbnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants (that cannot be safely held for biopsy) that would preclude tumor and skin biopsies\r\n* For fulvestrant: ongoing anticoagulation that would preclude an IM injection\r\n* For tamoxifen: documented hypercoagulable state not receiving anticoagulationXx_NEWLINE_xXThe subject has a primary brain tumorXx_NEWLINE_xXThe subject has tumor in contact with, invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXConsent to provide archived tumor biopsy material (all patients)Xx_NEWLINE_xXReceived intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy / Transurethral Resection of Bladder Tumor (TURBT) to starting study treatmentXx_NEWLINE_xXFor Cohort 6 (subjects with epithelioid sarcoma undergoing mandatory tumor biopsy):Xx_NEWLINE_xXTumor that is accessible for mandatory biopsyXx_NEWLINE_xXApproximately 1 mg (1 cm3) of accessible and dispensable tumor that will not interfere with pathologic stagingXx_NEWLINE_xXInsufficient tumor available to produce vaccineXx_NEWLINE_xXSubject must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit but based on evidence gathered in this study or from external sources, the Sponsor in consultation with the Investigators, may decide to limit to specific tumor types.Xx_NEWLINE_xXAvailability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)Xx_NEWLINE_xXCircumferential radial margin not involved with tumor on pelvic MRIXx_NEWLINE_xXParticipants must be eligible to undergo laparoscopic or robotic low anterior resection with or without a temporary diverting stoma, based on multidisciplinary tumor board consensusXx_NEWLINE_xXMust undergo a new tumor biopsy for acquisition of resistant tumor tissue; subjects unable to undergo a new tumor biopsy are not eligible for Part BXx_NEWLINE_xXSolid Tumor\r\n* Failed or ineligible to receive autologous transplant or if autologous transplant would not offer > 20% chance of cure\r\n* Neuroblastoma\r\n** High risk with relapsed or refractory disease\r\n* Soft tissue sarcoma (rhabdomyosarcoma, Ewing sarcoma, primitive neuroectodermal tumor, or other high-risk extracranial solid tumors)\r\n** Relapsed or primary refractory metastatic\r\n** 1st complete remission, but very high-risk features (i.e., < 20% survival with conventional therapy)\r\n* Osteosarcoma\r\n** Failure to achieve complete remission (CR) following initial therapy\r\n** Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and/or chemotherapyXx_NEWLINE_xXMust have at least 1 liver lesion amenable to SBRT with tumor size < 15 cm (single lesion or sum); up to 3 lesions will be irradiatedXx_NEWLINE_xXEligibility Criteria\n\n          -  Age: 3-21 years.\n\n          -  Group 1 or Group 3: histologically proven initial diagnosis of primary malignant brain\n             tumor, with no known curative treatment options.\n\n          -  Group 2: histologically proven initial diagnosis of high-grade glioma (WHO grade III\n             and IV), ependymoma, medulloblastoma, or other primary central nervous system tumor.\n\n          -  Group 3b: Patients with a radiographic diagnosis or histologically proven diagnosis of\n             diffuse intrinsic pontine glioma (DIPG).\n\n          -  MRI confirmation of tumor progression or regrowth.\n\n          -  Patients must be able to swallow whole capsules.\n\n          -  Patients with metastatic disease are eligible for enrollment.\n\n          -  Lansky or Karnofsky performance status score must be > 50%.\n\n          -  Seizure disorders must be well controlled on antiepileptic medication.\n\n          -  DIPG patients enrolled to Group 3b must not have been previously treated with\n             radiation or any medical therapy.\n\n          -  Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are\n             eligible for enrollment.\n\n        Exclusion Criteria\n\n          -  Prior invasive malignancy, other than the primary central nervous system tumor, unless\n             the patient has been disease free and off therapy for that disease for a minimum of 3\n             years\n\n          -  Patients with baseline QTc interval of more than 470 msec at study entry, and patients\n             with congenital long QTc syndrome.\n\n          -  Active autoimmune diseaseXx_NEWLINE_xXSurgical Stage III disease includes those patients with positive adnexa, parametrial involvement, tumor invading the serosa, positive pelvic and/or para-aortic nodes, or vaginal involvement.Xx_NEWLINE_xXPatient’s carcinoma must express the mucin 16 (MUC16) ectodomain (ecto) antigen detectable by immunohistochemistry (IHC) analysis of banked (paraffin embedded) or freshly biopsied tumorXx_NEWLINE_xXSubjects with tumor amenable to potentially curative therapyXx_NEWLINE_xXPatients must not have tumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXMust not have received any tumor vaccines within previous six weeksXx_NEWLINE_xXcTis-T3 cancer judged to benefit (by treating radiation oncologist) from a tumor bed boostXx_NEWLINE_xXPatients must have CDKN2A-deficient tumor (deletion or mutation); definition of CDKN2A deficient tumor:\r\n* CDKN2A deletion or mutation by any Clinical Laboratory Improvement Amendments (CLIA)-certified sequencing OR\r\n* >= 30% of tumor cells with (at least) hemizygous deletion by fluorescent in situ hybridization (FISH); status will be determined from archived tissueXx_NEWLINE_xXSubjects with any tumor type (except lung) for which carboplatin plus paclitaxel chemotherapy would be appropriate • Paclitaxel Arm:Xx_NEWLINE_xXSubjects with any tumor type (except lung) for which paclitaxel chemotherapy would be appropriate • Anastrozole Arm:Xx_NEWLINE_xXRadiographic evidence of renal cancer with IVC tumor thrombusXx_NEWLINE_xXTumor thrombus must be >= level IIXx_NEWLINE_xXPatient eligible for SABR to the IVC tumor thrombus as decided by the treating radiation oncologistXx_NEWLINE_xXPatient eligible for IVC tumor thrombectomy as decided by the treating urologistXx_NEWLINE_xXSubjects who have had radiotherapy to a target within 3 cm of the IVC tumor thrombusXx_NEWLINE_xXBased on clinical and radiographic evidence the tumor needs to be deemed resectable preoperativelyXx_NEWLINE_xXUnresectable tumorXx_NEWLINE_xXAndrogen receptor positivity, defined as >= 10% of tumor cell nuclei with immunoreactivity for AR on central review at VanderbiltXx_NEWLINE_xXPrimary tumor sample collected before NACT started andXx_NEWLINE_xXPrimary tumor may be located anywhere in the pancreasXx_NEWLINE_xXThe patient must be able to have fiducial markers implanted into the pancreatic tumor, and receive radiation regimen as specified in the protocolXx_NEWLINE_xXPatient’s acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)Xx_NEWLINE_xXPatient’s tumor must be deemed resectable by the study team prior to registration; borderline resectable patients will be excludedXx_NEWLINE_xXAT THE TIME OF PROCUREMENT: Subjects having a tumor resectionXx_NEWLINE_xXPrincipal investigator (PI) to review the exam findings, photos and imaging study and determine whether the patient meets inclusion criteria in the study, based on BCCA size, location of tumor, and clinical assessment score\r\n* Orbital invasion or impending invasion by BCCA\r\n* Medial canthal BCCA within 7 mm of lacrimal apparatusXx_NEWLINE_xXPatients must have documented available tumor greater than 1 cm of bulk tumor mass or 200 cc of ascites fluid for tumor isolation prior to starting chemotherapyXx_NEWLINE_xXCohort 1: Any solid malignant tumor.Xx_NEWLINE_xXPatients with newly diagnosed or progressive DIPG as confirmed by gadolinium enhanced magnetic resonance imaging (MRI) are eligible; MRI must demonstrate that at least 2/3 of the tumor is situated in the pons and that the origin of the tumor is clearly in the pons; biopsy is not required; tumors with features not typical of diffuse intrinsic brainstem glioma are not eligible; these include dorsally exophytic brainstem gliomas, cervicomedullary junction tumors, and focal low grade gliomas of the midbrain or brainstem which should undergo resection and pathologic evaluation; patients, who have received re-irradiation for progression of the tumor, will be eligible if they show evidence of measurable progressive disease after the re-irradiation; patients at diagnosis with involvement of the spine will not be eligible, however if at progression features of spine involvement are present they will be eligible for stratum IIXx_NEWLINE_xXAt least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXAble, willing to give written consent for available archival tumor samples (not mandatory) and tumor biopsies before and during protocol therapy (mandatory).Xx_NEWLINE_xXAn HRD score >= 42 on the Myriad HRD Assay as assessed on a metastatic tumor biopsy sample; in the case that an adequate metastatic tumor tissue biopsy is not feasible, we will assess the HRD score from the primary breast tumorXx_NEWLINE_xXUncontrolled tumor related painXx_NEWLINE_xXPatients already enrolled to the separate Tumor Genomic Analysis and Molecular Testing for Personalized Cancer Therapy study, for which a personalized therapeutic plan has been successfully created under that protocol and selected by the multidisciplinary tumor board of experts (MTBE) for use in this therapeutic clinical trialXx_NEWLINE_xXWillingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treatedXx_NEWLINE_xXAt least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.Xx_NEWLINE_xXImmunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXPatients with any tumor obstructing the distal bile duct and causing an indwelling biliary SEMS occlusionXx_NEWLINE_xXPatient has completed participation in one of the ONC201 protocol, has not shown tumor progression while on study treatment, and has tolerated the study drug without unacceptable toxicitiesXx_NEWLINE_xXTumor tissue for determination and/or confirmation of genetic pre-requisites (i.e. EGFR T790M positivity post progression on EGFR TKI for Group 1; cMet status for Group 2) must be provided for analysis Group 1 patients:Xx_NEWLINE_xXPatient will have a tumor suitable for fine needle aspirates (FNA) or core biopsy for research purposes (2 or more FNAs if core is not feasible)Xx_NEWLINE_xXPreoperative proctoscopy confirming tumor extent as no less than 5 cm and no greater than 12 cm from the anal vergeXx_NEWLINE_xXClinical T4 tumorXx_NEWLINE_xXTumor < 3 mm from the mesorectal fascia as seen on MRI or endorectal ultrasoundXx_NEWLINE_xXTumor-induced symptomatic bowel obstructionXx_NEWLINE_xXSubmission of tumor samples from the diagnostic biopsy and breast surgery is required for all patientsXx_NEWLINE_xXFollowing biopsy, prior to administration of D2C7-IT, the presence of recurrent tumor must be confirmed by histopathological analysisXx_NEWLINE_xXPatients with contrast-enhancing tumor component crossing the midline, actively growing multi-focal tumor, infratentorial tumor or tumor dissemination (subependymal or leptomeningeal)Xx_NEWLINE_xXTumor invading or encasing any major blood vesselsXx_NEWLINE_xXEvidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXPatients in the dose expansion part must have tumor that is amenable for biopsyXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of anaplastic thyroid cancer or undifferentiated thyroid cancer that demonstrates mutation in the ALK gene as assessed by sequencing of the tumor specimen for Arm A; other ALK abnormalities as detected by the approved fluorescence in situ hybridization (FISH) test (Abbott Molecular Inc), using Vysis breakapart probes (defined as 15% or more positive tumor cells); or the Ventana immunohistochemistry (IHC) test will also be seen as evidence of ALK abnormality and meeting eligibility requirementXx_NEWLINE_xXMetastatic disease is allowed if investigator feels liver directed therapy could offer palliative benefit (i.e., minimal extrahepatic tumor burden)Xx_NEWLINE_xXPatients with intradural or intramedullary lesions, or lesions with < 2 mm distance from tumor to spinal cordXx_NEWLINE_xXBilirubin < 2.0 mg/dL unless secondary to bile duct blockage by tumorXx_NEWLINE_xXPatients with gastrointestinal stromal tumor (GIST)Xx_NEWLINE_xXPatients must have a measurable primary tumor (undetectable NSCLC primary tumor is ineligible)Xx_NEWLINE_xXPresence of nodules considered neoplastic in the same lobe or other ipsilateral lobe as the primary tumor (stage T3-4), unless the nodule can be encompassed in the stereotactic boost (gross tumor volume [GTV]boost) without exceeding a total GTVboost size of 10 cm as defined by the sum of the largest CT axial dimensions of each noduleXx_NEWLINE_xX< 90% solid component of tumor on screening cross-sectional imagingXx_NEWLINE_xXPre-existing tumor-infiltrating lymphocytes in an archived tumor specimen or fresh biopsy, defined as an average of >= 4 TILs/high power field (HPF) in 5 consecutive HPFs, within the area with the highest TILs at low power; or, DNA mismatch repair deficiency, determined by immunohistochemistry or polymerase chain reaction per Memorial Sloan-Kettering Cancer Center (MSKCC) institutional standard practice; DNA mismatch repair deficient tumors may be TIL positive or negativeXx_NEWLINE_xXMeasurable metastatic disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria,\r\n* Must be amenable to ultrasound or computed tomography (CT)-guided biopsy of one metastatic lesion\r\n* Peritoneal disease as the sole site of occult metastasis or presenting as malignant ascites is acceptable if a cell block of tumor cells can be obtained showing > 20% viable tumor cellsXx_NEWLINE_xXCity of Hope (COH) Clinical Pathology confirms IL13R alpha 2+ tumor expression by immunohistochemistry (>= 20%, 1+)Xx_NEWLINE_xXWeight loss of > 10% over the past 6 months which is due to tumor wasting syndromeXx_NEWLINE_xXConfirmation that primary tumor expresses mammaglobin-A by IHCXx_NEWLINE_xXTumor proliferation-related Ki-67 antigen (Ki67) value is reported as “low” after 14 days of endocrine therapyXx_NEWLINE_xXPatients with sub-optimal resection (any single tumor larger than 1 cm)Xx_NEWLINE_xXPatients with pathology demonstrating mucinous, carcinosarcoma or low malignant potential tumor histology are excluded; in addition, non-ovarian malignancies, malignant germ cell or stromal tumors are also excludedXx_NEWLINE_xXIDH1^R132H expression in primary tumorXx_NEWLINE_xXImaging studies show evidence of recurrent tumor(s); if a patient is going to be enrolled to dose level two or higher, the patient must have a component of supratentorial disease (so as to enable placement of a Rickham reservoir/catheter) that is amenable to resection or biopsyXx_NEWLINE_xXParticipant must be in need of a craniotomy for tumor resection or a stereotactic brain biopsy for the purpose of diagnosis or differentiating between tumor progression versus treatment-induced effects following radiation therapy +/- chemotherapyXx_NEWLINE_xXBased on the neurosurgeon’s judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventriclesXx_NEWLINE_xXTumor size > 7 cm in one directionXx_NEWLINE_xXTumor within 1 cm of the spinal cordXx_NEWLINE_xXPatients must agree to undergo two separate biopsies of a malignant lesion; biopsies do not need to be done if one of the following apply:\r\n* If either the site investigator or person performing the biopsy judges that no tumor is accessible for biopsy or that biopsy poses too great of a risk to the patient (if the only tumor accessible for biopsy is also the only lesion that can be used for RECIST v1.1 response evaluation, then the patient may be exempt from biopsy after discussion with the MSK principal investigator)\r\n* The goal will be to have a minimum of 6 patients from Cohort A and 3 patients from Cohort B attempt to have one or both of these research biopsies done (for a total of 9 patients total); accrual may be limited only to subjects for whom tumor is accessible for biopsy and attempt at biopsy is considered safe if continued enrollment of those who are not candidates for biopsy make it impossible to reach the accrual goals for research biopsies described above (e.g., if 19 [of 25] patients are accrued to Cohort A without any biopsies having been obtained within the cohort, then all further subjects who are registered to that cohort must qualify for attempted research biopsy in order to be enrolled into the study [i.e., subjects who would have been excluded from having biopsies done due to the above reasons would be excluded from participating in the study; these conditions also apply to Cohort B])Xx_NEWLINE_xXCOHORT A: Confirmation in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory that one of the patient’s thyroid tumors (primary tumor, recurrent tumor, or metastasis) has an neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homolog (KRAS) or Harvey rat sarcoma viral oncogene homolog (HRAS) mutation at G12, G13, or Q61; this group of patients will also be referred to as “RAS MUT”Xx_NEWLINE_xXCOHORT B: Confirmation in a CLIA certified laboratory that one of the patient’s thyroid tumors (primary tumor, recurrent tumor, or metastasis) does not have any of the following mutations:\r\n* Mutation at V600 of the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene\r\n* Mutation in NRAS or KRAS or HRAS at G12, G13, or Q61\r\n* These patients will be designated “BRAF/RAS wild type (WT)”Xx_NEWLINE_xXPatient amenable to liver tumor biopsyXx_NEWLINE_xXPatients must be deemed able to undergo optimal cytoreductive surgery (CRS) defined as cytoreduction (CC)-score of 0 or 1 based on imaging\r\n* Cytoreduction is defined as the burden of residual disease nodules left at the end of surgery (CC-0: no visible disease; CC-1: residual tumor nodules =< 2.5 mm in size; CC-2: residual tumor nodules 2.5 mm-2.5 cm in size; CC-3: residual tumor nodules > 2.5 cm in size)Xx_NEWLINE_xXTumor not suitable for resection at the time of study entry; (transplant eligible patients are allowed)Xx_NEWLINE_xXImmunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines.Xx_NEWLINE_xXT4 tumorXx_NEWLINE_xXSubmit an evaluable tumor sample for analysis.Xx_NEWLINE_xXThe subject has tumor abutting, invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXDocumented recurrent disease: recurrent disease is defined either as radiological confirmation of the tumor, as an increase in tumor size of at least 25% based upon serial magnetic resonance (MR) images, or as development of a new site of disease\r\n* Tumor volume will be calculated using the sum of the largest cross-sectional perpendicular diameters of contrast-enhancing tumor, the sum of the largest cross-sectional perpendicular diameters of fluid attenuated inversion recovery (FLAIR) abnormality, or as worsened spectroscopic characteristics for any tumor type (development of >= 2 new voxels with choline to N-acetyl aspartate index [CNI] >= 3, or >= 25% increase in the sum of the CNI ratios within a group of previously abnormal voxels [where abnormal is defined as CNI ? 3])\r\n* Disease must be evaluable, but does not need to be measurable\r\n* The target site for SRS does not need to be located in a previously-irradiated areaXx_NEWLINE_xXPatients with history of activating RAS mutation positive tumors regardless of interval from current study; however, patients may have concurrent BRAFV600 and RAS mutations in the tumor to be treated with protocol therapyXx_NEWLINE_xXHigh risk for distal recurrence defined as any of the following conditions: A) Confirmed both monosomy 3 and 8q amplification; B) Class II tumorXx_NEWLINE_xXTumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatmentXx_NEWLINE_xXPatients must have an extra-cranial primary tumor diagnosisXx_NEWLINE_xXPrimary brain tumorXx_NEWLINE_xXpatients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.Xx_NEWLINE_xXAn archived tumor specimen is available for collectionXx_NEWLINE_xXThe subject has a primary brain tumorXx_NEWLINE_xXThe subject has tumor in contact with, invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXPatient’s tumor must have documentation of the presence of an IDH-1 and/or IDH-2 mutation of any typeXx_NEWLINE_xXRecurrent tumor must be a solid, single, supratentorial, contrast-enhancing HGG which have a tumor diameter no larger than 4 cm or volume of 34 cm^3Xx_NEWLINE_xXContrast-enhancing tumor which crosses the midlineXx_NEWLINE_xXNonparenchymal tumor dissemination (e.g., subependymal or leptomeningeal)Xx_NEWLINE_xXThe patient's tumor is HPV positive by polymerase chain reaction (PCR) or in situ hybridization (ISH) assay of tumor biopsyXx_NEWLINE_xXBorderline resectable per National Comprehensive Cancer Network (NCCN) criteria (no distant metastases, venous involvement of the portal vein/superior mesenteric vein [SMV], demonstrating tumor abutment and narrowing of the lumen, encasement of the portal vein/SMV without encasement of the nearby arteries, or short-segment venous occlusion resulting from either tumor thrombus or encasement but with suitable vessel proximal or distal to this area of vessel involvement, allowing for safe resection and reconstruction; gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to the celiac axis; tumor abutment of the superior mesenteric artery [SMA] not to exceed 180 degrees of the circumference of the vessel wall)Xx_NEWLINE_xXPatients with tumor-caused symptomatic bowel obstructionXx_NEWLINE_xXMaximum tumor size ?1.5 cm in its greatest diameterXx_NEWLINE_xXTumor with ?25% IDC componentsXx_NEWLINE_xXSingle tumor less than 5 cmXx_NEWLINE_xXA volume of enhancing tumor which falls within the treatment field volume being evaluated in the respective cohortXx_NEWLINE_xXEvidence of recent hemorrhage on screening MRI of the brain with the following exceptions: presence of hemosiderin; resolving hemorrhagic changes related to surgery; presence of punctate hemorrhage in the tumorXx_NEWLINE_xXDisease should be determined as \borderline resectable\ according to the Expert Consensus Statement published by Callery et al:\r\n* No distant metastasis\r\n* Venous involvement of the superior mesenteric vein (SMV)/portal vein demonstrating tumor abutment with or without impingement and narrowing of the lumen, encasement of the SMV/portal vein but without encasement of the nearby arteries, or short segment venous occlusion resulting from either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection and reconstruction\r\n* Gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to the celiac axis\r\n* Tumor abutment of the superior mesenteric artery (SMA) not to exceed greater than 180 degrees of the circumference of the vessel wallXx_NEWLINE_xXTumor located in the brainstemXx_NEWLINE_xXNewly diagnosed MCL: Patients with bi-dimensional measurable disease with a tumor >= 10 cmXx_NEWLINE_xXThe tumor lesion is 5-15 cm from anal vergeXx_NEWLINE_xXTumor measures at least 1 centimeter on imaging or physical examXx_NEWLINE_xXEvidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen or high likelihood of CD19 expression based on disease histologyXx_NEWLINE_xXNo prior therapy, unless an emergency situation requires local tumor treatment (discuss with principal investigator [PI])Xx_NEWLINE_xXCD19-positive tumorXx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXMultifocal primary tumorXx_NEWLINE_xXTumor staging by standard imaging within the past 30 days (Step 1 subjects only)Xx_NEWLINE_xXThe primary tumor involves true vocal cord(s) (glottis) or arytenoid(s)Xx_NEWLINE_xXPatient must be able to have fiducials placed; if not, the tumor must be posterior and adjacent to the aorta and treatment will only be permitted at the discretion of the principal investigatorXx_NEWLINE_xXOne of the following criteria must be met: (a) Tumors that are microscopically multifocal must be 3.0 cm or less in total aggregate size and encompassed within a single scar (b) Patient does not have microscopically multifocal tumor.Xx_NEWLINE_xXMust not have an advanced malignant hepatic tumorXx_NEWLINE_xXDocumented expression of CD30 on tumor cellsXx_NEWLINE_xXMust be willing and able to accept at least two tumor biopsiesXx_NEWLINE_xXPresence of a prolactinoma (prolactin-releasing pituitary tumor)Xx_NEWLINE_xXPatients must undergo pre-treatment direct laryngoscopy (DL) endoscopic tumor staging and CT scanningXx_NEWLINE_xXT4 tumor with direct invasion of esophagus, spinal cord, major blood vessel, or heartXx_NEWLINE_xXPatients must be willing to undergo 2 tumor biopsiesXx_NEWLINE_xXA tumor sample must be shipped to a Novartis designated laboratory for identification of biomarkers (PI3K activation status)Xx_NEWLINE_xXFor the dose escalation phase, the trial population will be limited to solid tumor typesXx_NEWLINE_xXPatients whose tumor is not accessible for a core biopsyXx_NEWLINE_xXPrevious irradiation for head and neck tumor, skull base, or brain tumorsXx_NEWLINE_xXEBV positive tumor (can be pending)Xx_NEWLINE_xXEBV positive tumorXx_NEWLINE_xXPatients in the tumor-specific endometrial carcinoma expansion cohort that have known mutation must be willing to provide consent for biopsiesXx_NEWLINE_xXThe targeted tumor tissue is located in the cerebral hemispheres, > 2.5 cm from the inner table of the skull. Non-targeted parts of the tumor may extend outside the treated tumor limits.Xx_NEWLINE_xXSize of the targeted portion of the tumor (i.e. prescribed ROT) is less than 2.5 cm in diameter (8 cm3 in volume). The non-targeted tumor tissue may exceed the targeted volume.Xx_NEWLINE_xXThe tumor's not visible on the pre-therapy imagingXx_NEWLINE_xXThe tumor presenting the following imaging characteristicsXx_NEWLINE_xXThe sonication pathway to the tumor involvesXx_NEWLINE_xXThe most recent brain tumor pathology obtained for the patient must be glioblastoma or anaplastic astrocytomaXx_NEWLINE_xXPatients with the following histologies are excluded: melanoma, other soft tissue or bony sarcomas, giant cell tumor, aneurismal bone cyst or metastatic lesions from other histologiesXx_NEWLINE_xXPatients must have either (1) a diagnosis of NB as defined by international criteria i.e., histopathology (confirmed by the Memorial Sloan-Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow (BM) metastases plus high urine catecholamine levels, or (2) a tumor that is GD2-positive by immunostaining with m3F8\r\n* A non-NB tumor is defined as GD2-positive by immunostaining with m3F8; if fresh or frozen tumor is not available for immunostaining, patients will be considered eligible if published reports show that > 50% of that tumor type is GD2-positive by immunohistochemistry; (Note: tissues must be fresh/frozen as fixed, paraffin-embedded specimens are unsuitable for anti-GD2 immunostaining); tumors known to be GD2-positive by this criteria do not need immunostaining; these include: melanoma (> 50%), desmoplastic small round cell tumors (70%), osteosarcoma (88%) and soft tissue sarcomas including liposarcoma, fibrosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, and spindle cell sarcoma (93%)Xx_NEWLINE_xXPatients with primarily infra-tentorial or spinal cord tumor are not eligibleXx_NEWLINE_xXUncontrolled tumor in the brainXx_NEWLINE_xXHave metastatic and/or unresectable pathologically confirmed well-differentiated, typical or atypical neuroendocrine tumor of the lungXx_NEWLINE_xXWillingness to undergo a pre-treatment and on-treatment tumor biopsy to obtain the specimen.Xx_NEWLINE_xXHistological or cytological confirmation of thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants); NOTE: medullary and anaplastic thyroid cancers are excluded; Hurthle cell carcinomas are excluded (defined as having an invasive tumor composed of > 75% oncocytic [Hurthle] cells lacking the nuclear features of papillary carcinoma, tumor necrosis, and marked mitotic activity); patients with oncocytic (Hurthle cell) variants of papillary thyroid carcinoma (defined as a tumor composed of a majority of oncocytic [Hurthle] cells having the nuclear features of papillary carcinoma) are eligible to participateXx_NEWLINE_xXtumor that carries a missense HRAS mutationXx_NEWLINE_xXSubject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor statusXx_NEWLINE_xXParticipants with sarcoma of head and neck, lung, heart or extremity origin; or histopathology demonstrating rhabdomyosarcoma, extraosseous primitive neuroectodermal tumor (PNET) soft tissue Ewing's sarcoma, osteosarcoma, Kaposi's sarcoma, angiosarcoma, aggressive fibromatosis (desmoid tumor), or dermatofibrosarcoma protuberans or chondrosarcoma other than extraskeletal chondrosarcoma; or well differentiated liposarcoma where the target volume cannot be adequately distinguished from the normal retroperitoneal fat are excludedXx_NEWLINE_xXSerum bilirubin < 1.5 mg%, regardless of whether patients have liver involvement secondary to tumorXx_NEWLINE_xXPatients with primary tumor histology of lymphoma, leukemia, or germ cell tumorXx_NEWLINE_xXICGCT including pure germinoma and MMGCT; patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor will be eligible for the study; patients with mature/immature teratoma who have tumor marker elevations are eligible on this study; patient with ONLY mature and/or immature teratoma are ineligible in the absence of the tumor marker elevationsXx_NEWLINE_xXPatients with NO elevation of serum and/or CSF HCGB and AFP MUST have histological diagnosis of malignant germ cell tumor (GCT) or germinomaXx_NEWLINE_xXPatients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the studyXx_NEWLINE_xXGross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 3 cm or less; (patients with microscopic multifocality are eligible as long as total pathologic tumor size is 3 cm or less)Xx_NEWLINE_xXCD30 positive tumor (can be pending at this time)Xx_NEWLINE_xXCD30 positive tumorXx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXTumor type demonstrated on imaging to be infiltrative, tumor volume > 70% of the target liver volume, or tumor nodules too numerous to count, or tumor volume > 50% combined with an albumin < 3 g/dL, or complete occlusion of the main portal vein.Xx_NEWLINE_xXPresence of metastatic disease for patients in Stratum A, B, D and E; patients with metastatic high grade gliomas diagnosed at < 1 year of age are eligible for Stratum D at the time of recurrence; patients with low grade gliomas (Stratum C) may have tumor spread within the CNS; patients in Stratum F must have tumor spread within the CNSXx_NEWLINE_xXWHO grade I: tumor that are newly diagnosed and tumors that are incompletely excised; tumors that have recurred post resectionXx_NEWLINE_xXWHO grade II: any tumor, either completely or incompletely excised; any recurrent tumorXx_NEWLINE_xXWHO grade III and hemangiopericytoma: any tumor, either completely or incompletely excised; any recurrent tumorXx_NEWLINE_xXPatients must have the diagnosis of (a) DSRCT with peritoneal involvement or (b) other 8H9-positive solid tumors involving the peritoneum (e.g. adrenocortical carcinoma, Wilm's tumor)Xx_NEWLINE_xXThe tumor has been excised with a breast-conserving resection and there is no tumor seen at any of the margins of the resectionXx_NEWLINE_xXDetectable tumor prior to mobilization regimenXx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at restXx_NEWLINE_xXPrevious vaccination with the allogeneic GM-CSF-secreting breast tumor vaccineXx_NEWLINE_xXGrowing teratoma syndrome, defined as enlarging tumor masses with normal serum markers during chemotherapy for nonseminomatous GCTXx_NEWLINE_xXSubjects must have had histologic verification by a pathologist of cancer at original diagnosis; the tumor must be a non-CNS solid tumor; for subjects to be enrolled on the intratumoral arm, at least one lesion must be amenable to HSV1716 injection without undue risk, as determined by the interventional radiologist; disease must be considered refractory to conventional therapy or for which no conventional therapy existsXx_NEWLINE_xXThe tumor volume must be a minimum of three times the injection volume; in the first and second dose levels, the lesion to be injected must be at least 18 mm in each of 3 dimensions as determined by computed tomography (CT) or magnetic resonance imaging (MRI) scans; lesions not meeting this requirement may be used if volumetric measurements show it to be >= 3 mL; in the third dose level, the lesion(s) to be injected must meet minimal tumor measurements and volume for each 1 mL fractionation of the injection volume (5mL); a single lesion meeting this requirement may be injected or the total volume may be distributed in up to 3 lesions meeting measurement and volume requirements as follows:\r\n* 5 mL of HSV1716; 30 mm minimum tumor length in each dimension; 15 mL minimum tumor volume\r\n* 4 mL of HSV1716; 28 mm minimum tumor length in each dimension; 12 mL minimum tumor volume\r\n* 3 mL of HSV1716; 26 mm minimum tumor length in each dimension; 9 mL minimum tumor volume\r\n* 2 mL of HSV1716; 23 mm minimum tumor length in each dimension; 6 mL minimum tumor volume\r\n* 1 mL of HSV1716; 18 mm minimum tumor length in each dimension; 3 mL minimum tumor volume\r\n** Thus, the full 5 mL may be injected into a >= 15 mL tumor; 2 mL each may be injected into two >= 6 mL tumors plus 1 mL into a >= 3 mL, tumor, etc.; if a patient has multiple lesions but these criteria for injection cannot be met, they may be considered for the intravenous armXx_NEWLINE_xXPatients with skin involvement, regardless of tumor sizeXx_NEWLINE_xXConfirmed diagnosis of metastatic intrahepatic carcinoma; the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as AFPXx_NEWLINE_xXConfirmed diagnosis of intrahepatic carcinoma; the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as alpha fetoprotein (AFP)Xx_NEWLINE_xXPatient has a radiologically and /or pathologically confirmed diagnosis of a renal tumorXx_NEWLINE_xXPoor Prognosis Non-Seminomas Germ Cell Tumor in >= partial response (PR)1/complete response (CR)1 or Good or Intermediate Prognosis Seminomas and Non-Seminomas Germ Cell Tumor in >= PR1 or >= CR2 as defined by the International Germ Cell Cancer Consensus Classification; Patients with increasing tumor markers only (i.e., no imaging evidence of progressive disease) are eligible for transplantXx_NEWLINE_xXINCLUSION CRITERIA FOR CCT: patients must have the diagnosis of malignant chromaffin cell tumor (CCT) i.e. malignant pheochromocytoma or malignant paragangliomaXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of a malignancy known to be 8H9 reactive; 8H9 expression must be confirmed by immunohistochemical staining of tumor and assessed by the Department of Pathology or by immunofluorescence of bone marrow except for patients confirmed to have neuroblastoma or an embryonal tumor (such as medulloblastoma, retinoblastoma, rhabdomyosarcoma and desmoplastic small round cell tumor [DSRCT])Xx_NEWLINE_xXMust be willing to release tumor biopsy specimen used for diagnosis of metastatic NSCLC (if available) for additional exploratory tumor molecular profiling.Xx_NEWLINE_xXMust be willing to provide blood samples prior to the start of treatment on this study for exploratory tumor molecular profiling analyses.Xx_NEWLINE_xXMust be willing to provide a tumor biopsy specimen 9 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.Xx_NEWLINE_xXSubject's tumor expresses CLDN18.2 in ? 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing.Xx_NEWLINE_xXSubject has a HER2-Negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen.Xx_NEWLINE_xXMalignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.Xx_NEWLINE_xXPatient must have confirmed HER2 overexpression or gene-amplified tumorXx_NEWLINE_xXTumor thrombus involving main trunk of portal vein or inferior vena cavaXx_NEWLINE_xXHigh FGFR1 or 3 mRNA (Messenger ribonucleic acid) expression levels (RNAscope score of 3+ or 4+; measurement is part of this protocol) in archival or fresh Tumor biopsy specimenXx_NEWLINE_xXSubject must have an advanced solid tumorXx_NEWLINE_xXConsent to undergo on treatment biopsy if tumor is accessible and safe to biopsyXx_NEWLINE_xXPrevious surgery for this lung or mediastinum tumorXx_NEWLINE_xXWillingness to undergo a tumor biopsy prior to treatment.Xx_NEWLINE_xXWillingness to undergo a tumor biopsy while on study treatment.Xx_NEWLINE_xXBaseline tumor biopsy must be adequateXx_NEWLINE_xXHas a newly diagnosed tumor and a curative treatment option or approved therapy is availableXx_NEWLINE_xXCarotid artery involvement by tumor had a neck dissection on that sideXx_NEWLINE_xXPatients with M1 stage according to the Tumor, Node and Metastasis Classification of Malignant Tumours (TNM)Xx_NEWLINE_xXTumor HPV status establishedXx_NEWLINE_xXThe patient must have failed at least one line of standard treatment, with the following exceptions in which a PD-1 antibody is Food and Drug Administration (FDA) approved in the first-line setting: \r\n* Melanoma patients\r\n* Non-small cell lung cancer patients without EGFR or ALK genomic tumor aberrations whose tumors have high PD-L1 expression (tumor proportion score [TPS] >= 50%) as determined by an FDA-approved testXx_NEWLINE_xXAt least one measureable tumor lesion that that has not been previously locallyXx_NEWLINE_xXInvasion of the main portal vein and/or tumor involvement in more than 50% of the liver (applicable only for the dose-escalation part)Xx_NEWLINE_xXIs able to submit a fresh tumor biopsy sample prior to starting study treatment if not already submitted for HER3 expressionXx_NEWLINE_xXcMET dysregulated advanced solid tumorXx_NEWLINE_xXMetastatic tumor that has been biopsiedXx_NEWLINE_xXCentrally assessed KIR3DL2 expression on tumor cells.Xx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXInclusion criteria include the following:\n\n          1. Is a male or female, ? 18 years of age, who has provided written informed consent.\n\n          2. Has histologically or cytologically confirmed advanced, unresectable, metastatic solid\n             tumor(s) for which the patients have no available therapy likely to provide clinical\n             benefit.\n\n          3. Must have an archival FFPE tumor sample available, to be provided to the Sponsor upon\n             request.\n\n          4. In the Expansion Phase: patients should be willing to undergo tumor core biopsy\n             procedure at pre-treatment and on Day 4, Cycle 1 if, in the judgment of the\n             investigator, it is considered clinically safe and appropriate to do so. This\n             requirement is optional but preferred for patients in Dose Escalation.\n\n          5. Has adequate organ function.\n\n        Women of childbearing potential must have a negative pregnancy test (urine or serum) within\n        7 days prior to starting the study drug. Both males and females and must agree to use\n        effective birth control during the study if conception is possible during this interval.\n\n        Exclusion:\n\n          1. Has received prior treatment with TAS-119.\n\n          2. Has received treatment with any proscribed treatments within specified time frames\n             prior to study drug administration.\n\n          3. Has a serious illness or medical condition(s).Xx_NEWLINE_xXPatients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study.Xx_NEWLINE_xXTumor foci detected below the tentorium or beyond the cranial vault.Xx_NEWLINE_xX30 days must have elapsed since previous treatment of the brain tumor with any other agentsXx_NEWLINE_xXMust not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndromeXx_NEWLINE_xXSufficient tumor available to determine if expresses a mutation in KITXx_NEWLINE_xXAgreement to allow tumor to be evaluated for mutations in KIT and BRAFXx_NEWLINE_xXEmbolization procedure or ablation procedure to treat tumor within 4 weeks of first dose of STA-9090Xx_NEWLINE_xXAll patients must have tumor specimens adequate for analysis of EGFR mutations and have tumor accessible to biopsy and must consent to biopsy.Xx_NEWLINE_xXChronic Obstructive Pulmonary Disease, defined as being associated with a hospitalization for pneumonia or respiratory decompensation within 12 months of diagnosis; this does not include obstruction from tumorXx_NEWLINE_xXTargeted tumor is in the skullXx_NEWLINE_xXTarget (most painful) tumor-bone interface is less then 1cm from nerve bundles, bowels or bladder.Xx_NEWLINE_xXThe targeted tumor tissue is located in the cerebral hemispheres, > 2.5 cm from the inner table of the skull. Non-targeted parts of the tumor may extend outside the treated tumor limits.Xx_NEWLINE_xXSize of the targeted portion of the tumor (i.e. prescribed Region Of Treatment) is less than 2.5 cm in diameter or 8 cm3 in volume. The non-targeted tumor tissue may exceed the targeted volume.Xx_NEWLINE_xXAvailability of tumor specimens is mandatory for patients in the confirmation phase;Xx_NEWLINE_xXSubjects diagnosed with other malignant primary tumorXx_NEWLINE_xXPatients with primary tumor location of brainstem or spinal cordXx_NEWLINE_xXSubjects with a total tumor size of ?2 cm following TURBT are eligible. Subjects with a tumor or tumors totaling >2 cm at screening must undergo a second debulking TURBT to reduce the tumor(s) to ?2 cm to be eligible for treatment.Xx_NEWLINE_xXEnough tumor material must be available for central confirmation of diagnosis, otherwise a new tumor biopsy is mandated.Xx_NEWLINE_xXThe maximum tumor diameters for each Cohort for both Arm A and Arm B should achieve a dose of approximately 1x1011 viral particles (vp)/cm3 of tumor volume. (see Table 1). Please refer to Table for calculating tumor volume.Xx_NEWLINE_xXFavorable biomarker profile defined by either wild type p53 gene sequence or less than 20% p53 positive tumor cells by immunohistochemistryXx_NEWLINE_xXHepatic insufficiency not due to tumor resulting in clinical jaundice or bilirubin >1.5 x ULN and/or coagulation defectsXx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Clinical status of either subject or tumor such that administration of 10 day neoadjuvant IRX-2 1 or 2 before surgery would be medically inappropriateXx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with T4b cancer:\r\n* Involvement of pterygopalatine fossa, maxillary sinus, or facial skin\r\n* Gross extension of tumor to the skull base\r\n* Pterygoid plate erosion\r\n* Sphenoid bone or foramen ovale involvement\r\n* Direct extension to involve prevertebral fascia\r\n* Extension to superior nasopharynx or Eustachian tube\r\n* Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)\r\n* Suspected invasion (encasement) of the common or internal carotid arteries; encasement will be assessed radiographically and will be defined as tumor surrounding the carotid artery 270 degrees or greater\r\n* Direct extension of neck disease to involve the external skin\r\n* Direct extension to mediastinal structures\r\n* Regional metastases to the supraclavicular neck (low level VB and IVB)Xx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Clinical status of either subject or tumor such that administration of neoadjuvant nivolumab or IRX-2 before surgery would be medically inappropriateXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with T4b cancer:\r\n* Involvement of pterygopalatine fossa, maxillary sinus\r\n* Gross extension of tumor to the skull base\r\n* Pterygoid plate erosion\r\n* Sphenoid bone or foramen ovale involvement\r\n* Direct extension to involve prevertebral fascia\r\n* Extension to superior nasopharynx or Eustachian tube\r\n* Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)\r\n* Suspected invasion (encasement) of the common or internal carotid arteries; encasement will be assessed radiographically and will be defined as tumor surrounding the carotid artery 270 degrees or greater\r\n* Direct extension of neck disease to involve the external skin\r\n* Direct extension to mediastinal structures\r\n* Regional metastases to the supraclavicular neck (low level VB and IVB)Xx_NEWLINE_xXPrior history of specific mutations (specified in the protocol) in the tumor at the time of any previous assessment.Xx_NEWLINE_xXStaining for PD-L1 in less than half of the tumor cells using the 22C3 antibody (0% staining is acceptable).Xx_NEWLINE_xXImmunohistochemistry (IHC) results from tumor biopsy for NY-ESO-1 positiveXx_NEWLINE_xXHigh FGFR mRNA expression levels (RNAscope score of 3+ or 4+; measurement is part of this protocol) in archival or fresh tumor biopsy specimen.Xx_NEWLINE_xXPrevious or concurrent cancer that is distinct from tumor for which the patient is enrolled in study, with exceptionsXx_NEWLINE_xXDocumentation of tumor activating EGFR mutation, specifically either DEL19 or L858R.Xx_NEWLINE_xXExpression of PD-L1 in ?50% of tumor cells determined by the commercially available assay performed by the central laboratoryXx_NEWLINE_xXTumor >1.5 cm.Xx_NEWLINE_xXTumor intended for immunotherapy manufacture is not embedded in bone and does not contain luminal tissue (e.g. bowel, ureter, bile duct).Xx_NEWLINE_xXHistory of other previous or concurrent cancer that would interfere with the determination of safety or efficacy assessment of RXDX-106 with respect to the qualifying solid tumor malignancy.Xx_NEWLINE_xXAt least one lesion (metastasis or primary tumor) being considered accessible for a biopsyXx_NEWLINE_xXMethotrexate or non-BRAF/MEK non-cytotoxic anti-tumor drug ? 2 weeksXx_NEWLINE_xXTumor with androgen receptor (AR) expressed >= 4580 copies/ug ribonucleic acid (RNA)Xx_NEWLINE_xXPrior therapy with tumor vaccineXx_NEWLINE_xXRecurrent glioma, or tumor involving the brainstem or cerebellum. Prior low-grade glioma without prior RT, now with malignant progression are eligible.Xx_NEWLINE_xXThe subject has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXHistological or cytologically confirmed NSCLC that shows moderate or stronger mesothelin expression in 30% of tumor cells by a companion assay; MSLN expression score using Ventana immunohistochemistry (IHC) SP74 assay; Phase I only: In addition 5- 30% tumor cells and 1, 2, or 3+ MSLN score; Phase II only: 30% tumor cells and either 2+/3+Xx_NEWLINE_xXPatients must have completed standard radiation therapy with concurrent TMZ and must not have evidence of progressive disease on post treatment imaging. Progression can only be defined using diagnostic imaging if there is new enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line) or if there is unequivocal evidence of viable tumor on histopathologic sampling (e.g., solid tumor areas [i.e, > 70% tumor cell nuclei in areas], high or progressive increase in MIB-1 proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor). Note: Given the difficulty of differentiating true progression from pseudoprogression, clinical decline alone, in the absence of radiographic or histologic confirmation of progression, will not be sufficient for definition of progressive disease in the first 12 weeks after completion of concurrent chemoradiotherapy. (For Stage 1: Post-chemoradiation group only)Xx_NEWLINE_xXTumor expression of NY-ESO-1 (2+ staining or > 25%) by immunohistochemistry (IHC).Xx_NEWLINE_xXDiagnosis of an advanced solid tumor malignancy; there must be a target tumor which is measurable, palpable or clearly identifiable under ultrasound or radiographic guidance and amenable to percutaneous injection of C. novyi-NT spores; the targeted lesion must have a longest diameter ? 1 cm and < 12 cm and be measurable as defined by RECIST 1.1 criteria; the target lesion must not be located in either the thoracic, abdominal or pelvic cavities or in the brain; there must be no clinical, no functional, and no radiographic evidence of bone involvement at the site of the target lesionXx_NEWLINE_xXPatient has a tumor sample from C. novyi-NT planned injected tumor lesion (newly obtained biopsy) for PD-L1 and immunologic response assessments; patients must submit the tumor sample during screening at a central pathology laboratoryXx_NEWLINE_xXPRE-REGISTRATION: Patients older than 21 years must have a solid tumor considered by study doctor to be of the childhood cancer type.Xx_NEWLINE_xXPRE-REGISTRATION: At least one documented histological verification of solid tumor diagnosis. Can be from original diagnosis or more recent.Xx_NEWLINE_xXPrimary or recurrent retroperitoneal or abdominal tumorXx_NEWLINE_xXPresence of distant metastases; intra-abdominal (regional) spread is allowable if meets inclusion criterial indeterminate or small volume pulmonary nodules may be eligible, if the treating physicians recommend curative-intent resection of the primary tumor despite the presence of possible lung metastasesXx_NEWLINE_xXPrior craniotomy and gross total or sub-total resection of tumor at this recurrenceXx_NEWLINE_xXPatients with non-bulky/non-bulky squamous cell carcinomas of the head and neck, with an indication for surgical therapy\r\n* T1N1-N2B, T2-4N0-N2b stage are generally eligible\r\n* If determined per tumor board that a low-volume/non-bulky tumor of another stage is appropriate for resection (e.g. small volume T4 with a small amount of bone invasion) such tumors may also be considered for this study if recommendation in tumor board is suchXx_NEWLINE_xXTumor expressing PRAME and/or COL6A3.Xx_NEWLINE_xXFor phase I dose expansion cohorts the patient’s tumor must harbor a KRAS mutation detected by a CLIA certified laboratoryXx_NEWLINE_xXHer-2 positive gastric tumorXx_NEWLINE_xXConfirmed wild-type status in KRAS exons 2, 3, and 4; NRAS exons 2, 3, and 4; and BRAF, by standard of care testing of tumor specimen; tissue used for testing may have been collected prior to treatment with cetuximabXx_NEWLINE_xXPatient must have been already tested and have available results of the mutations status of KRAS/NRAS/BRAF and EGFR from the circulating tumor DNA within 10 weeks prior to starting study therapyXx_NEWLINE_xXBiopsy-accessible breast tumor of significant size for core needle biopsy (>= 2cm)Xx_NEWLINE_xXHistopathologic documentation any metastatic gastrointestinal tumorXx_NEWLINE_xXT4 tumorXx_NEWLINE_xXSurgery is done prior to IMT if needed for palliation, tumor debulking, pathological documentation of tumor recurrence; the patients may continue on study therapy even if they do not have measurable diseaseXx_NEWLINE_xXSevere increased intracranial pressure, status epilepticus, or other serious complications from the brain tumor, requiring emergency or urgent interventionXx_NEWLINE_xXPatients must have biopsiable tumor and agree to study biopsyXx_NEWLINE_xXThe subject must have a complete removal of the primary HNSCC lesion with negative gross and microscopic margins; documentation of margins by frozen sections at surgery is recommended; patients who have already had surgery and have available banked tumor samples can be enrolled AFTER surgeryXx_NEWLINE_xXThe presence of diffuse leptomeningeal disease will be an exclusion criterion for this study; this is secondary to the inadequacy of measuring the extent of the tumor burden within this setting and the very poor prognosis of these patientsXx_NEWLINE_xXA tumor lesion that can be readily biopsied using a core needle via clinical exam or imaging-guidanceXx_NEWLINE_xXPatients with bulky tumor on imaging are ineligible; bulky tumor is defined as:\r\n* Tumor with any evidence of uncal herniation or midline shift\r\n* Tumor that in the opinion of the site investigator, shows significant mass effect\r\n** Treating physicians are encouraged to contact the study chair to request a rapid central imaging review to confirm fulfilment of these eligibility criteria, if they have concernsXx_NEWLINE_xXDocumented RAS-mutated tumor without activating PIK3CA mutations or PTEN mutation (loss of PTEN or silencing)Xx_NEWLINE_xXTumor must have high Delta-like protein 3 (DLL3) expression defined as having ? 75% tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.Xx_NEWLINE_xXDiagnosis during dose escalation (Part 1) - Pathologically documented, definitively diagnosed non-resectable advanced solid tumor.Xx_NEWLINE_xXAll patients treated at doses > 120 mg per day must have medullary thyroid cancer (MTC), or a RET-altered solid tumor per local assessment of tumor tissue and/or blood.Xx_NEWLINE_xXDiagnosis during dose expansion (Part 2) - All patients in Groups 1, 2 and 4 must have a RET-altered (excluding synonymous and nonsense mutations) solid tumor, as determined by local testing of tumor or circulating tumor nucleic acid in blood; as detailed below.Xx_NEWLINE_xXGroup 4 - patients must have a pathologically documented, definitively diagnosed advanced solid tumor with a RET alteration, other than NSCLC and MTC.Xx_NEWLINE_xXFor the expansion patients must provide a fresh tumor biopsy at enrolmentXx_NEWLINE_xXAn interval of at least 12 weeks from the completion of radiation therapy to start of study drug unless there is a new area of enhancement consistent with recurrent tumor outside the radiation field (defined as the region outside the high-dose region or 80% isodose line) or there is unequivocal histologic confirmation of tumor progressionXx_NEWLINE_xXPatients must have histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas; as both of those terms are categories rather than specific diagnoses, specific guidance on eligible tumor types is provided belowXx_NEWLINE_xXWell-differentiated (G1 or G2) based on local pathology report, non-functional neuroendocrine tumor of GI, pancreatic or thoracic (including lung and thymus) origin.Xx_NEWLINE_xXTumor biopsy material must be provided for all patients for the purpose of biomarker analysisXx_NEWLINE_xXA single glioblastoma or gliosarcoma tumor with histopathological confirmation for first or presenting second recurrence of glioblastoma or gliosarcoma at the time of consentXx_NEWLINE_xXPrior anti-tumor therapies must have been completed within time periods specified in the protocol prior to DNX-2401 injectionXx_NEWLINE_xXTumor location on both sides of the brain and/or involvement that would present the risk of injecting DNX-2401 into the ventricles of the brainXx_NEWLINE_xXTumor location in the brain stemXx_NEWLINE_xXSimultaneous primary cancers or separate bilateral primary tumor sites.Xx_NEWLINE_xXWilling to undergo tumor biopsies from injected and distal lesionsXx_NEWLINE_xXThe primary tumor must be excised via breast conserving surgery (“lumpectomy”) with negative margins (no ink on tumor) in the final specimenXx_NEWLINE_xXThe tumor must be =< 2 cm (T1) in the largest dimensionXx_NEWLINE_xXThe invasive component of the tumor has a grade 3 histologyXx_NEWLINE_xXThe subject has tumor in contact with, invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXDiagnosis of adenocarcinoma of the rectum with the major portion of the tumor intact; Note: prior to randomization, the investigator must specify and document each of the following: \r\n* Distance of the lowest tumor margin from the anal verge; and \r\n* Intent for sphincter sparing or non-sphincter sparing surgical resection according to the primary surgeon; and\r\n* The majority of the untreated tumor must be < 12 cm from the anal verge or below the peritoneal reflection as determined by the treating surgeonXx_NEWLINE_xXPatient must have adequate tumor specimen available for submissionXx_NEWLINE_xXPatients with primary refractory disease with progression of the primary tumor on initial therapyXx_NEWLINE_xXPatients must have known v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutational status of tumor; wild-type (WT) or mutated, prior to randomizationXx_NEWLINE_xXSubjects with histologically confirmed CNS embryonal tumor (primitive neuroectodermal tumor [PNET], medulloblastoma, atypical teratoid rhabdoid tumor [ATRT], medulloepithelioma, pineoblastoma or ependymoblastoma), or germ cell tumor, are eligible; tumors must be relapsed or refractory to first-line therapy; diagnosis will be made on the basis of computed tomography (CT)-assisted or stereotactic biopsy, open biopsy, surgical resection, cerebrospinal fluid (CSF) cytology, or elevated tumor markersXx_NEWLINE_xXFor the phase II portion of the study, subjects must have disease that is evaluable for response; subjects who have had radiation to all sites of disease are not eligible unless there is imaging evidence of active tumor, ie: increased blood volumeXx_NEWLINE_xXThe subject has an infra-tentorial tumor or multifocal diseaseXx_NEWLINE_xXTissue available from primary and/or recurrent disease to evaluate tumor expression of NY-ESO-1 or PDL1 by immunohistochemistry (IHC) and/or reverse transcriptase-polymerase chain reaction (RT-PCR), and for measurement of DNA methylationXx_NEWLINE_xXNo requirement for tumor expression of NY-ESO-1Xx_NEWLINE_xXPatients with gross total resection of the primary tumor prior to enrollment are not eligible; patients who have experienced tumor recurrence after gross total tumor resection are not eligibleXx_NEWLINE_xXWilling to undergo a baseline tumor core needle biopsy for correlative science studies; this study does not restrict eligibility based on PD-L1 expressionXx_NEWLINE_xXIn addition, patients with NF1 and with malignant peripheral nerve sheath tumor (MPNST)Xx_NEWLINE_xXThe target tumor is limited to neuroblastoma and other GD2-positive solid tumors; diagnosis should be histologically verified at Children’s Hospital of Michigan (CHM) or Memorial Sloan Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXTREATMENT: Patient must have predefined targeted mutation in tumor biopsyXx_NEWLINE_xXPatients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink)Xx_NEWLINE_xXPatients must have CSF tumor markers obtained prior to enrollment unless medically contraindicated; ventricular CSF obtained at the time of CSF diversion procedure (if performed) is acceptable for tumor markers but lumbar CSF is preferred; in case CSF diversion and biopsy/surgery are combined, CSF tumor markers should be collected firstXx_NEWLINE_xXPatients with mature teratoma or completely resected immature teratoma with normal tumor markers are not eligibleXx_NEWLINE_xXDiagnosis of MPM, confined to single pleural cavity, with histologic confirmation of the primary tumorXx_NEWLINE_xXPatients must have tumors determined to be easily accessible for biopsy and must be willing to have serial biopsies (with a third biopsy upon evidence of disease progression); tumor biopsies will be performed on the most accessible biopsable site of disease; all possible precautions to avoid complications will be taken, including discussions in multidisciplinary meetings, if needed; patients affected by glioma will not be considered for study biopsiesXx_NEWLINE_xXFor subjects with glioma, specific inclusion criteria are as follows:\r\n* The disease should be recurrent or transformed glioma; subjects must not have had prior surgery (biopsy allowed) or radiation therapy within 3 weeks of enrollment\r\n* There must be an enhancing component of disease, as evaluated on pre-treatment magnetic resonance imaging (MRI)\r\n* For patients with World Health Organization (WHO) grade III or IV glioma and progressive disease < 12 weeks after completion of chemoradiotherapy, progression can be defined by the following set of criteria:\r\n** New enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line)\r\n** If there is unequivocal evidence of viable tumor on histopathologic sampling (e.g., solid tumor areas. i.e., > 70% tumor cell nuclei in areas), high or progressive increase in MIB-1 proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor);\r\n** Note: Given the difficulty of differentiating true progression from pseudoprogression, clinical decline alone, in the absence of radiographic or histologic confirmation of progression, will not be sufficient for definition of progressive disease in the first 12 weeks after completion of concurrent chemoradiotherapy\r\n* For patients with WHO grade III or IV glioma and progressive disease >= 12 weeks after completion of chemoradiotherapy, progression can be defined by the following set of criteria:\r\n** New contrast-enhancing lesion outside of radiation field on decreasing, stable, or increasing doses of corticosteroids\r\n** Increase by >= 25% in the sum of the products of perpendicular diameters between the first post-radiotherapy scan, or a subsequent scan with smaller tumor size, and the scan at 12 weeks or later on stable or increasing doses of corticosteroids\r\n** For patients receiving antiangiogenic therapy, significant increase in T2/fluid attenuated inversion recovery (FLAIR) non-enhancing lesion may also be considered progressive disease; the increased T2/FLAIR must have occurred with the patient on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy and not be a result of comorbid events (e.g., effects of radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or other treatment effects)\r\n** Note: Clinical deterioration alone is not attributable to concurrent medication or comorbid conditions is sufficient to declare progression on current treatment but not for entry onto a clinical trial for recurrence\r\n* For patients with WHO grade II glioma progression is defined by any one of the following:\r\n** Development of new lesions or increase of enhancement (radiological evidence of malignant transformation)\r\n** A 25% increase of the T2 or FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not attributable to radiation effect or to comorbid eventsXx_NEWLINE_xXTumor sample must be available for HPV p16 and PD-L1 testingXx_NEWLINE_xXPatients must have Clinical Laboratory Improvement Act (CLIA) confirmed somatic KRAS G12R mutation as determined by sequence analysis of matched normal deoxyribonucleic acid (DNA) from any specimen obtained from the individual; patients must provide tumor sample for KRAS analysis or be willing to undergo mandatory screening biopsyXx_NEWLINE_xXPatients must be willing to undergo 2 tumor biopsiesXx_NEWLINE_xXMaximum diameter of enhancing tumor (target lesion) should be =< 4 cmXx_NEWLINE_xXHas recurrent or persistent tumor (enhancing area) greater than 4 cm in maximum diameterXx_NEWLINE_xXThe tumor must be primarily supratentorial in location as determined by diagnostic imaging performed preoperativelyXx_NEWLINE_xXRadiographic contrast enhancement attributable to residual tumor on post-operative imaging performed within 72 hours of resection must not exceed 1 cm in biperpendicular planes (> 1 cm in one plane but < 1 cm in other planes will be allowed)Xx_NEWLINE_xXAdequate tumor content as determined by institutional pathologist for nucleic acid extraction and DNA sequence analysisXx_NEWLINE_xXRadiographic evidence of contrast-enhancing tumor crossing midline, leptomeningeal dissemination, gliomatosis cerebri or infratentorial tumorXx_NEWLINE_xXPathologic proven diagnosis of solid tumor malignancyXx_NEWLINE_xXRadiosensitive or non-solid (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologiesXx_NEWLINE_xXCohort II (MTD): willing to provide the biologic specimens as required by the protocol; note: this is part of the mandatory translational research component; note: patients with the only tumor accessible for biopsy in the pancreas will not be eligible as core biopsies are associated with significant increase in risk for the patientXx_NEWLINE_xXThe subject has tumor in contact with, invading or encasing any major blood vesselsXx_NEWLINE_xXRecipient leukocyte infusion (RLI) might involve the infusion of circulating tumor cells to the patients; to minimize this risk, patients who have evidence of circulating tumor cells by light microscopy and flow cytometry will be excludedXx_NEWLINE_xXPatients with acute leukemia will be excluded because they will likely have a much greater circulating tumor burden, which would increase the risk of infusion of clonal tumor cellsXx_NEWLINE_xXDiagnosis of \tumor of low-malignant potential\.Xx_NEWLINE_xXPatients with confirmed p53 mutation by molecular analysis and/or evidence of p53 overexpression by immunohistochemistry (>= 10% of cells within tumor staining positive) will be eligible; this will be assessed semi-quantitatively by a Clinical Laboratory Improvement Act (CLIA) approved pathology core pathologist, using CLIA approved mutational analysis or immuno-histochemistry techniques on formalin-fixed paraffin-embedded tissue; in the case of equivocal immunohistochemistry (IHC) results, p53 involvement may be confirmed by detection of p53 molecular analysis on tumor deoxyribonucleic acid (DNA); patients on whom molecular analysis of p53 mutations is already available, will not require IHC analysis; molecular analysis may be performed as an additional research procedure at the end of the study (distinct from eligibility determination) if the principal investigator (PI) deems it of scientific value and research funding is available to cover the cost; patients must have PD-L1 positive ovarian cancer in order to be eligible for this clinical trial (defined as >= 1% PD-L1 expression within the tumor section, assessed by immunohistochemical staining)Xx_NEWLINE_xXThe T stage must be Tis, T1, or T2; if T2, the tumor must be =< 3.0 cm in maximum diameterXx_NEWLINE_xXDocumented evidence of a tumor with 1 or more EGFR mutations excluding exon 20\n             insertionXx_NEWLINE_xXFor cohort 3 only, patients must be able to safely undergo pre and post-treatment biopsy, i.e., at least one readily accessible lesion or palpable lymph node metastasis arising from any solid tumor cancer or lymphoma\r\n* NOTE: this may include cutaneous and subcutaneous tumors using injection by palpation or ultrasound guidance\r\n* NOTE: the target lesion must be >= 1.5 cm on its longest diameter, be at least 5 mm thick, and have distinct borders\r\n* NOTE: deep seated lesion(s) that are deemed hazardous to inject or lesion(s) close to vital structures that might be impinged with tumor swelling are excluded as targeted tumor\r\n* NOTE: cohort 3 should be selected for patients with injectable cutaneous lesion(s), unless the patient elects not to receive IT injection and/or undergo pre and post-treatment biopsiesXx_NEWLINE_xXPatients with newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or primitive neuroectodermal tumor (PNET) of bone or soft tissue are eligible for this study; note:\r\n* For the purpose of this study, chest wall tumors with ipsilateral pleural effusions, ipsilateral positive pleural fluid cytology or ipsilateral pleural based secondary tumor nodules will be considered localized disease\r\n* Patients with regional node involvement, based on clinical suspicion confirmed by pathologic documentation are considered to be non-metastatic\r\n* Patients with discontinuous osseous lesions within the same bone are considered to be non-metastatic\r\n* Tumors arising in the bony skull (extra-dural) are considered to be extracranialXx_NEWLINE_xXNo prior chemotherapy or radiation therapy is allowed; patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgeryXx_NEWLINE_xXThe tumor location must be suitable for either lobar or sublobar resection (wedge or segment)Xx_NEWLINE_xXSupratentorial primitive neuroectodermal tumor (PNET) (any M-stage) will be eligible for study entryXx_NEWLINE_xXChildren less than 8 months of age at the time of definitive surgery with or without measurable radiographic residual tumor with M0 stage medulloblastoma will be eligible for study entryXx_NEWLINE_xXPatients with anaplastic medulloblastoma are eligible regardless of M-stage or residual tumorXx_NEWLINE_xXBrain tumor patient is planning to undergo tumor resection or biopsy for the purpose of differentiating between tumor progression versus treatment-induced effects following radiation therapy and/or chemotherapy\r\n* If a patient has magnetic resonance imaging (MRI) findings consistent with tumor but does not already have a histopathologic diagnosis of cancer, s/he may sign the consent form, but final eligibility for study enrollment will be determined based on results of the frozen section at time of surgeryXx_NEWLINE_xXMacrovascular tumor invasion of portal and/or hepatic vein(s)Xx_NEWLINE_xXExtracapsular tumor extensionXx_NEWLINE_xXBiopsy accessible tumor depositsXx_NEWLINE_xXDiagnosis of presumed non-muscle invasive bladder cancer based on office based cystoscopy (primary or recurrent), and planned transurethral resection of bladder tumor (TURBT)Xx_NEWLINE_xXSubjects must have positive mesothelin expression in the archival tumor tissue, defined as the mesothelin membrane intensity score of 2+ or 3+ (on the 0-3 scale) expressed on the membrane of >= 10% of tumor cellsXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXPatients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse \r\n* Primary strata\r\n** Wilms tumor\r\n** Rhabdomyosarcoma\r\n** Neuroblastoma\r\n* Secondary strata: miscellaneous CD56-expressing tumors:\r\n** Pleuropulmonary blastoma\r\n** Malignant peripheral nerve sheath tumor (MPNST)\r\n** Synovial sarcomaXx_NEWLINE_xXConfirmed p53 involvement: patients with p53 over-expression by immunohistochemistry (>= 10% of cells within the tumor staining positive) or those with a p53 mutation as determined by mutational analysis of tumor tissue will be eligible; patients with prior exposure to p53-based vaccines will be eligibleXx_NEWLINE_xXPatients must be untreated with curative-intent surgery for current diagnosis of stage III, IVa, or IVb disease; diagnostic biopsy of primary tumor and/or nodal sites is permitted\r\n* Diagnostic simple tonsillectomy is permitted, provided patient has Response Evaluation Criteria in Solid Tumors (RECIST)-measurable nodal disease\r\n* Patients with a second HNSCC primary tumor are eligible for this study, provided more than 2 years have elapsed since the first diagnosis of HNSCC, the original tumor was managed with surgery only (no adjuvant chemotherapy or radiotherapy), and has not recurredXx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at restXx_NEWLINE_xXp16 positive by immunohistochemistry (defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells, confirmed by central pathology review)Xx_NEWLINE_xXPatients with simultaneous primary cancers or separate bilateral primary tumor sites are excluded with the exception of patients with bilateral tonsil cancersXx_NEWLINE_xXPatients that require urgent therapy due to tumor mass effects or spinal cord compressionXx_NEWLINE_xXCOHORT EXPANSION PHASE: At least one tumor lesion amenable to core needle biopsy without unacceptable risk of a major procedural complication (one pretreatment and at least one on-treatment biopsy will be performed)Xx_NEWLINE_xXImmunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXPatients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic or unresectable; in the dose expansion phase, the tumor must express AR by immunohistochemistry; if >= 1% of the tumor cells express AR, it will be considered positive for this trialXx_NEWLINE_xXPatients must have recurrent or persistent ovarian, fallopian tube, peritoneum, and endometrial clear cell carcinoma; primary tumors must be at least 50% clear cell histomorphology in order to be eligible or have a histologically documented recurrence with at least 50% clear cell histomorphology; in addition, the tumors should be negative for expression of Wilms tumor 1 (WT-1) antigen (with the exception of endometrial cancers where WT-1 stains are not required) and estrogen receptor (ER) antigen by immunohistochemistry; focal, weak, ER staining of tumor cells (< 5%) is permitted; appropriate tissue sections must be available for histologic evaluation for central pathology review by Gynecologic Oncology Group (GOG); immunohistochemical stained slides for ER and WT-1 antigen must be available for review by GOG\r\n* If the primary tumor had at least 50% clear cell histomorphology, a biopsy of the recurrent or persistent tumor is not required; however, immunohistochemical studies of the primary tumor for ER and WT-1 antigens should be performed and the slides submitted to the GOG for review; the percentage of clear cell histomorphology must be documented in the pathology report or in an addendum to the original report; if slides of the primary tumor are not available for review due to disposal of slides by the histology laboratory (typically 10 years after diagnosis), biopsy of recurrent or persistent disease is required\r\n* If the primary tumor had less than 50% clear cell histomorphology (or if slides of the primary tumor are not available for review), a biopsy of the recurrent or persistent tumor is required to confirm at least 50% clear cell histomorphology and lack of immuno-reactivity for ER and WT-1 antigens by immunohistochemistry; the percentage of involvement must be documented in the pathology report or in an addendum to the original reportXx_NEWLINE_xXPre-surgery tumor deemed amenable to core biopsy (with at least 100 mm^3 tumor volume per biopsy)Xx_NEWLINE_xXImaging studies show evidence of recurrent, supratentorial tumor(s); the presence of infratentorial tumor is allowed as long as the patient also has supratentorial disease that is amenable to resection or biopsyXx_NEWLINE_xXThe patient must be in need of a craniotomy for tumor resection or a stereotactic brain biopsy for the purpose of diagnosis or differentiating between tumor progression versus treatment-induced effects following radiation therapy +/- chemotherapyXx_NEWLINE_xXBased on the neurosurgeon's judgement, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventriclesXx_NEWLINE_xXSubmission of tumor samples is required for all patients; the local pathology department policy regarding release of tumor samples must be considered in the screening process; patients whose tumor samples are located in a pathology department that by policy will not submit any samples for research purposes should not be approached for participation in the B-52 trialXx_NEWLINE_xXDocumented laboratory (lab) results confirming tumor mutational status must be obtained at screening; patients in whom mutational status cannot be determined will be deemed ineligibleXx_NEWLINE_xXUnresectable stage III or IV validated by clinical criteria (including recurrent melanoma), or patients with multiple skin/soft tissue metastases of melanoma that may be resectable but are judged to have a future recurrence risk exceeding 70% (e.g., large adenopathy, distant skin metastases or multiple in-transit melanoma metastases); tumor deemed amenable to biopsy (excisional, incisional, or core, with at least 100 mm^3 tumor volume per biopsy date) and fine-needle aspiration (FNA) biopsy\r\n* NOTE: optimally, patients will have tumor approachable for three serial biopsies during the trial; for patients with only one or two tumors approachable for biopsy, available tumor blocks from prior biopsies can serve as the pretreatment sample, but only if formalin-fixed tumor tissue is available and adequate to provide at least 20 unstained slides with sufficient tumor for analysis\r\n* NOTE: patients with unresectable advanced stage III or IV melanoma (including recurrent melanoma) are only eligible if they have failed at least one other first-line systemic therapy (other than adjuvant therapy); exceptions to this requirement are those patients who have refused and/or are ineligible for other systemic therapies\r\n* NOTE: v-raf murine sarcoma viral oncogene homolog B inhibitor (BRAFi) should be considered for all ‘unresectable” or metastatic melanoma with BRAFV600E mutation; for low burden in-transit disease patients may enter trial without prior systemic therapy\r\n** Stage IV no evidence of disease (NED) is excluded by this criterionXx_NEWLINE_xXPatient must agree to allow 3 separate biopsies of any malignant lesion; biopsies do not need to be done if:\r\n* Tumor is not considered accessible by either the investigator or the person performing the biopsy (it is determined the risk is too high due to location near vital organs or too great of a risk of an adverse event)\r\n* Patient is on anticoagulation and it would be unsafe to temporarily hold the anticoagulation\r\n* Consent of the principal investigator (PI) not to have a biopsy done\r\n* A minimum of 8 subjects must participate in the biopsy part of the studyXx_NEWLINE_xXAny hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registrationXx_NEWLINE_xXTumor diameter =< 7 cmXx_NEWLINE_xXInclusion Criteria (summary):\n\n          -  Age between 18 and 75 years (inclusive) at screening.\n\n          -  Karnofsky performance status (KPS) of 70 or higher or Eastern Cooperative Oncology\n             Group (ECOG) 0-1 at screening.\n\n          -  Subjects with a histological or cytopathological confirmed diagnosis of a locally\n             advanced or metastatic solid tumor malignancy for which primary treatment is no\n             longer effective or does not offer curative or life-prolonging potential per\n             clinician judgment, with the understanding that DCVax-Direct is not intended as a\n             treatment of last resort.\n\n          -  Not eligible for complete resection due to either tumor location, physician's\n             assessment or subject's choice.\n\n          -  Must have completed at least one recent treatment regimen in the metastatic or\n             advanced setting in the disease currently under treatment to reduce tumor burden.\n\n          -  Any steroid therapy >2 mg dexamethasone or equivalent dose should be stopped or have\n             been tapered down 2 weeks prior to the leukapheresis.\n\n          -  At least one measurable tumor mass, i.e. a lesion that can accurately be measured by\n             CT/MRI in at least one dimension with longest diameter ? 1 cm, that is accessible for\n             injection either with or without imaging (CT/ultrasound) guidance.\n\n          -  Adequate hematological, hepatic, and renal function,\n\n          -  Adequate blood coagulation parameters\n\n          -  Life expectation of >3 months.\n\n        Exclusion Criteria (Summary):\n\n          -  Positive HIV-1, HIV-2, or Human T-lymphotropic virus (HTLV-I/II) tests.\n\n          -  History of current or prior (within the last two years) active clinically significant\n             malignancy other than the tumor type for which DCVax-Direct treatment is considered,\n             and except for primary tumor in the case of metastases and adequately treated basal\n             cell or squamous cell skin cancer or in situ cervical cancer.\n\n          -  Heavily pretreated (HP) subjects are not eligible for this study, unless treatments\n             have occurred more than 1 year in the past.\n\n          -  Presence of brain metastases, unless treated surgically and/or irradiated and\n             clinically stable off steroids or on low dose (< 2 mg per day) steroids for ? 14\n             days, or presence of leptomeningeal disease.\n\n          -  History of immunodeficiency or unresolved autoimmune disease.\n\n          -  Requirement for ongoing immunosuppressants.\n\n          -  Prior active immunotherapy for cancer within the past 2 years.\n\n          -  Ongoing medical need for continuous anti-coagulation or anti-platelet medication.\n\n          -  Known genetic cancer-susceptibility syndromes.\n\n          -  Acute or active uncontrolled infection\n\n          -  Ongoing fever ? 101.5 degrees F/38.6 degrees C at screening.\n\n          -  Unstable or severe intercurrent medical conditions such as unstable angina,\n             uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.\n\n          -  Females of child-bearing potential who are pregnant or lactating or who are not using\n             adequate contraception (surgical, hormonal or double barrier, i.e. condom and\n             diaphragm).\n\n          -  Allergy or anaphylaxis to any of the reagents used in this study.\n\n          -  Inability to obtain informed consent because of psychiatric or complicating medical\n             problems.\n\n          -  Inability or unwillingness to return for required visits and follow-up exams.Xx_NEWLINE_xXInclusion Criteria (summary):\n\n          -  Age between 18 and 75 years (inclusive) at screening.\n\n          -  Karnofsky performance status (KPS) of 70 or higher or Eastern Cooperative Oncology\n             Group (ECOG) 0-1 at screening.\n\n          -  Subjects with a histological or cytopathological confirmed diagnosis of a locally\n             advanced or metastatic solid tumor malignancy for which primary treatment is no\n             longer effective or does not offer curative or life-prolonging potential per\n             clinician judgment, with the understanding that DCVax-Direct is not intended as a\n             treatment of last resort.\n\n          -  Not eligible for complete resection due to either tumor location, physician's\n             assessment or subject's choice.\n\n          -  Must have completed at least one recent treatment regimen in the metastatic or\n             advanced setting in the disease currently under treatment to reduce tumor burden.\n\n          -  Any steroid therapy >2 mg dexamethasone or equivalent dose should be stopped or have\n             been tapered down 2 weeks prior to the leukapheresis.\n\n          -  At least one measurable tumor mass, i.e. a lesion that can accurately be measured by\n             CT/MRI in at least one dimension with longest diameter ? 1 cm, that is accessible for\n             injection either with or without imaging (CT/ultrasound) guidance.\n\n          -  Adequate hematological, hepatic, and renal function,\n\n          -  Adequate blood coagulation parameters\n\n          -  Life expectation of >3 months.\n\n        Exclusion Criteria (Summary):\n\n          -  Positive HIV-1, HIV-2, or Human T-lymphotropic virus (HTLV-I/II) tests.\n\n          -  History of current or prior (within the last two years) active clinically significant\n             malignancy other than the tumor type for which DCVax-Direct treatment is considered,\n             and except for primary tumor in the case of metastases and adequately treated basal\n             cell or squamous cell skin cancer or in situ cervical cancer.\n\n          -  Heavily pretreated (HP) subjects are not eligible for this study, unless treatments\n             have occurred more than 1 year in the past.\n\n          -  Presence of brain metastases, unless treated surgically and/or irradiated and\n             clinically stable off steroids or on low dose (< 2 mg per day) steroids for ? 14\n             days, or presence of leptomeningeal disease.\n\n          -  History of immunodeficiency or unresolved autoimmune disease.\n\n          -  Requirement for ongoing immunosuppressants.\n\n          -  Prior active immunotherapy for cancer within the past 2 years.\n\n          -  Ongoing medical need for continuous anti-coagulation or anti-platelet medication.\n\n          -  Known genetic cancer-susceptibility syndromes.\n\n          -  Acute or active uncontrolled infection\n\n          -  Ongoing fever ? 101.5 degrees F/38.6 degrees C at screening.\n\n          -  Unstable or severe intercurrent medical conditions such as unstable angina,\n             uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.\n\n          -  Females of child-bearing potential who are pregnant or lactating or who are not using\n             adequate contraception (surgical, hormonal or double barrier, i.e. condom and\n             diaphragm).\n\n          -  Allergy or anaphylaxis to any of the reagents used in this study.\n\n          -  Inability to obtain informed consent because of psychiatric or complicating medical\n             problems.\n\n          -  Inability or unwillingness to return for required visits and follow-up exams.Xx_NEWLINE_xXNo tumor in contact with, invading or encasing any major blood vesselsXx_NEWLINE_xXNo evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of treatmentXx_NEWLINE_xXNo evidence of tumor potentially causing airway obstructionXx_NEWLINE_xXTumor may have a v-raf murine sarcoma viral oncogene homolog B (B-RAF) V600 mutation or be BRAF wild type, and patients must not have been previously treated with ipilimumabXx_NEWLINE_xXPatients must have histologically diagnosed American Joint Committee on Cancer (AJCC) stage II, III, or IV HCC not eligible for curative resection, transplantation, or ablative therapies\r\n* Cases with mixed, composite, or combined HCC-cholangiocarcinoma histology are eligible with approval from study chair and provided the treating investigator believes it is in the best interest of the patient to treat the tumor with therapy targeted towards the HCC component of tumor based upon review of pathology and clinical\r\ncharacteristicsXx_NEWLINE_xXBiliary tract cancers or fibrolamellar variant tumors are excluded\r\n* Cases with mixed, composite, or combined HCC-cholangiocarcinoma histology are eligible with approval from study chair and provided the treating investigator believes it is in the best interest of the patient to treat the tumor with therapy targeted towards the HCC component of tumor based upon review of pathology and clinical characteristicsXx_NEWLINE_xXPatients with histology consisting of endometrial stromal sarcoma, leiomyosarcoma or malignant mixed Mullerian tumor (MMMT or carcinosarcoma)Xx_NEWLINE_xXPretreatment tumor biopsy with sufficient tumor for HPV or p16 analysis is required; the tumor must be HPV(+) or p16(+)Xx_NEWLINE_xXPatients must have, in the opinion of a treating physician, tumor that is accessible to biopsy in the clinicXx_NEWLINE_xXTumor must have a v-raf murine sarcoma viral oncogene homolog B (B-RAF) V600E, D or K mutation by Cobas pyrosequencing assay or equivalentXx_NEWLINE_xXNote: optional tumor biopsies (punch, fine needle aspiration [FNA], core or excisional) at pre-treatment, week 1, and at progression will be presented to subjects considering this study; we anticipate approximately 1-3 patients per cohort to have tumors biopsied for correlative studies; the additional subjects at the recommended phase II dose (RP2D) (expansion cohort) are required to have correlative studies (blood collection and tumor biopsies at the defined time points)Xx_NEWLINE_xXAll patients who have received prior chemotherapy for histologically proven advanced non-small cell lung cancer, and whose tumors display the appropriate phenotype, i.e. high ISG15 (ISG15H), are eligible; results of tumor screening will be sent in writing from Lovelace Respiratory Research Institute within 14 days of submitting tumor specimens for screening; screening may occur prior to failure of frontline, second, or third line regimen\r\n* Note: A separate informed consent document will be available for patients to undergo screening for ISG15H statusXx_NEWLINE_xXSubjects with a histologic diagnosis of solid tumor cancers of epithelial origin.Xx_NEWLINE_xXPatients with T4 disease with radiographic evidence of massive invasion of a large pulmonary artery and tumor causing significant narrowing and destruction of that artery are excludedXx_NEWLINE_xXAbility and willingness to undergo repeat tumor biopsies (the biopsy is optional and only applicable to subjects considered for the expansion cohort stage of the study)Xx_NEWLINE_xXIf tumor size is < 1 cm on mammography and all calcifications are removed on core biopsy the patient will be excludedXx_NEWLINE_xXInoperable tumor or residual disease after resectionXx_NEWLINE_xXPathologic proven diagnosis of solid tumor malignancyXx_NEWLINE_xXRadiosensitive (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologiesXx_NEWLINE_xXPositive staining of tumor tissue with antibodies to 1 or more of the following: human melanoma black (HMB) 45 for gp100, or cancer-testis antigen (NY-ESO-1)Xx_NEWLINE_xXPatients must have a paraffin embedded tumor specimen from the kidney or metastatic site available for central review of tumor histology; tumor samples will be shipped as specifiedXx_NEWLINE_xXAt least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXPatients are preferred to have either a tumor mass amenable to core needle biopsy during the dosimetry phase, or a measurable tumor mass with at least one site of involvement measuring 2.0 cm in largest dimension on computed tomography (CT) imaging for purposes of planar and/or single-photon emission CT (SPECT)/CT tumor dosimetry (patients with disease that does not allow tumor dosimetry will be allowed on study since they still can contribute toward achieving the primary endpoint, but these patients will be given a lower priority over those with evaluable disease)Xx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXPathologically (histologically or cytologically) confirmed diagnosis of recurrent or second primary squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, larynx, or recurrent neck metastases with unknown primary; exception from pathology confirmation of tumor recurrence is accepted for patients who originally had pathologically confirmed SCC of the Head and Neck, the new tumor is located in the head and neck area and it is clinically considered as a recurrence of the original tumor, and a tumor biopsy is technically difficult and would expose the patient to unjustified risk; the treating physicians should agree and document the clinical definition of tumor recurrence and should document the increased risk for biopsyXx_NEWLINE_xXPrior history of head and neck radiation for head and neck squamous cell carcinoma to no more than 72 Gy and most (> 75%) of the recurrent or second primary tumor volume should be in areas previously irradiated to > 45 GyXx_NEWLINE_xXFolate receptor alpha positive tumor expression as defined in the protocolXx_NEWLINE_xXAll visible papillary tumors must be resected and those with persistent T1 disease on transurethral resection of bladder tumor (TURBT) should undergo an additional re-TURBT within 14 to 60 days prior to beginning study treatment. Obvious areas of CIS should also be fulgurated.Xx_NEWLINE_xXPatients with T1 disease accompanied by the presence of hydronephrosis secondary to the primary tumorXx_NEWLINE_xXPatients must have had progressive disease on, after, or refused, appropriate approved therapy for their tumor type.Xx_NEWLINE_xXPatients must have hepatocellular carcinoma (HCC) with one of the following: \r\n* Microvascular/macrovascular invasion, \r\n* Tumor outside of Milan criteria, \r\n* Poor tumor differentiation; \r\n* Elevated surrogate markers (AFP > 500 or PIVKA [DCP] > 400) pre transplant and with biopsy proven HCC prior to orthotopic liver transplantation (OLT) or on explantsXx_NEWLINE_xXRhabdoid tumor:Xx_NEWLINE_xXNI1-negative tumor:Xx_NEWLINE_xXEpithelioid malignant peripheral nerve sheath tumorXx_NEWLINE_xXFor subjects with ATRT, MRT, RTK, or selected tumors with rhabdoid features only, the following test results must be available: Morphology and immunophenotypic panel consistent with rhabdoid tumor and loss of INI1 or SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 or SMARCA4 loss/mutation when INI1 or SMARCA4 IHC is equivocal or unavailableXx_NEWLINE_xXFor subjects with INI1 negative tumor only, the following test results must be available: Morphology and immunophenotypic panel consistent with INI1-negative tumors, and loss of INI1 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 loss/mutation when INI1 IHC is equivocal or unavailableXx_NEWLINE_xXEpithelioid malignant peripheral nerve sheath tumorXx_NEWLINE_xXCohort 4 - Tumor types eligible for Cohorts 1 through 3 or synovial sarcoma with SS18-SSX rearrangementXx_NEWLINE_xXFor subjects with ATRT/MRT/RTK only - Has the following test results available: Morphology and immunophenotypic panel consistent with rhabdoid tumor, and loss of INI1 or SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 or SMARCA4 loss/mutation when INI1 or SMARCA4 IHC is equivocal or unavailableXx_NEWLINE_xXMolecular confirmation of tumor bi-allelic INI1 loss/mutation when INI1 IHC is equivocal or unavailableXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXDLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment of banked or otherwise representative tumor tissue. Positive is defined as staining in ? 1% of tumor cells.Xx_NEWLINE_xXSubjects (NSCLC and gastric adenocarcinoma) must be determined to have HA-high levels from their tumor biopsies.Xx_NEWLINE_xXPatients must have stage cT2-T4a N0 M0 disease; clinical T stage is based on the transurethral resection of bladder tumor (TURBT) sample and imaging studies; patients must undergo cystoscopy and TURBT as part of the staging procedure within 56 days prior to registration; to exclude non-bulky/low-risk tumors and ensure adequate tissue for assessment, subjects must have documented muscle invasion with at least one of the following:\r\n* Disease measuring at least 5 mm on cross-sectional imaging or by endoscopic assessment; bladder thickening on imaging without definable tumor is not adequate; pathology verification of >= 0.5 cm of viable tumor (longest diameter) from the biopsy sample and represented on the submitted slides is also acceptable\r\n* The presence of tumor-associated hydronephrosisXx_NEWLINE_xXPatients must be offered the opportunity to participate in the ultra pure Circulating Tumor Cells (upCTCs) studyXx_NEWLINE_xXTumor sample must be available for analysis of PDL1 (Programmed death-ligand 1) and HPV [Human Papilloma Virus (oropharynx only)]Xx_NEWLINE_xXPatient must agree to undergo central tumor HRD testingXx_NEWLINE_xXTest result showing genetic change in MET tumor geneXx_NEWLINE_xXAt least one tumor that can be measured on a radiographic scanXx_NEWLINE_xXUncontrolled tumor in the brainXx_NEWLINE_xXSubjects with an active severe infection or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).Xx_NEWLINE_xXPortion A: Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy or B cell lymphoma, for which no curative therapy is available. Portion A expansion includes patients who have documented disease progression on a checkpoint inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose expansion stage are required to provide archival or baseline (obtained during the screening period) tumor biopsies.Xx_NEWLINE_xXPatients K-ras status must be wild type (not mutated); K-ras status determination may be based on either primary or metastatic tumor\r\n* NOTE: the assay must be performed by a Clinical Laboratory Improvement Amendments (CLIA) approved laboratoryXx_NEWLINE_xXPatient is after surgical resection of the tumor where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor and with available archival tumor tissue from the surgical specimenXx_NEWLINE_xXPart 4: select advanced solid tumor or hematologic malignancyXx_NEWLINE_xXFresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of the most recent prior chemotherapy regimen) are required for all cohorts except glioblastomaXx_NEWLINE_xXb) Solid tumor treated curatively more than 5 years previously without evidence of recurrence orXx_NEWLINE_xXMSI status is, respectively, determined by examining CRC tumor.Xx_NEWLINE_xXBaseline archival tumor specimen available or willing to undergo a prestudy treatment tumor core or excisional biopsy of a tumor lesion not previously irradiated, to obtain the specimen.Xx_NEWLINE_xXProvide a baseline tumor biopsyXx_NEWLINE_xXLocally advanced, relapsed, or metastatic sarcoma with measurable tumor burden following therapy, as defined by RECIST v1.1; the total of all lesions must be ?12 cm (for synovial sarcoma) or ?15 cm (for myxoid/round cell liposarcoma [MRCL]).Xx_NEWLINE_xXTumor histology consistent with synovial sarcoma or MRCL.Xx_NEWLINE_xXTumor specimen positive for NY-ESO-1 expression by IHC.Xx_NEWLINE_xXPatient must have archived primary tumor biopsies or surgical specimens, or biopsies of recurrent or metastatic samplesXx_NEWLINE_xXPatient must be amenable to serial peripheral blood sampling, urine sampling, and tumor biopsies during the studyXx_NEWLINE_xXPatients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.Xx_NEWLINE_xXUncontrolled tumor-related pain.Xx_NEWLINE_xXNon epithelial tumor or ovarian tumors with low malignant potential (ie, borderline tumors).Xx_NEWLINE_xXTumor specimen positive for NY-ESO-1 expression by IHC and/or RT-PCR. At least one tumor must be accessible and patients must consent for biopsies in Arms C and D.Xx_NEWLINE_xXNon-GI solid tumors (like non-small cell lung cancer or breast cancer) should have confirmed CEA expression in tumor tissue >/= 20% of tumor cells staining with at least moderate to high intensity of CEA expression are required (immunohistochemistry [IHC]2+ and IHC 3+). For CRC, pancreatic and gastric cancer participants, the CEA assessment will be performed retrospectively and the result is not needed to enroll the participant. For the biomarker cohort, only participants with moderate/low CEA expression (< 20% of tumor cells with IHC2+/3+ and/or >/= 20% of tumor cells with IHC1+) and very low CEA expression (< 20% of tumor cells with IHC1+) will be enrolled. CEA expression should be determined prior to enrollment, if no archival tumor tissue is available, a fresh biopsy will be collected.Xx_NEWLINE_xXDocumented HER2 overexpression or gene-amplified tumor by a validated approved methodXx_NEWLINE_xXFor certain subjects, willing and able to provide pre-treatment and on-treatment fresh tumor biopsyXx_NEWLINE_xXKRAS or NRAS mutation detected in tumor specimenXx_NEWLINE_xXTumor in contact with, invading or encasing any major blood vessels found on radiology reportXx_NEWLINE_xXEvidence of endotracheal or endobronchial tumorXx_NEWLINE_xXIf primary tumor has not been resected, it must be clinically stableXx_NEWLINE_xXTumor replacement <50% of total liver volumeXx_NEWLINE_xXTotal (aggregate) gross tumor volume > 500 cm^3 (500 cc’s or 0.5 liters)Xx_NEWLINE_xXHistologically confirmed high-grade upper tract transitional cell carcinoma at Memorial Sloan-Kettering Cancer Center (MSKCC) or a participating site and/or radiographically visible tumor stage T2-T4a N0/X M0 disease with positive selective urinary cytology; hydronephrosis associated with tumor on imaging or biopsy will be considered invasive by definitionXx_NEWLINE_xXThe tumor is unresectable and not amenable to curative therapy.Xx_NEWLINE_xXHas an adequate tumor sampleXx_NEWLINE_xXAvailability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testingXx_NEWLINE_xXTumor accessible for biopsyXx_NEWLINE_xXMust be willing to undergo tumor biopsy at study entry for biologic correlates.Xx_NEWLINE_xXIf patient > 18 years, must be willing to undergo on-treatment tumor biopsy unless medically contra-indicatedXx_NEWLINE_xXFive grams of resected tumor available for vaccine manufacture as determined by institutional pathologist; seven grams of tumor is preferredXx_NEWLINE_xXFirst recurrence after concurrent or adjuvant chemoradiotherapy. Imaging confirmation of first tumor progression or regrowth as defined by the RANO criteria . A minimum of 12 weeks must have elapsed from the completion of radiotherapy to study entry to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, unless there is a new lesion outside the radiation field or unequivocal evidence of viable tumor on histopathological sampling.Xx_NEWLINE_xXPatients who have undergone recent surgery for recurrent or progressive tumor are eligible provided that:Xx_NEWLINE_xXEvidence of recent hemorrhage on baseline MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving hemorrhagic changes related to surgery, or presence of punctuate hemorrhage in the tumor are eligible.Xx_NEWLINE_xXThe subject is willing to undergo tumor biopsy during the Screening period, or if the tumor is inaccessible for biopsy, archived tumor material must be available for submission;Xx_NEWLINE_xXParticipants must have histological diagnosis consistent of Anaplastic Thyroid Cancer (ATC). Cytologic diagnosis by fine needle aspiration alone is not sufficient. Histologic diagnosis may be made by core needle biopsy, incisional biopsy, thyroidectomy, or other surgical biopsy. Fresh tumor biopsies (re-biopsy) should be obtained whenever feasible. The central pathology review may take place prior to or after the participant starts treatment with lenvatinib.Xx_NEWLINE_xXSubjects must have a previously treated advanced solid tumor to be eligibleXx_NEWLINE_xXWilling and able to provide pre-treatment and on-treatment fresh tumor biopsyXx_NEWLINE_xXAll subjects must consent to provide archived tumor specimenXx_NEWLINE_xXTumor specimen availabilityXx_NEWLINE_xXSolid tumors with tumor-induced painXx_NEWLINE_xXWillingness to provide archival tumor samplesXx_NEWLINE_xXSubject must not have been treated previously with talimogene laherparepvec or tumor vaccine.Xx_NEWLINE_xXTumor histology consistent with melanoma tumor specimen positive for NY-ESO-1 expression by IHC and/or RT-PCR.Xx_NEWLINE_xXPresence of multiple small bowel loops trapped within the immediate tumor bed (post hysterectomy or prostatectomy)Xx_NEWLINE_xXA tumor accessible for biopsies and consent to undergo tumor biopsies before and during MSC2363318A treatment. Subjects who do not have a tumor suitable for biopsy (such as, but not limited to, high procedural risk, inaccessible site for needle biopsy, etc.) but are otherwise eligible for this study may be considered for enrollment on a case-by-case basis after discussion with the Medical Monitor of the studyXx_NEWLINE_xXKnown tumor EGFR, KRAS, and/or Akt2 mutations or amplificationXx_NEWLINE_xXHistologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible\r\n* The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved; the pathology report must include documentation of the margin status and the size of the tumor; the pathology report must also include the status of the three major margins—bile duct, pancreatic parenchyma, and retroperitoneal (uncinate)Xx_NEWLINE_xXPer the operative and/or pathology report, positive margin(s) (defined as tumor present at the cut or inked edge of the tumor), nodal extracapsular extension, and/or gross residual disease after surgery; note: patients whose tumors had focally positive margins in the main specimen but negative margins from re-excised samples in the region of the positive margin are eligible; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patientXx_NEWLINE_xXNon-antibody immunotherapy (e.g., tumor vaccine) At least 42 daysXx_NEWLINE_xXArchival tumor samples must be obtained from primary and/or metastatic sitesXx_NEWLINE_xXIf archival tumor is available for submission, patients must be willing to submit tumor sampleXx_NEWLINE_xXSingle enhancing lesion that is >1 cm, but < 4 cm in cross-sectional dimension, including thalamic tumor (? 3 cm)Xx_NEWLINE_xXSymptoms due to mass effect of the tumor including high intracranial pressure, marked edema or ?5mm midline shift significantXx_NEWLINE_xXIncidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [Tumor, node, metastases (TNM)] clinical staging system).Xx_NEWLINE_xXResected tumor: No evidence of gross tumor at the surgical resection margin noted in the final surgery report. No evidence of gross residual adenopathyXx_NEWLINE_xXPrimary tumor is available for shipment to central laboratory for analysis of FR? expression by IHC.Xx_NEWLINE_xXHER-2 negative tumor (primary tumor or metastatic lesion)Xx_NEWLINE_xXHistologic or cytologic documentation of metastatic or Stage IIIc unresectable melanoma, with BRAFV600 mutation as assessed by BRAFV600 Mutation Test. Origin of the primary tumor may be of skin, mucosal, or acral locations but not of uveal origin. Participants having an unknown primary tumor may be eligible if uveal melanoma can be ruled outXx_NEWLINE_xXHistologically documented adenocarcinoma of the colon; the gross inferior (caudad) margin of the primary tumor must lie above the peritoneal reflection (i.e., patients with rectal cancer are not eligible); surgeon confirmation that the entire tumor was above the peritoneal reflection is only required in cases where it is important to establish if the tumor is a rectal or colon primaryXx_NEWLINE_xXPatients with synchronous colon cancers are eligible and staging for stratification will be based on higher N stage of the more advanced primary tumor; however, patients with synchronous colon and rectal primary tumors are not eligibleXx_NEWLINE_xXNon-antibody immunotherapy (e.g., tumor vaccine); at least 42 days since last doseXx_NEWLINE_xXDate of Mayo Clinic Genomics Tumor Board review =< 3 months prior to registrationXx_NEWLINE_xXAvailability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FLXx_NEWLINE_xXHave at least one untreated and progressing tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid TumorXx_NEWLINE_xXA fresh tumor biopsy for the purpose of screening or an available archival tumor sample. Tumor lesions used for fresh biopsies should not be the same lesions used as RECIST target lesions, unless there are no other lesions suitable for biopsy.Xx_NEWLINE_xXTumor involves a weight-bearing long bone of the lower extremity with the tumor causing > 50% loss of cortical boneXx_NEWLINE_xXHas undergone prior surgery at the tumor site or the index tumor has undergone previous surgery or ablation treatmentXx_NEWLINE_xXIndex tumor causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacementXx_NEWLINE_xXAnticipated treatment of the index tumor that would require iceball formation within 0.5 cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel (possibly achieved with additional maneuvers such as hydrodissection)Xx_NEWLINE_xXIndex tumor involves the skullXx_NEWLINE_xXSolid tumor contact with SMA > 180°Xx_NEWLINE_xXTumor MGMT promoter hypermethylation determined by central testing at MD AndersonXx_NEWLINE_xXHistory of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the participant has undergone potentially curative therapy with no evidence of that disease for 5 yearsXx_NEWLINE_xXHistologic diagnosis of a benign or borderline tumor (‘tumor of low malignant potential’) or of a malignant tumor of non-epithelial origin (such as a germ cell tumor, sex-cord stromal tumor) of the ovary, fallopian tube or peritoneumXx_NEWLINE_xXA representative tumor specimen must be available for molecular testing.Xx_NEWLINE_xXPatients who have had gross total excision of the primary tumor.Xx_NEWLINE_xXPatients with primary tumor of oral cavity, nasopharynx, sinuses or salivary glands.Xx_NEWLINE_xXTumor replacement > 70% of total liver volume based on visual estimation by investigator OR tumor replacement >50% of total liver volume in the presence of albumin <3 mg/dLXx_NEWLINE_xXPatients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)Xx_NEWLINE_xXBiopsies (DLBLC, MM): Diagnostic archival FFPE (either in tumor blocks or sectioned/mounted specimens) may be submitted in lieu of a pre-study research biopsy if it has been obtained no more than 1 year prior to enrollment and only after discussion with the Celgene Medical MonitorXx_NEWLINE_xXIf not specified above as tumor specific parameter subjects must have the following laboratory and hematologic parameters as follows:Xx_NEWLINE_xXDocumentation of ER positive (? 1% positive stained cells by local standards) based on the most recent tumor biopsy, unless bone-only diseaseXx_NEWLINE_xXHistory of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor typeXx_NEWLINE_xXTumor sites that can be accessed for repeat biopsiesXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXOperable tumor measuring >= 1.5 cm in maximal diameter\r\n* Any nodal status\r\n* Multifocal and multicentric disease is permitted\r\n* Synchronous bilateral invasive breast cancer is permitted\r\n* The tumor should be more than 5 mm from the skinXx_NEWLINE_xXTumor amenable to cryoablation as determined by radiologistXx_NEWLINE_xXpredominantly epithelial (?50% tumor component) pleural or peritoneal mesotheliomaXx_NEWLINE_xXhave at least 1 measurable lesion assessable by radiological imaging. Tumor lesions located in a previously irradiated area are considered measureable if progression has been demonstrated in such lesionsXx_NEWLINE_xXhave prior or concurrent malignancies, inclusive of hematologic, primary brain tumor, sarcoma, and other solid tumors, unless in complete remission with no therapy for a minimum of 5 yearsXx_NEWLINE_xXClinical status of either subject or tumor such that administration of 21 day neoadjuvant IRX-2 Regimen 1 or 2 before surgery would be medically inappropriateXx_NEWLINE_xXTumor of the oropharynxXx_NEWLINE_xXTumor involvement of the following sites or any of these signs or symptoms likely to be associated with T4b cancer:Xx_NEWLINE_xXgross extension of tumor to the skull base;Xx_NEWLINE_xXTumorXx_NEWLINE_xXFor dose escalation part: Patients with MCL at high risk for tumor lysis syndromeXx_NEWLINE_xXAvailability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL or DLBCLXx_NEWLINE_xXInoperable, locally recurrent or metastatic disease (tumor resectability should be assessed by a local surgeon or multidisciplinary team)Xx_NEWLINE_xXHistological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesionXx_NEWLINE_xXLocally recurrent tumor which is amenable to curative resection (as deemed by a local surgeon or multidisciplinary team)Xx_NEWLINE_xXTumor relapse/progression within 6 months of completion of a cisplatin-based chemoradiotherapy regimen for the treatment of early stage tumorsXx_NEWLINE_xXPrevious use of systemic chemotherapy or other investigational drugs for the treatment of inoperable locally recurrent or metastatic tumors (previous use of radiotherapy or chemotherapy in this setting is not an exclusion criterion if: 1) non-irradiated target tumor lesions are present at randomization for the purpose of tumor response assessment or 2) in the absence of non-irradiated target tumor lesions, progression of the irradiated tumor lesions according to the RECIST criteria version 1.1 is documented)Xx_NEWLINE_xXUncontrolled tumor painXx_NEWLINE_xXParticipation in Iowa Neuroendocrine Tumor RegistryXx_NEWLINE_xXA pre-treatment tumor biopsy demonstrating high TAM content as assessed per the central laboratoryXx_NEWLINE_xXPrimary tumor diameter ?40 mmXx_NEWLINE_xXEvidence of remaining tumorXx_NEWLINE_xXSubmission of copies of tumor measurements and scansXx_NEWLINE_xXPrior treatment with another experimental anti-tumor vaccine is permissibleXx_NEWLINE_xXSubjects must have archival tumor tissues or agree to a tumor biopsy for analysis of predictive biomarkers such as PD-L1. (Fresh tumor biopsies are strongly recommended at baseline for biomarker analysis in subjects with readily accessible tumor lesions and who consent to the biopsies.)Xx_NEWLINE_xXConsent to paired tumor biopsy, for accessible tumorsXx_NEWLINE_xXPatients must be able to enter into the study within ten weeks of their most recent diagnostic procedure, which is usually a diagnostic biopsy, a transurethral resection of bladder tumor (TURBT) procedure or positive urine cytology.Xx_NEWLINE_xXPatients with well-differentiated neuroendocrine carcinoma (carcinoid tumor)Xx_NEWLINE_xXPatients with one-sided, somatic pain due to tumor involvement below the shoulder level (C5 dermatome)Xx_NEWLINE_xXPatients with a history of obstructive jaundice due to the primary tumor must have a metal biliary stent in placeXx_NEWLINE_xXMaximum diameter of enhancing tumor (target lesion) should be =< 3.5 cmXx_NEWLINE_xXHas recurrent or persistent tumor (enhancing area) greater than 3.5 cm in maximum diameterXx_NEWLINE_xXThe tumor must be unifocal, confined to the supratentorial compartment and have undergone a gross total or near gross total resection; this will increase the likelihood that the patient will not require corticosteroids or develop pseudoprogressionXx_NEWLINE_xXPatient must have a palpable, superficial tumor, safely accessible for bedside injection that will be radiated and can be accurately localized and stabilized if neededXx_NEWLINE_xXPD-L1 strong expressing tumor as determined by immunohistochemistry (IHC) at a central laboratoryXx_NEWLINE_xXParticipants with multifocal tumors (more than one tumor confined to the same quadrant as the primary tumor) are eligible provided all discrete lesions are sampled and centrally confirmed as HER2 positiveXx_NEWLINE_xXKnown hormone receptor status of the primary tumorXx_NEWLINE_xXPresence of an archived tumor sample (no size requirements)Xx_NEWLINE_xXMust provide a tumor sample (archival or newly obtained biopsy) that is adequate for determination of PD (programmed cell death)-Ligand 1 status by immunohistochemistry at a central pathology laboratory prior to enrollment. Note: Adequacy of the tumor sample for PD-Ligand 1 testing is not required prior to enrollment in Part 1CXx_NEWLINE_xXNegative histologic margins of partial mastectomy or re-excision specimen; margins generally are positive if there is invasive or noninvasive tumor at the inked resection margin, close but negative if the tumor is within 2 mm of the inked margin and negative if the tumor is at least 2 mm away from the inked edgeXx_NEWLINE_xXSkin involvement, regardless of tumor sizeXx_NEWLINE_xXPatients must have a tumor protein (p)53 mutation which is defined as cytoplasmic positivity by immunohistochemistry and/or next gene mutation sequencingXx_NEWLINE_xXPatients must have their tumor sent for v-Raf murine sarcoma viral oncogene homolog B1(BRAF) mutational analysisXx_NEWLINE_xXPhase 1b: Prior talimogene laherparepvec, ipilimumab, other CTLA-4 inhibitors, PD-1 inhibitors, or tumor vaccineXx_NEWLINE_xXPhase 2: Prior talimogene laherparepvec, other oncolytic virus therapies, or tumor vaccinesXx_NEWLINE_xXThe subject has a primary brain tumorXx_NEWLINE_xXThe subject has tumor invading (or concern for invasion) major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXPatients with skin metastases must agree to tumor fine-needle aspiration (FNA) required by protocolXx_NEWLINE_xXAny \clinical\ T4 tumor as defined by primary tumor/regional lymph nodes/distant metastasis (TNM), including inflammatory breast cancerXx_NEWLINE_xXSubject must undergo mandatory biopsies, including one pretreatment and one post treatment tumor biopsy procedureXx_NEWLINE_xXCD30 positive tumor (result can be pending at this time)Xx_NEWLINE_xXCD30 positive tumorXx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXUp to two (2) cancerous lesions may be identified in the prostate; each tumor is not more than 10 mm in maximal linear dimension; each tumor should comply with the maximal 7 Gleason score requirement.Xx_NEWLINE_xXSubjects with distance of the less than 2mm margin between the tumor and the prostate capsuleXx_NEWLINE_xXPatients must have a high grade urothelial carcinoma stage Ta or T1 that has recurred within 540 days after completion of the initial treatment (transurethral resection bladder tumor [TURBT] and intravesical bacillus Calmette-Guerin [BCG] immunotherapy) or on initial presentation with a T1 high grade tumor, the participating urologist judged BCG therapy is contraindicated or unsuitable because the patient is found to be intolerant of BCG therapy or because this patient may be immuno-compromised in ways other than that mentioned in severe, active co-morbidity or because the patient refuses BCG therapyXx_NEWLINE_xXPatients must have an adequately functioning bladder as judged by the participating urologist and radiation oncologist and have undergone a re-staging TURBT by the participating urologist that showed (or was present in the outside pathology specimen) a high grade stage Ta or T1 tumor with uninvolved muscularis propria in the specimen and, if on prostatic urethral biopsy mucosal carcinoma is present, there is no evidence on biopsy in the prostatic stroma of tumor invasionXx_NEWLINE_xXEvidence of tumor-related hydronephrosisXx_NEWLINE_xXAt the time of study enrollment, the patient’s treatment regimen must be identified; if the patient’s primary tumor was resected prior to the day of enrollment and a blood specimen for the determination of serum alpha fetoprotein was not obtained prior to that surgery, the patient will be considered to have alpha fetoprotein of greater than 100 ng/mL for the purpose of treatment assignment; if tumor samples obtained prior to the date of enrollment were not sufficient to determine whether small cell undifferentiated (SCU) histology was present, treatment assignment will be made assuming SCU is not present in the tumorXx_NEWLINE_xXMust be willing and able to accept at least two tumor biopsiesXx_NEWLINE_xXRAS (KRAS and NRAS) wild-type in primary or metastatic tumor tissueXx_NEWLINE_xXAvailability of archived or representative tumor material for assessment of DLL3 expressionXx_NEWLINE_xXTumor-related pain increased above baseline for 2 weeks and not controlled by a stable dose of opiatesXx_NEWLINE_xXPatients enrolled in the expansion stages must agree to a tumor biopsy to be obtained during the screening period and during Cycle 2 or at the time of PD, if earlier. If a biopsy is deemed by the investigator to not be in the patient's best interest, prior approval must be obtained from the Medical Monitor to waive this requirement.Xx_NEWLINE_xXPatient must have a site of disease for biopsy, and be a candidate for tumor biopsy according to the institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening, and again during therapy on this study.Xx_NEWLINE_xXConfirmation of the availability of a tumor sample from the primary or recurrent cancer must be providedXx_NEWLINE_xXPresence of tumor cells in the brain or spinal cord that have not been treatedXx_NEWLINE_xXMETex14 skipping alterations, as determined by the central laboratory (plasma and/or tumor biopsy sample)Xx_NEWLINE_xXHave a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocolXx_NEWLINE_xXPatients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligibleXx_NEWLINE_xXMeets Milan criteria: a single tumor that is < 5 cm or a maximum of 3 tumors with each tumor < 3 cm AND/OR meets UCSF criteria: a single tumor that is < 6.5 cm in diameter or 2 lesions < 4.5 cm with total tumor diameter < 8 cm AND/OR is outside of both Milan and UCSF criteria and is being evaluated for downstagingXx_NEWLINE_xXPatient must agree to testing of GBM tumor promoter methylation status of the MGMT gene and tumor (IDH1) gene mutation status. Tissue may be tested at study entry, if not done previously, or data may be obtained from last known test result for MGMT and IDH1. IDH1 status may be assessed at study entry, but MGMT status is required prior to randomization.Xx_NEWLINE_xXEvidence of diffuse subependymal disease or tumor in the brainstem, cerebellum, spinal cord, or CSF.Xx_NEWLINE_xXPresence of punctate hemorrhage in the tumor.Xx_NEWLINE_xXPatients with active tumor lysis syndrome (TLS) either from laboratory or clinical changesXx_NEWLINE_xXTumor cell programmed death-ligand 1 (PD-L1) score of tumor cells (TC)1-3 and immune cell PD-L1 score of tumor-infiltrating immune cells (IC)0-3 as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained after the last line of therapyXx_NEWLINE_xXWillingness to undergo a tumor biopsyXx_NEWLINE_xXPatients must agree to pretreatment tumor biopsyXx_NEWLINE_xXCancer Tumor Size: T4Xx_NEWLINE_xXHave radiographic evidence of pulmonary intratumor cavitation, regardless of tumor histology.Xx_NEWLINE_xXAvailability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL or DLBCLXx_NEWLINE_xXContraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapyXx_NEWLINE_xXPatient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue develop within the past 6-months that are =< 5.0 cm or < 250 cm^3Xx_NEWLINE_xXPatient must have had their primary tumor treated with surgery and/or radiationXx_NEWLINE_xXHistologic confirmation of malignancy (primary or metastatic tumor)Xx_NEWLINE_xXSubjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (for nonsquamous NSCLC) or mRECIST (for epithelial pleural mesothelioma). Subjects with resected primary tumors who have documented metastases are eligible.Xx_NEWLINE_xXSurgically eligible for tumor resection with curative intentXx_NEWLINE_xXWilling to attempt a baseline tumor biopsy procedureXx_NEWLINE_xXPatient must have a diagnosis with urothelial carcinoma of the bladder with clinically apparent tumor Ta, G1-G2.Xx_NEWLINE_xXUrethral tumor (prostatic urethra included).Xx_NEWLINE_xXAny invasive bladder tumor known to be other than tumor Ta, G1-G2.Xx_NEWLINE_xXAny bladder tumor with histology other than TCC.Xx_NEWLINE_xXPatient has a tumor in a bladder diverticulum.Xx_NEWLINE_xXFor patients with recurrent tumor, the patient had at least a 6-month cystoscopically-confirmed tumor-free interval between the last tumor recurrence and screening cystoscopic examination.Xx_NEWLINE_xXIntact primary tumor (for Immune Response Cohort only)Xx_NEWLINE_xXInability to undergo two sequential EUS-directed core biopsies of the primary tumor (for Immune Response Cohort only)Xx_NEWLINE_xXTumor must have a supratentorial componentXx_NEWLINE_xXAny patient that has had a biopsy only or less than 25% of their tumor removedXx_NEWLINE_xXPatients will have at least one melanoma deposit that can undergo serial biopsy (at least 2 time points) during the neoadjuvant phase of the protocol; patients must be willing to provide tumor samples at the time points specified in the Study Procedure TablesXx_NEWLINE_xXPrimary tumor resectedXx_NEWLINE_xXAt least one measurable tumor accessible for intratumoral injection and EP on investigator’s assessmentXx_NEWLINE_xXOne of the following:\r\n* Upfront resectable disease; this is defined as:\r\n** No arterial tumor contact (celiac axis [CA], superior mesenteric artery [SMA], or common hepatic artery [CHA]); AND\r\n** No tumor contact with the superior mesenteric vein (SMV) or portal vein (PV), or =< 180 degree contact without vein contour irregularity\r\n* Borderline resectable disease; There are multiple definitions of borderline resectable PDAC including the MD Anderson definition and the criteria developed during the Consensus Conference sponsored by the American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, and Society for Surgery of the Alimentary Tract; borderline resectable PDAC cases will be identified per the definition developed in the currently running inter-group pilot trial for borderline resectable pancreatic cancer (NCT01821612); per this trial, borderline resectable PDAC is defined as the presence of any one or more of the following on CT or MRI:\r\n** An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring >= 180 degrees of the circumference of the vessel wall\r\n** Short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction\r\n** Short segment interface (of any degree) between tumor and hepatic artery with normal artery proximal and distal to the interface that is amenable to resection and reconstruction\r\n** An interface between the tumor and SMA measuring < 180 degrees of the circumference of the vessel wallXx_NEWLINE_xXCentrally confirmed T790M mutation positive tumor status from a tumor sample taken after confirmation of disease progression on the most recent anticancer treatment regimenXx_NEWLINE_xXPatient must have adequate tumor specimen available for submissionXx_NEWLINE_xXLiver function abnormalities as indicated by ongoing hepatic enzyme elevation (e.g. AST, ALT, GGT) > 2 x the ULN. Elevation related to direct tumor infiltration is allowed.Xx_NEWLINE_xXDocumented survivin-positive tumor statusXx_NEWLINE_xXThe patient must not have received any immunotherapy for their brain tumorXx_NEWLINE_xXUnicentric: patients with microscopic multifocality are eligible as long as the total pathologic tumor size is =< 2.5 cmXx_NEWLINE_xXThe final margins of the resected specimen must be histologically free of tumorXx_NEWLINE_xXPathologic tumor > 2.5 cm in sizeXx_NEWLINE_xXHistological confirmation of a high grade (grade 3 or 4) primary brain tumor either classified as a glioma (including astrocytoma, anaplastic oligodendroglioma and glioblastoma multiforme), medulloblastoma, atypical teratoid/rhabdoid tumor (AT/RT) or primitive neuroectodermal tumor (PNET)\r\n* Note: Patients with diffuse intrinsic pontine glioma (DIPG) are exempt from this confirmation of tumor if characteristic radiologic findings are noted on magnetic resonance imaging (MRI)Xx_NEWLINE_xXEvidence of tumor progression by MRI scan following radiation therapy or following the most recent anti-tumor therapy; note: patients who have had surgical treatment at recurrence are eligible if they had a resection with measurable residual disease on postoperative imaging or if there is imaging evidence of disease progression as compared to the first postoperative scanXx_NEWLINE_xXConsent for tumor biopsies and blood draws for research purposesXx_NEWLINE_xXHistologic documentation of the original primary tumor.Xx_NEWLINE_xXPrimary brain tumorXx_NEWLINE_xXAll tumor removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy)\r\n* NOTE: management of axillary lymph nodes is up to the treating provider; however, all surgical margins should be clear of invasive cancer or DCIS (i.e., no tumor on ink); the local pathologist must document negative margins of resection in the pathology report; if all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed; likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removedXx_NEWLINE_xXELIGIBILITY FOR ENROLLMENT/SCREENING (ARMS 1 AND 2): Patients must be able to provide blood and tumor samples and undergo the procedures required for this protocolXx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 1: Evidence of WT1 tumor expressionXx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 2: Evidence of WT1 tumor expressionXx_NEWLINE_xXTumor tissues (archived or new biopsy) must be provided for biomarker analysisXx_NEWLINE_xXConsent to screening tumor biopsy (for accessible tumors when appropriate) (optional in dose escalation, mandatory in dose expansion)Xx_NEWLINE_xXPrimary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Participants may not have a primary tumor site of nasopharynx (any histology)Xx_NEWLINE_xXHas tumor localized primarily to the brainstem or spinal cordXx_NEWLINE_xXHas tumor primarily localized to the brainstem or spinal cordXx_NEWLINE_xXA retrospective review of all patients entered will be performed to confirm clear cell histology; patients must have recurrent or, progressive clear cell ovarian cancer not solely based on cancer antigen (CA)-125; primary tumors must be at least 50% clear cell histomorphology in order to be eligible or have a histologically documented recurrence with at least 50% clear cell histomorphology; recurrence should be biopsy proven unless the tumor is located in an area deemed unsafe to biopsy by the surgeon; if a biopsy can be obtained without significant risk, then biopsy should be obtainedXx_NEWLINE_xXIf the primary tumor had at least 50% clear cell histomorphology, a biopsy of the recurrent or persistent tumor is not required; the percentage of clear cell histomorphology must be documented in the pathology report or in an addendum to the original report; if slides of the primary tumor are not available for review due to disposal of slides by the histology laboratory (typically 10 years after diagnosis), biopsy of recurrent or persistent disease is requiredXx_NEWLINE_xXIf slides of the primary tumor are not available for review, a biopsy of the recurrent or persistent tumor is required to confirm at least 50% clear cell histomorphology; the percentage of involvement must be documented in the pathology report or in an addendum to the original reportXx_NEWLINE_xXAll patients must submit unstained slides of primary or recurrent tumor for translational analysisXx_NEWLINE_xXPatients must have measurable CNS disease, either previously untreated (not counting systemic therapy), or progressed following previous radiation treatment; lesions that have progressed after prior radiosurgery should not be selected as measurable disease if they are suspected of being radionecrosis; the following measurement criteria are required (not counting tumor edema, as visualized by contrast enhanced magnetic resonance imaging [MRI] with slice thickness of 1.5 mm or smaller, unless prospective permission is obtained from the principal investigator [PI] allowing absence of contrast or thicker slices): \r\n* At least one CNS tumor measuring 10 mm or greater in longest diameter, OR  \r\n* At least one CNS tumor measuring 5-9 mm in longest diameter, plus one or two additional CNS tumors measuring 3 mm or greater in longest diameter, for which the sum of the longest diameters is equal to or greater than 10 mm; patient may have additional tumors as wellXx_NEWLINE_xXRepresentative tumor specimens as specified by the protocolXx_NEWLINE_xXA breast tumor with an ultrasound size of at least 2.0 cm.Xx_NEWLINE_xXRAS wild-type tumor; Note: evidence of EGFR expression in the tumor is not requiredXx_NEWLINE_xXAvailability of tumor sample:Xx_NEWLINE_xXLow risk for tumor lysis syndrome (TLS)Xx_NEWLINE_xXTumor enhancement involving both hemispheresXx_NEWLINE_xXAny hormonal therapy directed at malignant tumor must be discontinued at least one week prior to study treatment initiationXx_NEWLINE_xXPrior surgical therapy other than incisional or excisional biopsy and organ-sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an unknown primary tumor; residual tumor is required for enrollment on studyXx_NEWLINE_xXPatients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)Xx_NEWLINE_xXMRI/CT must demonstrate measurable enhancing tumor of at least 1 cm^2 in cross-sectional area to allow assessment of radiographic responseXx_NEWLINE_xXPatients will have cytoreductive surgery as part of their routine care for recurrent tumorXx_NEWLINE_xXSubjects must consent to provide archived tumor specimens and / or tumor biopsy for correlative biomarker studies.Xx_NEWLINE_xXAgreement to provide 2 tumor biopsiesXx_NEWLINE_xXFOR EXPANSION PHASE ONLY: Lack of accessible tumor for biopsyXx_NEWLINE_xXTumor location or involvement that would result in risk of ventricular penetration during tumor injectionXx_NEWLINE_xXTumor involving both hemispheres or that which involves the subependyma or suspected cerebrospinal fluid disseminationXx_NEWLINE_xXTumor involving brain stemXx_NEWLINE_xXAny medical condition that precludes the surgery necessary to administer DNX-2401 into the tumor using the cannulaXx_NEWLINE_xXSubjects must have measurable disease defined as at least one tumor lesion of at least 1.5 cm or a peripheral blood cluster of differentiation (CD)5+, CD19+ lymphocyte count of at least 5,000 cells/uLXx_NEWLINE_xXConfirmation in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory or in an Food and Drug Administration (FDA)-approved assay that one of the patient’s thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600Xx_NEWLINE_xXPatients must agree to undergo two research biopsies of a malignant lesion; patients may be exempt from biopsy if 1) the investigator or person performing the biopsy judges that no tumor is accessible for biopsy, 2) the investigator or person performing the biopsy feels that the biopsy poses too great of a risk to the patient, or 3) the patient’s platelet count is < 100,000/mcl or he/she cannot be safely removed from anti-coagulation therapy (if the anti-coagulation therapy needs to be temporarily held for the biopsy procedure); if the only tumor accessible for biopsy is also the only lesion that can be used for RECIST v1.1 response evaluation, then the patient may be exempt from biopsy; the goal will be to have a minimum of 3 patients undergo one or both of these research biopsies; accrual may be limited only to subjects whose tumor is safely accessible for biopsy to ensure the accrual goal for research biopsies described above is met (e.g., if 7 of 10 patients are accrued without any biopsies having been obtained, then all subsequent subjects who are registered must qualify for attempted research biopsy in order to be enrolled)Xx_NEWLINE_xXPatients agreeing to the optional biomarker study in the expansion phase only need to have an accessible primary tumor; (optional biomarker studies will be done in up to 18 patients in the expansion phase only)Xx_NEWLINE_xXPrimary tumor greater than (>) 2 centimeters (cm) in diameter, or > 5 millimeters (mm) in diameter and node-positiveXx_NEWLINE_xXParticipants who have had an incisional biopsy of the primary tumor or the primary tumor excisedXx_NEWLINE_xXAvailability of an archival tumor sample or a pre-treatment fresh tumor sample for confirmation of PRCC by a central laboratory and other biomarkerXx_NEWLINE_xXRepresentative tumor specimens as specified by the protocolXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXMeasurable disease: subjects must have measurable plexiform neurofibroma(s) amenable to volumetric MRI analysis; for the purpose of this study, the target lesion must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumor of interest; tumors must be at least 3 mL in volume (most PNs 3 cm in longest diameter will meet this criteria); if the tumor is < 3 cm in longest diameter, the subject may still be eligible; central review of the MRI of the target plexiform is required prior to enrollment to ensure that the tumor is measurable and amenable to volumetric analysisXx_NEWLINE_xXPatients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 monthsXx_NEWLINE_xXTumor not able to be reliably evaluated by volumetric analysisXx_NEWLINE_xXAT THE TIME OF PROCUREMENT: EBV positive tumorXx_NEWLINE_xXAT THE TIME OF INFUSION: EBV positive tumorXx_NEWLINE_xXEvidence of histology of the tumor other than papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma or mixed histology of the tumor;Xx_NEWLINE_xXArchived neuroendocrine tumor sample or biopsy sample (will also be used for genetic testing).Xx_NEWLINE_xXHistologically proven colon carcinoma with serosal invasion or peritoneal disease or a history of tumor rupture, and/or ascitesXx_NEWLINE_xXPatient should agree to a tumor biopsy prior to protocol enrollment; post therapy biopsy is optionalXx_NEWLINE_xXHave biomarker-positive solid tumorXx_NEWLINE_xXHistologically confirmed, soft-tissue sarcoma: excluding rhabdomyosarcoma (pleomorphic rhabdomyosarcoma patients are eligible), Ewing’s, primitive neuroectodermal tumor (PNET), osteosarcoma, or gastrointestinal stromal tumorXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXPatients with a history of malignant tumor who have been disease free for at least five years and are not currently being treated.Xx_NEWLINE_xXPD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratoryXx_NEWLINE_xXParticipants enrolled to the RP2D cohort must have disease that is accessible for tumor biopsies and must agree to pre and on-treatment tumor biopsiesXx_NEWLINE_xXAdvanced solid tumor for which no other higher priority therapies are availableXx_NEWLINE_xXPatients must have histological confirmation of a brain tumor at diagnosis or relapse for all tumorsXx_NEWLINE_xXThe cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)Xx_NEWLINE_xXPrior use of other investigational agents to treat the brain tumorXx_NEWLINE_xXAble and willing to give valid written consent for archival tumor samplesXx_NEWLINE_xXKnown hormone receptor status of the primary tumorXx_NEWLINE_xXAny clinical T4 tumor as defined by tumor-node-metastasis classification in UICC/AJCC 7th edition, including inflammatory breast cancerXx_NEWLINE_xXPatients must have evidence of radiographic progression as defined below:\r\n* Stratum 1: defined as >= 25% increase in the product of the greatest perpendicular diameters of the tumor as a whole (solid and cystic component) AND >= 0.4 cm increase in each of at least two dimensions of the tumor as a whole OR any new or worsening neurologic/vision deficit in conjunction with a lesser change in the solid or cystic component\r\n* Stratum 2: \r\n** For patients more than 6 months following radiation therapy (RT) (including radiosurgery or P32), progression is defined as a >= 25% increase in the product of the greatest perpendicular diameters of the solid component AND >= 0.4 cm increase in each of at least two dimensions of the solid component\r\n** For patients more than 12 months following RT (including radiosurgery or P32), progression is defined as >= 25% increase in each of the product of the greatest perpendicular diameters of the solid tumor AND >= 0.4 cm increase in each of at least two dimensions of the solid tumor; patients demonstrating predominantly cystic progression more than 12 months after RT must show a continued increase in the cystic component on two serial MRI scans performed at least 4 weeks apart OR re-accumulation of the cyst following one or more cyst aspirations; patients with progressive neurologic signs and/or symptoms associated with isolated cyst formation or progression are eligible if the neurologic signs and/or symptoms do not improve within 4 weeks of cyst aspirationXx_NEWLINE_xXPatients with resected primary must be active participants of the NSABP Patient Registry and Biospecimen Profiling Repository (MPR-1) study. Patients with intact primary and metastatic KRAS wild-type disease at presentation (treatment naive), must have signed consent for quadruple wild-type central testing for treatment-naive tumor sample submissionXx_NEWLINE_xXThe tumor tissue must have been determined to be KRAS, NRAS, BRAF, PIK3CA wild-type by central CLIA testing.Xx_NEWLINE_xXPathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases or peritoneal disease; the maximum dimension of the tumor must be =< 10 cmXx_NEWLINE_xXTargeted index tumor(s) defined as intra pulmonary or pleural with a maximum size of 3.5 cm, measured in the longest cross sectional dimension.Xx_NEWLINE_xXPatient's index tumor(s) is primary lung cancer.Xx_NEWLINE_xXPatients with any of the following sarcoma histologic subtypes will not be eligible for participation:\r\n* Alveolar soft-part sarcoma\r\n* Chondrosarcoma\r\n* Dermatofibrosarcoma\r\n* Ewing sarcoma\r\n* Gastrointestinal stromal tumor (GIST)\r\n* Kaposi sarcoma (non-human immunodeficiency virus [HIV] and HIV related disease)\r\n* Mixed mesodermal tumor/carcinosarcoma\r\n* Low grade (grade 1) sarcomas\r\n* Rhabdomyosarcoma (embryonal, alveolar)\r\n* Interdigitating dendritic sarcoma\r\n* Giant cell tumor of the boneXx_NEWLINE_xXSubjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.Xx_NEWLINE_xXSubjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.Xx_NEWLINE_xXMust have an FFPE tumor block with tumor cellularity of 20% or greater. NOTE: Prior to randomization, the tumor cellularity will be confirmed by central pathology review and percent values will be double checked at Paradigm (a Next Generation Sequencing Company).Xx_NEWLINE_xXMust have a a BRAF V600E mutation-positive tumor as confirmed by an approved local laboratory or a sponsor designated central reference laboratory. All subjects must provide an archived or fresh tumor sample (for solid tumors) or a fresh BM aspirate and peripheral blood sample (for HCL and MM) for confirmation testing of the BRAF V600E mutation by a sponsor designated central reference laboratory using a sponsor designated assayXx_NEWLINE_xXPatients must have histologically proven stage IIIB, IV or recurrent non-small cell lung cancer; patients must be willing to undergo a pre-treatment tumor biopsy, either core needle biopsy or equivalent amount or via excisional specimen (cytology specimen not acceptable for this purpose)Xx_NEWLINE_xXConsent to preservation of frozen and fixed samples of tumor cores for evaluationXx_NEWLINE_xXTumor diameter =< 2 cm on physical exam & imaging studiesXx_NEWLINE_xXGross residual tumor or positive margins after surgery that is un-excised, as radiation dose in the study will be limited to 60 Gy.Xx_NEWLINE_xXPatient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through CSF cytology.Xx_NEWLINE_xXContraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy.Xx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXMetastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor massesXx_NEWLINE_xXHas a locally determined non microsatellite instability high/ proficient mismatch repair (non-MSI-H/pMMR) tumor statusXx_NEWLINE_xXKIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST), for which there is no standard systemic therapy, orXx_NEWLINE_xXPhase 2: Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET), Rhabdomyosarcoma, High Grade Glioma (HGG) (all must have measurable disease); exclusion of Diffuse Intrinsic Pontine GliomaXx_NEWLINE_xXTumor is confirmed to be one of the following:\r\n* MSI-high, or\r\n* MMR-deficient, or\r\n* Hypermutated defined as >= 20 somatic mutations in the tumor by MSK-IMPACTXx_NEWLINE_xXGroup A: newly diagnosed patient less than 14 years of age at the time of diagnosis with histologically proven non-pelvic localized Ewing sarcoma family of tumor involving the bone or soft tissueXx_NEWLINE_xXPatients with elevated liver function tests including jaundiced patients (due to tumor) can be selectively operated on without resolution of jaundice preoperatively according to the judgment of the operating surgeonXx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in grade 2 or higher dyspnea at restXx_NEWLINE_xXPatients with histological or cytologically documented hepatocellular carcinoma (HCC) (documentation of original biopsy for diagnosis is acceptable if tumor tissue is unavailable) or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required; for subjects without cirrhosis histological confirmation is mandatoryXx_NEWLINE_xXTumor replacement > 70% of total liver volume based on visual estimation by the investigator OR tumor replacement > 50% of total liver volume in the presence of albumin < 3 mg/dLXx_NEWLINE_xXPatients must have a diagnosis and documented disease progression of a solid tumor malignancy, excluding primary brain tumor, for which standard, curative, or life prolonging treatment does not exist or is no longer effectiveXx_NEWLINE_xXPatients must have radiographically or clinically evaluable tumorXx_NEWLINE_xXAll tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection\r\n* All margins should be clear of invasive cancer or DCIS (i.e. no tumor on ink); the local pathologist must document negative margins of resection in the pathology report; if all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed; likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed; radiation therapy to the conserved breast is requiredXx_NEWLINE_xXThe patient must be discussed at GI Tumor Board, NCI and suitability for the interventional procedure (TACE or RFA) re-affirmedXx_NEWLINE_xXThere must be an interval of at least 12 weeks from the completion of radiotherapy to study registration except if there is unequivocal evidence for tumor recurrence per Response Assessment in Neuro-Oncology (RANO) criteria; when the interval is less than 12 weeks from the completion of radiotherapy, the use of positron emission tomography (PET) scan is allowed to differentiate between unequivocal evidence of tumor recurrence and pseudo progressionXx_NEWLINE_xXCandidate for MLA based on the size, location, and shape of the recurrent tumor as determined by the performing neurosurgeonXx_NEWLINE_xXLow- or intermediate-grade neuroendocrine carcinoma, including the following subtypes: carcinoid tumor, low- to intermediate-grade or well- to moderately-differentiated neuroendocrine carcinoma or tumor, atypical carcinoid tumor; documentation from a primary tumor or metastatic site is sufficient; patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligibleXx_NEWLINE_xXVenous involvement of the SMV/portal vein demonstrating tumor abutment with impingement and narrowing of the lumen, encasement of the SMV/portal vein but without encasement of the nearby arteries, or short-segment venous occlusion resulting from either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection and reconstructionXx_NEWLINE_xXTumor abutment of the SMA not to exceed greater than 180 degrees of the circumference of the vessel wall.Xx_NEWLINE_xXConcurrent administration of any other anti-tumor therapyXx_NEWLINE_xXNo available tumor material for correlative studiesXx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at restXx_NEWLINE_xXPatients must have a K-RAS wild-type (WT) tumorXx_NEWLINE_xXCystic component >= 25% the total volume of the tumorXx_NEWLINE_xXSubjects must have a target VS with the following qualities:\r\n* Not amenable to surgery due to patient refusal, high risk for surgical complications (e.g., damage to lower cranial nerve function, tumor size > 3 cm in longest diameter, or multilobulated tumor appearance on MRI scan)\r\n* Associated with a word recognition score of < 85% and > 5%\r\n* Documented clinical progression defined as EITHER:\r\n** Progressive hearing loss (defined as a decline in word recognition score below the 95% critical difference interval from baseline score related to VS (i.e., not due to prior interventions such as surgery or radiation) OR\r\n** Progressive tumor growth in the preceding 18 months, defined as >= 20% increase in volumeXx_NEWLINE_xXPresence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratoryXx_NEWLINE_xXTumor of the patient is p53wtXx_NEWLINE_xXPrimary tumors must be >= 5 cm in maximal diameter or an isolated local recurrence of any size; magnetic resonance imaging (MRI) or computed tomography (CT) of the primary tumor will be required; tumor size will be measured radiographically using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee; the tumor size will be accurately measured in at least one dimension and the largest diameter will be recorded in decimal fractions of centimetersXx_NEWLINE_xXRecurrent or persistent tumor greater than 6 cm in maximum diameterXx_NEWLINE_xXPatient’s tumor(s) to be treated is (are) =< 5.0 cm or =< 250 cm^3Xx_NEWLINE_xXHistological confirmation of malignancy (primary or metastatic tumor)Xx_NEWLINE_xXSTEP 1 ENROLLMENT: the patient has a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration; mixed tumors will be categorized by the predominant cell typeXx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: the patient has a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or fine-needle aspiration; mixed tumors will be categorized by the predominant cell typeXx_NEWLINE_xXPresence of BRAF mutation or genes fusion involving BRAF in tumor tissueXx_NEWLINE_xXPre-treatment fresh core, excision or punch tumor biopsyXx_NEWLINE_xXPatient must not have transoral robotic surgery (TORS) for a T3 or T4 primary tumorXx_NEWLINE_xXThe subject has tumor invading (or there is concern for invasion of) major blood vesselXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXPatients must have either (1) a diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow (BM) metastases plus high urine catecholamine levels, or (2) a tumor that is GD2-positive\r\n* A non-NB tumor is defined as GD2-positive by immunostaining with monoclonal antibody 3F8 (m3F8); if fresh or frozen tumor is not available for immunostaining, patients will be considered eligible if published reports show that > 50% of that tumor type is GD2-positive by immunohistochemistry; (note: tissues must be fresh/frozen as fixed, paraffin-embedded specimens are unsuitable for anti-GD2 immunostaining); tumors known to be GD2-positive by this criteria do not need immunostaining; these include: melanoma (> 50%), desmoplastic small round cell tumors (70%), osteosarcoma (88%) and soft tissue sarcomas including liposarcoma, fibrosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, and spindle cell sarcoma (93%)Xx_NEWLINE_xXResectable primary tumor of the head, body or tail of the pancreas defined as a visible mass in the pancreas and:Xx_NEWLINE_xXA definable tissue plane between the tumor and regional arterial structures including the celiac axis, common hepatic artery, and SMA.Xx_NEWLINE_xXDocumented cluster of differentiation (CD)30+ expression from either original diagnosis or a tumor biopsy in the relapsed settingXx_NEWLINE_xXTumor assayed for k-ras and other tumor genomic mutationsXx_NEWLINE_xXAll patients must have progressive disease for which craniotomy and tumor resection is recommended as treatmentXx_NEWLINE_xXPatients with infratentorial, multifocal, or pathologically confirmed cerebrospinal fluid (CSF) disseminated tumorXx_NEWLINE_xXPatients with a history of obstructive jaundice due to the primary tumor must have a metal biliary stent in place (or a percutaneous biliary drain)Xx_NEWLINE_xXTumor/vertebral body anatomy precluding fiducial placementXx_NEWLINE_xXPatients with tumor amenable to potentially curative therapyXx_NEWLINE_xXPatients who are deemed \borderline resectable\ will be included; borderline resectable is defined by the NCCN as tumors with venous involvement of the superior mesenteric vein (SMV)/portal vein demonstrating tumor abutment with or without impingement and narrowing of the lumen, either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection or reconstruction; gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to the celiac axis; or tumor abutment of the superior mesenteric artery (SMA) not to exceed greater than 180 degrees of the circumference of the vessel wall; tumors involving retroperitoneal structures that can be surgically removed (ie. kidney), will also be includedXx_NEWLINE_xXThe participant has a primary brain tumorXx_NEWLINE_xXThe participant has radiographic evidence of cavitating pulmonary lesion(s) or tumor in contact with, invading or encasing major blood vesselsXx_NEWLINE_xXTumor specimen must be available for a central pathology review and prognostic and predictive biomarker evaluationXx_NEWLINE_xXPatients with more than 30% replacement of hepatic parenchyma by tumor or any history of drug related hepatic encephalopathyXx_NEWLINE_xXPatient's tumor must be positive by histological assay for NY-ESO-1?²??T, according to the screening algorithm as described in Section 3.3.1. Positive expression is defined as ? 50% of cells that are 2+ and/or 3+ by immunohistochemistryXx_NEWLINE_xXPatients with diffuse tumor throughout bladder that is deemed unresectable by surgeonXx_NEWLINE_xXOnly untreated patients with high risk pancreatic adenocarcinomas will be eligible for the study; for this study, such patients are defined as those who meet one or more of the following radiographic or serologic criteria:\r\n* Primary tumor that involves the superior mesenteric vein causing a vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction\r\n* Primary tumor that involves =< 180 degrees of the superior mesenteric artery (SMA), celiac axis or any of its branches on CT or magnetic resonance imaging (MRI)\r\n* Primary tumor that abuts or encases (>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)\r\n* Patients with a high cancer antigen 19-9 (CA19-9) (>= 500 mg/dl) in the presence of a bilirubin =< 2.0 mg/dL\r\n* Radiographic findings consistent with malignant peripancreatic lymphadenopathy outside the planned field on CT or MRI\r\n* Radiographic findings of indeterminate liver or peritoneal lesions on CT or MRI concerning but not diagnostic of metastatic diseaseXx_NEWLINE_xXHistologic confirmation of prostatic adenocarcinoma by Memorial Sloan Kettering Cancer Center (MSKCC) inclusive of the following:\r\n* 3 or more positive biopsy cores or equivalent tumor specimen as confirmed by pathologist\r\n* At least 2 cores containing >= 3 mm of tissue with carcinoma or equivalent tumor specimen as confirmed by pathologist\r\n* A primary tumor Gleason score >= 7\r\n* Adequate primary biopsy tissue or equivalent tumor specimen as confirmed by pathologist available for protocol required analysis (i.e., bladder or transurethral resection of the prostate [TURP] specimen)Xx_NEWLINE_xXHistologic variants in the primary tumor (histologic variants other than adenocarcinoma)Xx_NEWLINE_xXBiopsy accessible tumor depositsXx_NEWLINE_xXTumor cell negative for CD20Xx_NEWLINE_xXEvidence of laboratory tumor lysis syndrome (TLS) by Cairo-Bishop definition of tumor lysis syndrome; subjects may be enrolled upon correction of electrolyte abnormalitiesXx_NEWLINE_xXAt the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysisXx_NEWLINE_xXTumor is well visualized through x-ray mammography or ultrasound imaging and amenable to image guidance therapy (a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have marginsXx_NEWLINE_xXUnifocal malignant tumor that does not exceed 20mm in diameter and measures at least 5mm away from the skin and chest wallXx_NEWLINE_xXSubjects with lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phylloides tumor, or Paget's diseaseXx_NEWLINE_xXSubjects with benign vascular tumorXx_NEWLINE_xXPatients must have recurrent or metastatic tumor located within a previously irradiated fieldXx_NEWLINE_xXTumor within the irradiated field is negatively impacting patient’s quality of life or threatening catastrophic complication if left untreated as determined by the treating physicianXx_NEWLINE_xXTumor sites eligible for inclusion on this protocol include thorax, abdomen, and pelvisXx_NEWLINE_xXDiagnosis of DIPG by MRI imaging defined as tumor that has a pontine epicenter and is diffuse (tumor that involves the majority [> 50%] of the brainstem) on T2 or fluid-attenuated inversion-recovery (FLAIR) imaging rather than focal; histologic confirmation is not requiredXx_NEWLINE_xXA tumor sample is required for enrollment (except for patients diagnosed > 7 years ago)Xx_NEWLINE_xXExtensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or disease that is considered by the investigator to be rapidly progressing or life threatening (eg, subjects who are intended for chemotherapy)Xx_NEWLINE_xXAt least one measurable VHL related lesion, which is undergoing surveillance, and patient is not at immediate risk of needing intervention for this or other lesions; biopsy is not required given the known likely etiology and natural history in the setting of a positive genetic test\r\n* Brain: asymptomatic hemangioblastoma, >= 0.5 cm\r\n* Spine: asymptomatic hemangioblastoma, >= 0.5 cm\r\n* Renal: solid mass suspicious for renal cell carcinoma (RCC) >= 1 cm or cystic mass (Bosniak 3-4) >= 1 cm\r\n* Pancreas: solid mass >= 1 cm and =< 3 cm suspicious for neuroendocrine tumor, or neuroendocrine tumor > 3 cm but not considered operable\r\n* Eye: asymptomatic peripapillary and/or macular hemangioblastoma, any size\r\n* Adrenal: asymptomatic or controlled pheochromocytoma greater than 1 cm in sizeXx_NEWLINE_xXConsent to biopsy of tumorXx_NEWLINE_xXLongest uni-dimensional measurement of contrast enhancing tumor >= 4 cm; tumors exceeding this limit may be eligible and any question should be directed to a radiation oncology investigator and the MSK PIXx_NEWLINE_xXTumor must not invade the corpus callosumXx_NEWLINE_xXTumor must not invade the brainstemXx_NEWLINE_xXAll standard tumor-staging procedures necessary to define baseline extracranial disease status completed =< 42 days prior to pre-registrationXx_NEWLINE_xXPatients must have a biopsy confirmed diagnosis based on a combination of histological and clinical criteria of CD30+ lymphomatoid papulosis, CD30+ primary cutaneous anaplastic large T-cell lymphoma (pc-ALCL), or CD30+ mycosis fungoides for the phase II trial; there is no specific limit or validated amount other than positive cells on immunohistochemistry (IHC) cells in tumor cellsXx_NEWLINE_xXEvidence of brainstem/cord/cauda or other neuromuscular or neurosensory malfunction from causes other than effects of local tumor growth or metabolic effects of tumorXx_NEWLINE_xXGross extension of tumor into the lumen of the duodenumXx_NEWLINE_xXTumor must express Retinoblastoma (Rb) protein, as defined as any measureable staining by immunohistochemistryXx_NEWLINE_xXUnwilling to provide consent for genetic studies of tumor, whole blood, or plasma specimensXx_NEWLINE_xXRadiographic evidence of regional or distant metastases with suspected tumor in an area that is safe to biopsyXx_NEWLINE_xXWillingness to undergo tumor biopsyXx_NEWLINE_xXThe subject has biopsy accessible tumor and is willing to undergo biopsy prior to planned protocol treatmentXx_NEWLINE_xXPatients must have an intact primary (not recurrent) invasive carcinoma of the breast; biopsy confirmation of the primary tumor should be by needle biopsy (preferred); incisional surgical biopsy is allowed as long as there is residual palpable or imageable tumor in the breastXx_NEWLINE_xXPatients cannot have more than 3 lung lesions\r\n* Patients with a single lung lesion other than the primary tumor and no other thoracic or extra-thoracic disease will not be eligibleXx_NEWLINE_xX* Primary tumor progression on first-line chemotherapyXx_NEWLINE_xXKnown endobronchial lesions or involvement of large pulmonary vessels by tumorXx_NEWLINE_xXEXPANSION COHORT ONLY: Known endobronchial lesions or involvement of large pulmonary vessels by tumorXx_NEWLINE_xXTumor: newly diagnosed non-disseminated diffuse intrinsic pontine glioma based on clinical AND radiographic findingXx_NEWLINE_xXExtensive (invasive) loco-regional tumor mass and/or metastatic spread, rendering patient inoperableXx_NEWLINE_xXPatients must be willing to forego other drug therapy against the tumor while being treated with bevacizumab and temozolomideXx_NEWLINE_xXSubject has had prior cytoreductive surgery yielding tumor for lysate preparationXx_NEWLINE_xXThe tumor must be supratentorial in locationXx_NEWLINE_xXThe planning target volume (PTV), defined as residual T1 post-contrast enhancing tumor and/or resection cavity plus 0.5 cm margin, must measure =< 150 cm^3 in volume; this volume will not be known at the initial consultation; it will be determined once the final radiation plan is completedXx_NEWLINE_xXTumor foci detected below the tentoriumXx_NEWLINE_xXIf the subject received at least 4 cycles of systemic therapy and no measurable tumor reduction compared to the previous scan is observed, such subject can be enrolledXx_NEWLINE_xXA solid tumor diagnosis in the setting of:Xx_NEWLINE_xXPatients must have progressed after at least one prior systemic therapy for GCT and meet one of the following criteria:\r\n* Patients with evidence of progressive or recurrent GCT after progression prior high dose chemotherapy (HDCT) treatment, defined as meeting at least one of the following criteria:\r\n** Tumor biopsy of new or growing or unresectable lesions demonstrating viable GCT; in the event of an incomplete gross resection where viable GCT is found, patients will be considered eligible for this study\r\n** Consecutive elevated serum tumor markers (HCG or AFP) that are increasing; increase of an elevated lactate dehydrogenase (LDH) alone does not constitute progressive disease\r\n** Development of new or enlarging lesions in the setting of persistently elevated HCG or AFP, even if the HCG and AFP are not continuing to rise\r\n* Patients deemed not to be a candidate for or benefit from potentially curative HDCT or other curative treatment options defined as follows:\r\n** Patients with inadequate renal function for HDCT\r\n** Patients who have had 3 or more lines of prior chemotherapy\r\n** Patients with late relapse (relapse > 2 years after last therapy)\r\n** Patient with inadequate stem cell collection to move forward with HDCT\r\n** Patients with significant medical or psychosocial comorbidities that are felt to be a contraindication to HDCT by the treating investigator\r\n* NOTE: There is no maximum number of prior treatments allowed\r\n* NOTE: Patients with clinically growing \teratoma\ (normal declining tumor markers and radiographic or clinical progression) should be considered for surgery; in patients with rising tumor markers as their only evidence of disease progression where AFP is < 30 or HCG is < 15, alternate causes of increased levels of these markers should be ruled out; (e.g., hypogonadism by testosterone suppression of luteinizing hormone [LH], hepatitis, use of marijuana)Xx_NEWLINE_xXTumor size of at least 5 centimetersXx_NEWLINE_xXPatient must agree to allow 2 separate biopsies of any malignant lesion; biopsies do not need to be done if:\r\n* Tumor is not considered accessible by either the investigator or the person performing the biopsy (it is determined the risk is too high due to location near vital organs or too great of a risk of an adverse event)\r\n* Patient is on anticoagulation and it would be unsafe to temporarily hold the anticoagulation\r\n* Consent of the principal investigator (PI) not to have a biopsy doneXx_NEWLINE_xXUnifocal primary tumor based on imaging and clinical assessment; microscopic multifocality is allowedXx_NEWLINE_xXTumor invasion of the skin including dermis, chest wall, or pectoralis musculatureXx_NEWLINE_xXConfirmed RAS/RAF wild type tumor; paraffin-embedded tumor tissue obtained from the primary tumor or metastasisXx_NEWLINE_xXa) Dose Evaluation Portion: Patients should have at least one lesion accessible for intratumoral injection and biopsy. b) Melanoma Expansion Cohort: Patients must have at least one target lesion by Response Evaluation Criteria for Solid Tumors (RECIST v1.1), with at least one lesion accessible for intratumoral injection. Tumor biopsies are not required in the expansion cohort.Xx_NEWLINE_xXProvides a core needle biopsy consisting of at least 2 separate tumor cores from the primary tumor at screening to the central laboratory.Xx_NEWLINE_xXHigh Tumor Mutation BurdenXx_NEWLINE_xXAvailable tumor sample for Programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) and exon 20 T790M testingXx_NEWLINE_xXHistological confirmation of malignancy (primary or metastatic tumor)Xx_NEWLINE_xXBleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapyXx_NEWLINE_xX(continued from no. 1) Those patients with stage III cancer in which the largest maximal diameter of any residual tumor implant at the completion of this initial surgery is no greater than 1 cm will be defined as optimal; all others will be defined as suboptimal.Xx_NEWLINE_xXTumor positive for infection with human papillomavirus (HPV) virus type 16 or other types such as per Johns Hopkins (JH) Pathology assessmentXx_NEWLINE_xXT stage 1, 2, 3; surgery of the primary tumor is limited to incisional or excisional biopsies (i.e., tonsillectomy) even without macroscopic disease left; positive resection margins and/or gross residual disease at the primary site are allowed; evaluation of primary tumor extent may require the use of a flexible fibroscope if deemed clinically necessary by the treating physicianXx_NEWLINE_xXOropharyngeal sites of tumor include tonsil, soft palate, base of tongue, lateral and posterior pharyngeal wall; laryngeal sites of tumor include the supraglottic, glottis and subglottic larynx; nasopharyngeal sites include the posterior nasopharyngeal wall, right and left fossa of Rosenmuller; the hypopharyngeal sites of tumor include the post-cricoid area, posterior pharyngeal wall and the pyriform sinusesXx_NEWLINE_xXThere must be documentation of evaluable tumor within four weeks of beginning therapyXx_NEWLINE_xXFor the purpose of the Pediatric study patients with histologic diagnosis of ESFT including: Ewing's sarcoma or primitive neuroectodermal tumor (malignant neuroepithelioma) of the bone or soft tissues, Askin's tumor of the chest and with central nervous system tumors are eligible.Xx_NEWLINE_xXClinically (medically) indicated procedure (i.e. biopsy of lesions of recurrent disease, palliative management via resection, thoracentesis, etc.) to collect tumor in sufficient quantity (\golf ball size\ estimated weight 10-30 grams, pleural, and/or ascites fluid estimated volume ? 500 mL) for vaccine processing.Xx_NEWLINE_xXConcurrent tumor-specific hormonal therapy or antiestrogens. (Individuals manufactured under CL-PTL 105 (Phase II Ovarian) are not subject to this exclusion).Xx_NEWLINE_xXDiagnosis of primary brain tumorXx_NEWLINE_xXParticipants must have histologically confirmed germ cell tumor or elevated alpha-fetoprotein (AFP) (serum > 10 IU/L or cerebrospinal fluid [CSF] > than institutional norm) or beta-human chorionic gonadotropin (B-HCG) (serum or CSF > than institutional norm) in the setting of radiographic disease consistent with a germ cell tumor; disease must be confined to the central nervous systemXx_NEWLINE_xXThe tumor should be approximately at least 1 cm, to account for variability in imaging and imaging occult disease (physical exam, mammography, ultrasound); we recognize that from time to time because of this variation, there might not be enough tissue available for analysis after surgical excision but this will allow the greatest opportunity to capture as many eligible patients as possibleXx_NEWLINE_xXOptional: Willing to provide a fresh tumor sample if a sufficient quantity of archival tumor sample is not available (Arms B, C, and D). See Section 5.3.9 for tumor sample details.Xx_NEWLINE_xXPatients must have paraffin-embedded tumor specimen available for submission for pathological review and determination of 1p/19q deletion status\r\n* NOTE: it is recommended that patients not be pre-registered until the required tumor specimens are on hand and ready for submission; if submission of tissue will be submitted more than 5 working days after pre-registration, immediately notify the Mayo Clinic Cytogenetics Laboratory via emailXx_NEWLINE_xXNo previous radiation, cytotoxic chemotherapy, radio surgery, or investigational treatment directed at the brain tumor at any time; no limit on number of previous surgical procedures of this tumorXx_NEWLINE_xXPatients that require urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compressionXx_NEWLINE_xXMGMT promoter methylation analysis of surgically resected tumor or tumor biopsy must demonstrate an unmethylated or hypomethylated MGMT promoter statusXx_NEWLINE_xXTumor must be accessible for injection and must not be located in the brainstem or deep midbrainXx_NEWLINE_xXNo other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression)Xx_NEWLINE_xXPrior surgery for a low grade tumor is allowed, provided histological confirmation of anaplastic tumor is present at the time of progressionXx_NEWLINE_xXTumor size greater than 4 cm;Xx_NEWLINE_xXGross total resection as determined by the intraoperative observations of the neurosurgeon of record and confirmed by postoperative MR imaging; gross total resection is defined as residual tumor or imaging abnormality (not definitive for residual tumor) whose size is < 1 cm^2 on postoperative computed tomography (CT) or MR imagesXx_NEWLINE_xXIf there is brain stem invasion by the tumor in the absence of imaging evidence of residual tumor (tumor size < 1 cm^2) and the patient otherwise meets criteria for enrollment on the low-risk arm, the patient will be classified as low-riskXx_NEWLINE_xXPatients who have undergone recent resection of recurrent or progressive tumor will be eligible as long as they have recovered from the effects of surgery. Evaluable or measurable disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual measurable disease post-operatively, a MRI should be done no later than 96 hours in the immediate post-operative period or 4-6 weeks post-operatively.Xx_NEWLINE_xXMassive tumor (> 20 cm in greatest dimension)Xx_NEWLINE_xXAmputation of the affected leg as treatment of tumorXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of a malignancy known to express GD2; such tumors include medulloblastoma/primitive neuroectodermal tumor of the central nervous system (CNS), high grade astrocytomas, malignant glioma, neuroblastoma, retinoblastoma, ependymoma, rhabdoid tumors, sarcomas, melanoma or small cell lung carcinoma; for patients with other tumor types, GD2 expression must be confirmed by immunohistochemical staining and assessed by the Department of Pathology using prior frozen tissue, bone marrow or cerebrospinal fluid (CSF) cytologyXx_NEWLINE_xXPatients are only eligible if complete tumor resection is not feasible, or if a patient with a surgical option refuses surgery; patients must have measurable residual tumor present; for the purpose of this study a measurable lesion will be defined as a lesion of at least 3 cm measured in one dimension; evidence of recurrent or progressive disease is NOT necessary; patients must be at least 21 days from surgery, if performed, prior to receiving their first dose of study drugXx_NEWLINE_xXHistory of malignant peripheral nerve sheath tumorXx_NEWLINE_xXAt least 42 days must have elapsed after the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXAvailability of an adequate archival tumor specimen or willingness to undergo a pretreatment tumor biopsy.Xx_NEWLINE_xXSubjects enrolled in Expansion Cohort 3 must be willing to have 2 on-treatment tumor biopsies.Xx_NEWLINE_xXVessels providing flow to the tumor that are less than 1.5 mm in diameter.Xx_NEWLINE_xXSubjects must have evidence of recurrent or metastatic carcinoma by one or more of the following:\r\n* The appearance of metastatic disease on chest x-ray or computed tomography (CT) scan\r\n* The appearance of rising tumor marker: AFP or beta-human chorionic gonadotropin (HCG)\r\nNOTE: if a rising tumor marker is the only evidence of progressive disease, at least 2 consecutive rising values at least one week apart are needed; subjects with only evidence of disease as rising tumor marker AFP and beta-HCG will be assessed for alternate causes of increased serum levels of these markers, such as cross reaction with luteinizing hormone (LH) (can be tested if needed by testosterone suppression of LH), hepatitis, use of marijuana, or second primary tumorXx_NEWLINE_xXFor Expansion Cohorts only: patients must have tumor accessible for biopsies (core needle biopsy or excision preferred).Xx_NEWLINE_xXHas ability to submit archived or fresh tumor sample during the screening periodXx_NEWLINE_xXPathologically documented diagnosis of advanced solid tumor malignancy that progressed after appropriate prior therapy or has no potential for cure with currently available treatments.Xx_NEWLINE_xXImmunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines. Renal and Hepatic FunctionXx_NEWLINE_xXFor subjects receiving adjuvant therapy only, subjects must have undergone complete resection of the primary tumor with clean surgical margins, or subjects must have undergone resection of the primary tumor and be scheduled for further treatment of the primary tumor with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomizationXx_NEWLINE_xXTumor sample is available for retrospective CDH6 expression testingXx_NEWLINE_xXPhase 1a: Have histologic or cytologic confirmation of advanced solid tumorXx_NEWLINE_xXIneligible for curative resection or for liver transplantation according to the Milan criteria (single tumor =< 5 cm in size or =< 3 tumors each =< 3 cm in size) or the downstaging criteria already establishedXx_NEWLINE_xXThe participant has an untreated brain tumorXx_NEWLINE_xXT1a and T2a squamous cell carcinoma of the glottic larynx (tumor limited to one vocal cord with normal cord mobility)Xx_NEWLINE_xXPatients who have an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, patients with tumor fever may be enrolled.)Xx_NEWLINE_xXSubject's baseline tumor specimen (obtained after subject developed resistance to EGFR TKI therapy) is T790M negative.Xx_NEWLINE_xXFDG avid malignancy\r\n* Patients must have an FDG avid tumor(s)\r\n* FDG avid tumors are defined as a primary tumor with an increased uptake in the region of the tumor that has an SUV of > 5.0 or a tumor:liver SUV ratio of > 1.5Xx_NEWLINE_xXPrior treatment with panitumumab for subjects with KRAS and NRAS wt tumorXx_NEWLINE_xXPrior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumorXx_NEWLINE_xXSubject must have a pathologically documented, definitively diagnosed, advanced solid tumorXx_NEWLINE_xXAccessible tumor that can be biopsied at acceptable clinical risk (as judged by the investigator) and must consent to pre-treatment and on-treatment tumor biopsies; tumor biopsy sites need not be distinct from evaluable lesions but must not have been irradiated prior to study entryXx_NEWLINE_xXVenous involvement of the SMV/portal vein demonstrating tumor abutment with impingement and narrowing of the lumen, encasement of the SMV/portal vein but without encasement of the nearby arteries, or short-segment venous occlusion resulting from either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection and reconstructionXx_NEWLINE_xXTumor abutment of the SMA not to exceed greater than 180 degrees of the circumference of the vessel wall.Xx_NEWLINE_xXFor Phase 2, has archived or fresh tumor biopsy samples (obtained during screening) sufficient for genotyping.Xx_NEWLINE_xXHistory of symptomatic metastatic brain or meningeal tumors unless the subject is longer than 3 months from the end of definitive therapy before the first dose of the investigational drug and has clinically or radiologically no evidence of tumor growth.Xx_NEWLINE_xXCohort Expansion: Subjects must be determined to be HA-high based on tumor biopsy that meets the requirements noted in the previous inclusion criterion.Xx_NEWLINE_xXPatients must have at least one tumor accessible for intratumoral injection and EP on investigator's assessment.Xx_NEWLINE_xXTumor must be surgically resectable and curable with conventional surgeryXx_NEWLINE_xXTumor foci below the tentorium or beyond the cranial vault.Xx_NEWLINE_xXThe cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)Xx_NEWLINE_xXc-MET positive (defined by c-MET IHC intensity score +2 in ? 50% of tumor cells and MET gene copy number ? 5 by FISH or IHC intensity score +3 in ? 50% of tumor cells) and K/NRAS WT status for mCRC patients onlyXx_NEWLINE_xXAfter a restaging transurethral resection of bladder tumor (TURBT), patients with histologically proven primary high grade and/or pT1 transitional cell carcinoma of the bladder, with or without pTis and pTis alone are regarded as being at high risk for tumor recurrence and progressionXx_NEWLINE_xXDirect tumor extension into the stomach, duodenum, small bowel or large bowelXx_NEWLINE_xXPatients must show signs of progression (by imaging, or tumor marker elevation) after being treated with a first line or greater treatment for their un-resectable or metastatic colorectal cancerXx_NEWLINE_xXWillingness to undergo leukapheresis and biopsy procedures for the autologous components (peripheral blood mononuclear cells, plasma and fresh tumor specimen) required for manufacture of AGS-003Xx_NEWLINE_xXParticipants must be a candidate for a trans-urethral resection of the bladder tumor (TURBT), cystectomy (partial or radical) or cystoscopy with biopsy at a participating organizationXx_NEWLINE_xXAny treatment for the bladder tumor other than intravesical therapy between the pre-study cystoscopy or radiologic imaging which identified the suspected bladder tumor and the scheduled surgical removal or cystoscopy-guided biopsy of that tumorXx_NEWLINE_xXA tumor lesion that can be safely biopsied as judged by the treating oncologist and physician performing the procedure and has not been radiatedXx_NEWLINE_xXCoagulopathy or anticoagulation therapy that cannot be safely corrected or interrupted for tumor biopsyXx_NEWLINE_xXThe primary tumor must be in a location amendable to RFA within the kidneyXx_NEWLINE_xXPatients with renal cell carcinoma less than 8 cm in maximum diameter, patients with metastatic RCC who require local palliation or are progressing through systemic disease, patients who are poor surgical candidates and have tumor location not amenable to RFA, or patients who would prefer a noninvasive means of treatment are eligible for the non-randomized SBRT cohort\r\n* Renal cell carcinoma must be pathologically provenXx_NEWLINE_xXThere are no limitations based on location of the primary tumor within the kidneyXx_NEWLINE_xXAssessment by the attending thoracic surgeon that the primary tumor is resectable in pts with NSCLC and pleural spread; tumor will be deemed resectable if there is no extension through fascia, no bony chest or vertebral body involvement, and no radiographic evidence of mediastinal involvementXx_NEWLINE_xXMeasurable, non-bony disease (at least one lesion on radiographic or physical exam assessment measuring >= 2 cm in longest axis), as demonstrated by imaging or physical exam performed =< 28 days of study entry, provided no anti-tumor therapies or interventions have occurred in that time periodXx_NEWLINE_xXTumor accessible for unrestricted illumination for interstitial photodynamic therapy (PDT) (accessibility as determined by the physician)Xx_NEWLINE_xXTumor invading a major blood vessel (such as the carotid artery)Xx_NEWLINE_xXLocation and extension of the tumor precludes an effective I-PDTXx_NEWLINE_xXRadiographic evidence of contrast-enhancing tumor crossing midline, leptomeningeal dissemination, gliomatosis cerebri or infratentorial tumorXx_NEWLINE_xXPatients must be amenable to receiving 1 dose of HSV1716 intra-operatively with planned HSV1716 injection sites >= 1 cm from the ventricular system AND meet at least one of the criteria below based upon pre-surgical magnetic resonance imaging (MRI):\r\n* Tumor is >= 1 cm from the ventricular system\r\n* Patients whose tumors that are =< 1 cm from the ventricular system are eligible if there is sufficient space within the tumor cavity and/or residual tumor to perform the HSV 1716 injections that are >= 1 cm from the ventricular systemXx_NEWLINE_xXTumor MET amplified by protocol-specified centralized testing.Xx_NEWLINE_xXCurrently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatmentXx_NEWLINE_xXClinical stage I-III invasive breast cancer with the intent to treat with surgical resection of the primary tumor; tumor must be >= 2 cm to provide adequate tissueXx_NEWLINE_xXTargeted tumor(s) are accessible to the ExAblate deviceXx_NEWLINE_xXPatients in whom the targeted volume within the tumor is located deeper than 1 cm from the skinXx_NEWLINE_xXTarget volume in tumor is less than 1 cm from neurovascular bundles, major blood vessels, bowel or bladderXx_NEWLINE_xXPreferentially radiologically by tumor growth or new lesions, or byXx_NEWLINE_xXMandatory tumor biopsy at study entry (pre-randomization, unless already collected after sorafenib progression but within 3 months of enrollment and no systemic anticancer therapies received)Xx_NEWLINE_xXTumor volume ? 70% of liver volume (determined by visual estimation)Xx_NEWLINE_xXINCLUSION CRITERIA:\n\n        Pre-Treatment Phase: Tissue Procurement and Establishment of Tumor Cell Line\n\n          1. Histologic diagnosis of invasive melanoma.\n\n          2. Measurable metastatic melanoma with at least one lesion amenable to -resection Stage\n             III: recurrent regional disease, including regional disease with no known primary.\n\n             Stage IV: distant metastatic melanoma.\n\n          3. Age 18 years and older.\n\n          4. Sign the \Tissue Consent\, the pre-Clinical Informed Consent for Melanoma Tissue\n             Procurement and initiation of cell line effort granting Caladrius permission to\n             cryopreserve the tumor and/or to initiate an autologous tumor cell line from excess\n             tissue that has been removed during a medical procedure (e.g., surgically excised).\n\n          5. Initiation of Autologous Tumor Cell Line. Caladrius must have received a viable\n             melanoma tumor tissue specimen that has been obtained and processed according to\n             company SOPs to ensure tissue viability. The cell line can be initiated with either a\n             specimen of fresh tumor or tumor that has been previously cryopreserved.\n\n        Treatment Phase\n\n          1. Successful establishment of an autologous melanoma cell line by Caladrius.\n\n          2. Patients with multiple depots of distant metastatic disease must have previously\n             received at least one or more of the following standard treatments: interleukin 2\n             (IL-2), or ipilimumab, or vemurafenib (if tumor expresses the V600E mutation), or\n             dacarbazine or temozolomide, if not mutated for the V600E mutation, and not felt to be\n             medically appropriate for IL-2 or ipilimumab. These may have been given alone, or in\n             combination with other agents.\n\n          3. Medical fitness to undergo a leukapheresis, including peripheral venous access or\n             access by central vein if necessary.\n\n          4. Medical fitness for participation in a phase III clinical trial.\n\n               -  a. ECOG performance status of 0 or 1.\n\n               -  b. Adequate bone marrow function: absolute neutrophil count (ANC) greater than\n                  1000/mm (3), hematocrit greater than 30%, platelet count greater than 100,000/mm\n                  (3), no ongoing transfusion requirements.\n\n               -  c. Adequate hepatic function: total bilirubin less than 2.0 mg/dL, alanine\n                  aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the\n                  upper limit of normal (ULN), albumin greater than 3 g/dL.\n\n               -  d. Adequate kidney function: creatinine less than or equal to 2.0 mg/dL.\n\n               -  e. Negative pregnancy test for woman of childbearing potential and use of\n                  effective contraception (hormonal or barrier method of birth control) during\n                  therapy (women of childbearing potential and men).\n\n          5. Extent of disease established within 4 weeks of randomization.\n\n               -  a. History and Physical Exam by a licensed practitioner.\n\n               -  b. Fludeoxyglucose(FDG)-based PET/CT or PET scan and CT scan.\n\n               -  c. Brain MRI demonstrating no new untreated or uncontrolled metastases.\n\n          6. Recovery from previous therapies.\n\n               -  a. At least four weeks (28 days) must have elapsed since any prior systemic\n                  therapy at the time of the first dose (six weeks for anti-cytotoxic T\n                  lymphocyte-associated antigen 4 (anti-CTLA-4), and any toxicities experienced\n                  must have recovered to a grade 1 or less (except for alopecia or vitiligo).\n\n               -  b. More than three weeks (at least 22 days) since radiation therapy at the time\n                  of the first dose (7 days for single-dose stereotactic radiotherapy such as gamma\n                  knife) and recovery from acute toxicities. Patients treated with whole brain\n                  radiation must wait at least 22 days after completion of radiation and have\n                  radiographic confirmation of lack of progression before proceeding to\n                  randomization.\n\n        EXCLUSION CRITERIA:\n\n        Pre-Treatment Phase: Tissue Procurement and Establishment of Tumor Cell Line\n\n          1. Eastern Cooperative Oncology Group (ECOG) performance status greater than 2\n\n          2. Lack of a metastatic melanoma lesion that can be resected.\n\n        Treatment Phase\n\n          1. Known positive for hepatitis B or C or HIV.\n\n          2. Pregnant or lactating women.\n\n          3. Underlying cardiac disease associated with known myocardial dysfunction, or active\n             treatment with digoxin or other medications being given to treat heart failure, or\n             unstable angina related to atherosclerotic cardiovascular disease.\n\n          4. Diagnosis of any other invasive cancer that requires ongoing treatment or for which\n             there is evidence of active disease.\n\n          5. Active, unresolved infection and/or receiving concurrent treatment with parenteral\n             antibiotics (patients are eligible after antibiotics have been discontinued for at\n             least 7 days prior to first dose and evidence of infection has resolved).\n\n          6. Other active medical condition that could be imminently life threatening, in the\n             opinion of the investigator, including no active blood clotting or bleeding diathesis.\n\n          7. New or uncontrolled brain metastases or leptomeningeal disease and/or taking\n             pharmacological doses of corticosteroids. Brain metastases treated by gamma knife or\n             stereotactic radiotherapy are considered controlled, unless patient requires\n             pharmacologic doses of corticosteroids. It is recognized that tumor necrosis may be\n             confused with tumor progression in interpretation of Brain MRI.\n\n          8. Known autoimmune disease, immunodeficiency, or disease process that involves the use\n             of immunosuppressive therapy.\n\n          9. Taking other anticancer therapy.\n\n         10. Received another investigational drug within 28 days of the first dose.Xx_NEWLINE_xXHistologically confirmed diagnosis of glioblastoma (after initial tumor resection or biopsy) with radiographic evidence of recurrent tumor per RANO criteria.Xx_NEWLINE_xXSubjects must have at least one tumor lesion that is suitable for repeat biopsy, and must agree to two tumor biopsies (pre- and post- treatment).Xx_NEWLINE_xXDiagnosis of localized or metastatic unresectable MTC; the histological diagnosis of MTC must be confirmed on review of submitted tumor tissue by the Laboratory of Pathology in the National Cancer InstituteXx_NEWLINE_xXPatients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3, N1-N3 disease are eligible if deemed unresectable; patients with T4, any N are eligibleXx_NEWLINE_xXWillingness to provide at least one pre-and post-vaccination tumor biopsy sample.Xx_NEWLINE_xXPatients must have disease that is potentially amenable to curative resection as reviewed by the Medical University of South Carolina (MUSC) Gastrointestinal (GI) Tumor BoardXx_NEWLINE_xX>= 1 measurable lesion that is palpable, its size can be measured by bi-dimensional tape, ruler or caliper technique, and the minimum size of the largest tumor diameter is greater than 2.0 cm by imaging or physical examinationXx_NEWLINE_xXIf the index tumor is in the spine, there must be an intact cortex between the mass and the spinal canal and exiting nerve rootsXx_NEWLINE_xXPatients with a tumor involving a weight-bearing long bone of the lower extremity with the tumor causing > 50% loss of cortical boneXx_NEWLINE_xXIndex tumor(s) causing clinical or radiographic evidence of spinal cord or cauda equine compression/effacementXx_NEWLINE_xXAnticipated treatment of the index tumor that would require iceball formation within 1.0 cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel such as the aorta or inferior vena cava (IVC), bowel, or bladderXx_NEWLINE_xXIndex tumor involves the skull (treatment of other painful tumors in subjects with skull tumors is not excluded)Xx_NEWLINE_xXAn untreated tumor growth rate of < 6.1% during the Screening period may exclude some patients.Xx_NEWLINE_xXEvidence of MCPyV TAg tumor expressionXx_NEWLINE_xXTumor located in the supra-tentorial region of the brainXx_NEWLINE_xXTumor >= 0.5 cm from skin as defined by breast ultrasoundXx_NEWLINE_xXUnicentric tumorXx_NEWLINE_xXPatients with =< 10 cc largest tumor volume, and =< 15 cc total tumor volumeXx_NEWLINE_xXPatients with an obstructive synchronous colorectal tumor requiring up-front surgery or chemoradiationXx_NEWLINE_xXThe subject has a primary brain tumorXx_NEWLINE_xXThe subject has tumor in contact with, invading or encasing major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXPatient must have radiologic demonstration of stable disease or tumor responseXx_NEWLINE_xXPatients must have disease that is potentially amenable to curative resection as reviewed by the Medical University of South Carolina (MUSC) Gastrointestinal (GI) Tumor BoardXx_NEWLINE_xXPatients must have EGFR gene mutation in their tumors. This can be source - documented by one of the following: • Provide a pathology report that indicates the patient's tumor had EGFR activating mutation in the past. Or: • Perform testing (local or central) in an archival tumor or a fresh baseline biopsy tumor tissue to show the presence of EGFR activating mutation.Xx_NEWLINE_xXAvailability of a representative tumor specimen. Patients enrolled in Arm 3 of Phase II must have disease sites amenable to biopsy unless prior agreement between Novartis and the Investigator.Xx_NEWLINE_xXTumor foci below the tentorium or or beyond the cranial vaultXx_NEWLINE_xXAt least 2 organs involved in metastatic gastric tumor (including at least lung or liver or both) in addition to the site of primary tumor, where metastasis in distant lymph nodes, peritoneal metastasis, and malignant pleural effusion may count as \organs\ in this contextXx_NEWLINE_xXTumor biopsy specimen with ? 50% of MUC1 expressing tumor cells determined by Immunohistochemistry (IHC) staining on fixed pathological material. Biopsy may come either from the primary tumor or from a metastasis. Cytological material is not accepted for this analysisXx_NEWLINE_xXPatients with tumor amenable to potentially curative therapy as assessed by the investigatorXx_NEWLINE_xXPatients on stage 2 of the enrollment must have tumor sites that are easily biopsied and be willing to undergo pre- and post-treatment (around day 8 +/- 3 days) tumor biopsiesXx_NEWLINE_xXPatients with tumor amenable to potentially curative therapy as assessed by the investigatorXx_NEWLINE_xXParticipants must have cutaneous lesion(s) amenable to four (4) 5-mm tumor biopsies during the study (either 4 separate lesions measuring >= 5 mm each OR 2 separate lesions measuring >= 10 mm each) and at least five additional lesions measurable for assessment with no improvement over the past monthXx_NEWLINE_xXFor Part A, the subject has histological or cytological evidence of a solid tumor; for Part B, the subject has histological or cytological evidence of 1 of the following solid tumor types: melanoma, renal cell carcinoma, or ovarian cancerXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients with progressive DIPG, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis, OR the appearance of a new tumor lesion since diagnosis\r\n* Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation\r\n* Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma World Health Organization (WHO) II-IVXx_NEWLINE_xXAny hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registrationXx_NEWLINE_xXHas a core or excisional baseline tumor biopsy specimen available or willingness to undergo a pre study treatment tumor biopsy to obtain the specimen.Xx_NEWLINE_xXPancreatic tumor size =< 5 cmXx_NEWLINE_xXAndrogen receptor expression testing confirms that the patient’s tumor is AR (+); AR is considered positive if >= 1% of cell nuclei are immunoreactive using the Dako antibody (clone androgen receptor antibody [AR441]); receptor testing may be performed on either primary tumor specimen or tissue from a metastatic site; local testing permitted for eligibility but will require confirmation at Memorial Sloan-Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXTumor size 1 cm or greater; N any; M0 (Cohort 1)Xx_NEWLINE_xXTumor size 2 cm or greater; N any; M0 (Cohort 2)Xx_NEWLINE_xXHave histologic or cytologic documentation of solid tumor including EGFR mutated (EGFRm) NSCLCXx_NEWLINE_xXSubjects must consent to provide archived tumor specimens or tumor biopsies for correlative biomarker studies.Xx_NEWLINE_xXThe subject has tumor invading any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXHistopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types):Xx_NEWLINE_xXGastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type)Xx_NEWLINE_xXanti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative andXx_NEWLINE_xXPalpable primary breast tumor measuring >= 2.0 cm on physical exam or imaging prior to neoadjuvant chemotherapyXx_NEWLINE_xXPatients with evidence of other tumor masses in the spinal cord will be eligible unless there is evidence of spinal cord block radiographically or clinicallyXx_NEWLINE_xXConsent to provide archived tumor specimensXx_NEWLINE_xXThe subject has a tumor suitable for biopsy and is willing to undergo tumor biopsy, preferably of the primary tumor, within 28 days prior to Cycle 1/Visit Day 1;Xx_NEWLINE_xXDiagnosis of an advanced solid tumor malignancy. There must be a target tumor which is measureable, palpable or clearly identifiable under ultrasound or radiographic guidance and amenable to percutaneous injection of C. novyi-NT spores. The targeted lesion must have a longest diameter ? 1 cm and ? 12 cm and be measurable as defined by RECIST 1.1 criteria. The target lesion must not be located in either the thoracic, abdominal or pelvic cavities or in the brain. There must be no clinical, no functional, and no radiographic evidence of bone involvement at the site of the target lesion.Xx_NEWLINE_xXEvidence of tumor invading major blood vessels, cavitation of one or more pulmonary tumor mass(es) ortracheo-esophageal fistulaXx_NEWLINE_xXPatients should have either non-metastatic cancer of the thorax, or metastatic cancer to the thorax and candidate for definitive radiation dose to the thoracic tumor (not palliative intent), tumor radiation dose to at least BED2Gy 60 GyXx_NEWLINE_xXPart A: Any type of solid tumor (\all comer\)Xx_NEWLINE_xXAvailability of a tumor sample taken after progression on the most recent line of systemic tumor therapy or willing to undergo a tumor biopsy pre-study treatment.Xx_NEWLINE_xXThe participant has radiographic evidence of intratumor cavitation, regardless of tumor histologyXx_NEWLINE_xXRelapsed or progressive advanced solid tumor malignanciesXx_NEWLINE_xXSubject has cavitating pulmonary lesion(s) or a pulmonary lesion or tumor abutting or encasing a major blood vesselXx_NEWLINE_xXAt least 25% of cells >= 1+ for FRa staining based on diagnostic (i.e., prior to NAC) tumor biopsyXx_NEWLINE_xXAbility to comply with the collection of tumor biopsies; tumors accessible for biopsyXx_NEWLINE_xXOther concomitant anti-tumor therapy as determined by the study team.Xx_NEWLINE_xXBreast tumor ?1 centimeter (cm) in diameter, HR+, HER2-.Xx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXIf the subject received neoadjuvant therapy, residual tumor is present (to be determined by the primary surgeon)Xx_NEWLINE_xXAvailability of an archival or newly obtained tumor sample (collected at diagnosis or progression) with accompanying pathology reportXx_NEWLINE_xXPatients must have resectable pancreatic cancer OR must be deemed borderline resectable; potentially resectable is defined as a) no extrapancreatic disease, b) no evidence (on CT) of involvement of the celiac axis or superior mesenteric artery (SMA),and c) no evidence (CT or MRI) of occlusion of the superior mesenteric vein (SMV) or superior mesentericportal vein (SMPV) confluence; borderline resectable is defined by the National Comprehensive Cancer Network (NCCN) as tumors with venous involvement of the SMV/portal vein demonstrating tumor abutment with or without impingement and narrowing of the lumen, either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection or reconstruction; gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to the celiac axis; or tumor abutment of the SMA not to exceed greater than 180 degrees of the circumference of the vessel wall; tumors involving retroperitoneal structures that can be surgically removed (ie. kidney), will also be includedXx_NEWLINE_xXDiagnosis of cervical cancer with a tumor size greater than 2 cm.Xx_NEWLINE_xXSarcoma or Wilms tumor diagnosis (Group C) will require evaluation by physician in the St. Jude Solid Tumor Division, other than the referring physician, attesting that autologous stem cell transplant (SCT) provides the prospect of direct benefit for the participantXx_NEWLINE_xXSubjects with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at Thomas Jefferson University Hospital (TJUH) are eligible to participateXx_NEWLINE_xXBiopsy accessible tumor depositsXx_NEWLINE_xXAt least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccinesXx_NEWLINE_xXPart 1 (enrollment closed): an advanced, incurable solid tumorXx_NEWLINE_xXPart 2 (enrollment closed): an advanced, incurable solid tumor for whom a taxane would be considered a reasonable chemotherapy optionXx_NEWLINE_xXPrimary tumor and any positive node(s)measurable in 2 dimensionsXx_NEWLINE_xXTumor classifications T1N0, T2N0, T4N3, any TN classification with M1Xx_NEWLINE_xXPrior resection of jugular nodes ipsilateral to tumorXx_NEWLINE_xXDocumentation of lesion response during the course of therapy received prior to randomization (i.e., improvement or no worsening of tumor burden; the absence of new lesions)Xx_NEWLINE_xXUnwilling to allow removal of tumor biological samples for analysis, i.e., biopsies of tumor lesions, and/or collection of ascites fluid from abdominal ascites (if present)Xx_NEWLINE_xXNon epithelial tumor, including malignant mixed Müllerian tumors without high grade serous component, or ovarian tumors with low malignant potential (i.e., borderline tumors)Xx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement in the lungs resulting in dyspnea at restXx_NEWLINE_xXPatient willingness to undergo tumor biopsy at baseline and on treatment (optional for Phase 1; mandatory for Phase 2)Xx_NEWLINE_xXDocumented evidence in tumor of exon 20 insertion, small cell transformation, or MET amplificationXx_NEWLINE_xXWillingness to undergo two tumor biopsies: before and after administration of RO7070179.Xx_NEWLINE_xXRadiographic evidence of cavitating pulmonary lesions and tumor adjacent to or invading any large blood vessel unless approved by sponsor.Xx_NEWLINE_xXAt least one tumor amenable to excisional, core or forceps (transbronchial) biopsy; patients must be willing to undergo tumor biopsies before starting therapy and after the third (3rd) CDX-1401 injection; additionally, the first 12 patients enrolled must consent to a third tumor biopsy to be performed after the 3rd MPDL3280A infusionXx_NEWLINE_xXIntact breast tumor present and size measuring at least 1 cm at enrollmentXx_NEWLINE_xXConfirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600.Xx_NEWLINE_xXTumors in previously irradiated fields may be considered measureable if there is evidence of tumor progression after radiation treatment.Xx_NEWLINE_xXAnti-tumor therapy within 21 days of study Day 1Xx_NEWLINE_xXOne or more of the following “risk” criteria for failure with conventional SBRT treatment alone:\r\n* Peripheral tumor >= 4 cm in any dimension\r\n* Central tumor (i.e. gross tumor within 2 cm of a major bronchus/vessel, or heart/pericardium), including hilar lymph node(s)\r\n* Multiple tumors (i.e. satellitosis-defined T3-4, or bilateral synchronous primary lung cancer; note that the maximum number of total lesions allowable on this study for treatment with SBRT is 3 (three), and all lesions must be amenable to SBRT and treated with SBRT on this study; note that it is not necessary for all lesions felt to be malignant to be biopsiedXx_NEWLINE_xXPatients must express NY-ESO-1 in their tumor by immunohistochemistry (IHC) (> 5%) prior to leukapheresisXx_NEWLINE_xXPatient must have a biopsy-accessible tumor to be radiatedXx_NEWLINE_xXSubjects with a neuroendocrine tumor of the pancreas, an acinar tumor of the pancreas or a pancreatic tumor with mixed histologies.Xx_NEWLINE_xXAt least 1 measurable tumor lesion, as defined by mWHO criteria, that is not located in a previously irradiated areaXx_NEWLINE_xXT3 tumor defined by invasion of key structures (only T3 defined by size > 7 cm allowed)Xx_NEWLINE_xXWell-differentiated liposarcoma or atypical lipomatous tumorXx_NEWLINE_xXGastrointestinal stromal tumor (GIST)Xx_NEWLINE_xXSolitary fibrous tumorXx_NEWLINE_xXPEComa (perivascular epithelial cell tumor)Xx_NEWLINE_xXMyoepithelioma / mixed tumorXx_NEWLINE_xXOligometastatic or unresectable primary disease planned for SBRT with biopsy-proven primary disease histology of solid tumor categorization with the exception of small cell cancers; hepatocellular carcinoma does not need to be biopsy proven if imaging and clinical findings are consistent with the diagnosisXx_NEWLINE_xXTest results showing genetic change in tumor gene for CREBBP and/or EP300Xx_NEWLINE_xXAt least one tumor that can be measuredXx_NEWLINE_xXUncontrolled tumor in the brainXx_NEWLINE_xXPatient has a confirmed diagnosis of a select solid tumor (except breast cancer (however, triple negative will be included), liposarcoma, CRPC, melanoma and teratoma) or hematological malignancy (except mantle cell lymphoma).Xx_NEWLINE_xXPatient has a confirmed diagnosis of a select solid tumor (except ALK+ NSCLC) or hematological malignancy and is in need of treatment because of radiologic progression or relapse.Xx_NEWLINE_xXPatient's esophageal tumor length exceeds that which can be treated with a single stent (maximum lesion length 9.5cm)Xx_NEWLINE_xXMetastatic disease that involve major airways or blood vessels, or centrally located mediastinal tumor masses (< 30 millimeter from the carina) of large volumeXx_NEWLINE_xXNET tumor other than PNET or GI-NETXx_NEWLINE_xXPatients must have tumor accessible by interventional radiology or surgical intervention and suitable for biopsy with 5-6 passes of a 16 or 18 gauge needle for core biopsy (defined as at least 1 cm^3 tumor/50 mg accessible for biopsy), and must agree to undergo up to two surgical resections/biopsies to collect tumor for research purposes; the first of these biopsies will occur at the beginning of the study, prior to genetic analysis and treatment; the second biopsy will be performed at the time of disease progression/end of study should funding be availableXx_NEWLINE_xXPatient agrees to having a blood sample (approximately 10 mL) drawn and analyzed to compare their normal genetic profile to that of their tumor sampleXx_NEWLINE_xXBRAF V600 mutation-positive tumor: as confirmed by a Clinical Laboratory Improvement Amendments (CLIA) approved local laboratory or equivalent.Xx_NEWLINE_xXFor patients who have undergone resection of recurrent or progressive tumor prior to study enrollment, the following conditions must apply:Xx_NEWLINE_xXResidual disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual disease post-operatively, an MRI should be performed:Xx_NEWLINE_xXAt least 12 weeks from prior radiotherapy to the start of SL-701 unless there is new enhancement outside of the radiation field or unequivocal histopathologic evidence of recurrent tumor.Xx_NEWLINE_xXContrast-enhancing tumor that is any of the following:Xx_NEWLINE_xXHistory of cancer (other than GBM) within the past 2 years that has metastatic or local recurrence potential and could negatively impact survival and/or potentially confound tumor response assessments within this study.Xx_NEWLINE_xXIs willing to provide pre-existing diagnostic or resected tumor samples, such as paraffin-embedded sections. Providing a fresh tumor biopsy sample is optional.Xx_NEWLINE_xXSubjects with cutaneous melanoma must provide either a fresh or archived tumor sample for genetic analysis including determination of or confirmation of BRAF and NRAS genetic status based on local laboratory results. To ensure prompt delivery of tumor samples, tissue shipment tracking information must be provided before administration of study treatment can be initiated.Xx_NEWLINE_xXMust provide either a fresh or archived tumor sample for genetic analysis.Xx_NEWLINE_xXAccessible tumor for biopsy and willingness to provide pre-dose tumor biopsies on Days 1 and Day 15.Xx_NEWLINE_xXAn adequate tumor specimen obtained by either excisional biopsy, incisional biopsy or core needle biopsy must be sent to the central pathology lab for evaluation. The material must measure at least 0.8 × 0.1 cm in size or contain at least 50 tumor cells.Xx_NEWLINE_xXAn inadequate tumor specimen as defined by the central pathologist.Xx_NEWLINE_xXCurrent evidence/diagnosis of alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST), dermatofibrosarcoma (unless transformed to fibrosarcoma), Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, clear cell sarcomas.Xx_NEWLINE_xXMixed tumor histologyXx_NEWLINE_xXOther primary solid tumor with no known active disease in the opinion of the investigator that will not affect patient outcome in the setting of current HCC diagnosis.Xx_NEWLINE_xXBy tumor biopsy if conducted within 4 weeks of randomization.Xx_NEWLINE_xXAn interval of at least 12 weeks after last dose of radiation and temozolomide is required, unless cancer progression is proven by diagnostic tumor biopsy. If temozolomide is being used in a maintenance phase, there must be a 28-day washout period prior to Randomization.Xx_NEWLINE_xXTumor must be glucocorticoid receptor positive TNBC (?10% positive cells by IHC of tumor biopsy)Xx_NEWLINE_xXUnknown primary tumor.Xx_NEWLINE_xXDoes the patient have either (1) a single, enhancing tumor recurrence/progression that is ? 8 cm in greatest dimension, or (2) multiple enhancing tumor recurrences/progressions within the same surgical field where the sum of their greatest dimensions is ? 8 cm?Xx_NEWLINE_xXBased on the pre-operative evaluation, is the tumor recurrence/progression a candidate for ? 80% resection?Xx_NEWLINE_xXPatients may choose to undergo an optional tumor biopsy including collection of research blood samples pretreatment and at weeks 3 and 15Xx_NEWLINE_xXInfra-tentorial tumorXx_NEWLINE_xXBiopsy proven HER2 negative metastatic breast cancer (dose escalation portion and MTD expansion portion) or advanced solid tumor (dose escalation portion).Xx_NEWLINE_xXEligibility for phase 1 and phase 2 components:\r\n* Phase 1 – clinical T3 or T4 or N1 or M1 cancer which is untreated or previously treated with platinum based therapy with primary tumor still present in the bladder and amenable to sampling before and after treatment, as indicated\r\n* Phase 2 – clinical T2-4 N0 or N1 untreated with primary tumor still present in the bladder and amenable to sampling before and after treatment, as indicatedXx_NEWLINE_xXSubjects must provide tumor biopsies before treatmentXx_NEWLINE_xXSymptomatic metastatic brain or meningeal tumors unless the patient is > 3 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.Xx_NEWLINE_xXHave metastatic RCC with primary tumor in placeXx_NEWLINE_xXHistologic proof of presence of residual tumor in liver explants and /or positive resection marginsXx_NEWLINE_xXThe subject has tumor in contact with, invading, or encasing major blood vesselsXx_NEWLINE_xXPatients with a known history of NF1 (Neurofibromatosis Type 1) and either \r\n* A history of a tumor of the central nervous system (astrocytoma or optic glioma), or \r\n* A malignant peripheral nerve sheath tumor with a complete remission of < 1 year are not eligibleXx_NEWLINE_xXMeasurable tumor by physical or radiographic examinationXx_NEWLINE_xXArm 2 only: At least 1 tumor that is amenable to biopsy, as determined by the investigator, and participant must be willing to undergo a biopsy prior to and at least once following anti-macrophage migration inhibitory factor (anti-MIF) antibody treatmentXx_NEWLINE_xXAnti-tumor therapyXx_NEWLINE_xXOnly patients with a test result, using the 5-gene Hh signature assay, indicating Hhpathway activated MB are eligible for this study. All available tumor material obtained at any time during the course of the patient's disease should be submitted for these analysesXx_NEWLINE_xXTumor (primary or metastatic lesion) defined as MET-positive by IHCXx_NEWLINE_xXHER2-positive tumor (primary tumor or metastasis)Xx_NEWLINE_xXAvailability of histological material (primary tumor or metastases) for review of the diagnosis and demonstration of PAX8-PPARgamma fusion geneXx_NEWLINE_xXBiopsy accessible tumor (may use archived tumor samples under certain circumstances)Xx_NEWLINE_xXIf the maximum number of non-biopsy subjects has accrued to the study, willingness to undergo 2 tumor biopsies. NOTE: Tumor biopsies may be required, depending on the number of subjects who have agreed to undergo correlative studies.Xx_NEWLINE_xXFor dose escalation, tumor type that has high biomarker prevalence without molecular confirmation of biomarker status, or any tumor type with molecular confirmation of biomarker status; For MTD cohort expansion, only dedifferentiated liposarcoma will be included.Xx_NEWLINE_xXCalculated required PV-10 dose ? 15 mL (based on total tumor burden)Xx_NEWLINE_xXMaximum tumor length of 7 cm at time of brachytherapy treatment startXx_NEWLINE_xXHistory of symptomatic metastatic brain or meningeal tumors unless the subject is >3 months from the end of definitive therapy before the first dose of study drug and has clinically or radiologically no evidence of tumor growth.Xx_NEWLINE_xXHistologically confirmed solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, primary brain tumors, NF-1 associated PF and LCH. In subjects with brain stem gliomas the requirement for histological confirmation can be waived if a biopsy was not performed. For plexiform neurofibromas, histologic confirmation of tumor is not necessary in the presence of consistent clinical and radiological findings, but should be considered if malignant degeneration of a PN is clinically suspected.Xx_NEWLINE_xXSolid tumor cohort (B1) specific criteriaXx_NEWLINE_xXSubjects with NF-1 associated optic pathway tumors are excluded if they are actively receiving therapy for the optic pathway tumor or do not meet criteria for PN or malignant solid tumor.Xx_NEWLINE_xXSubjects with NF-1 actively receiving therapy for the optic pathway tumor.Xx_NEWLINE_xXUnequivocal radiographic evidence for tumor progression by MRI. It is understood that some patients may be resected prior to enrolling onto protocolXx_NEWLINE_xXTumor deemed unresectable or metastaticXx_NEWLINE_xXAR expression >= 5% by immunohistochemistry (IHC); in cases where multiple blocks are available staining will be performed on unstained slides from 3 separate blocks; if >= 5% AR tumor staining is seen on >= 1 slide the tumor will be considered to be AR+Xx_NEWLINE_xXCohort A: Stage IIA-IIIA (TanyN1M0 or T2b-4N0M0) (selected patients with single station N2 nodal involvement in close proximity to the primary tumor target may be considered eligible at the discretion of the principal investigator [PI] if all normal tissue guidelines can be met)Xx_NEWLINE_xXDirect tumor extension into aorta or pulmonary arteryXx_NEWLINE_xXThe subject has tumor invading or encasing any major blood vesselsXx_NEWLINE_xXThe subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXThe subject has tumor invading major blood vesselsXx_NEWLINE_xXThe subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinibXx_NEWLINE_xXEvidence of an optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapyXx_NEWLINE_xXHistologically confirmed all-rat sarcoma viral oncogene homolog (RAS) wild type; paraffin-embedded tumor tissue obtained from the primary tumor or metastasisXx_NEWLINE_xXHistologically proven ependymoma or anaplastic ependymoma; there must be pathologic or imaging confirmation of tumor progression or regrowth; the patients histologic diagnosis must be confirmed on central pathology review prior to registration step 2Xx_NEWLINE_xXPatients treated by BCS or mastectomy and axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm)\r\n* Note patients with additional nodal micrometastases (> 0.2-2 mm) or isolated tumor cells (=< 0.2 mm) are eligible; patients with nodal disease limited only to micrometastases or isolated tumor cells are not eligibleXx_NEWLINE_xXPatients treated by mastectomy and SLNB alone must have only 1 positive axillary node (macrometastases, > 2 mm)\r\n* Note patients with additional nodal micrometastases (> 0.2-2 mm) or isolated tumor cells (=< 0.2 mm) are eligible; patients with nodal disease limited only to micrometastases or isolated tumor cells are not eligibleXx_NEWLINE_xXPatients with nodal disease limited to micrometastases (pN1Mi, > 0.2 mm and =< 2 mm) or isolated tumor cells (pN0i+ < 0.2 mm)Xx_NEWLINE_xXValid results from central molecular analysis confirming PIK3CA/AKT1/PTEN-altered status in tumor tissue by next-generation sequencing (NGS)Xx_NEWLINE_xXPatients with ovarian tumors of non-epithelial origin (eg, germ cell tumor) or any low grade tumors.Xx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXA tumor sample must be shipped to a central lab for identification of biomarkers (PI3K activation status) before randomizationXx_NEWLINE_xXNeurosurgical patient population in the City of Hope brain and spinal tumor neurosurgical programs that have been diagnosed with a brain tumorXx_NEWLINE_xXPatients with any type of brain tumor will be eligible for participationXx_NEWLINE_xXi2DOS will be attempted for all quantities, consenting, and brain tumor patients; we anticipate approximately 5 initial patients will need to be imaged before signal to noise parameters are optimized; then 1 patient from the most common operative tumor types (e.g. low grade glioma, glioblastoma multiforme, astrocytoma, invasive meningioma, metastatic breast carcinoma, etc.) will be imaged to ascertain gross intrinsic optical spectroscopically differences that may distinguish these tumors from each other and normal white matter, gray matter, and blood vesselsXx_NEWLINE_xXThere are no exclusion criteria except for individuals without a brain tumor and the location of the craniotomy; if the exposed area of brain is not compatible with peripheral stimuli or volitional activity the subject cannot be enrolledXx_NEWLINE_xXMalignancies that are refractory to or intolerant of established therapy known to provide clinical benefit. Patients must not be candidates for anti-tumor regimes known to provide clinical benefit.Xx_NEWLINE_xXPatients with an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled.)Xx_NEWLINE_xXFor certain subjects, willing and able to provide pre- and post-treatment fresh tumor biopsiesXx_NEWLINE_xXPatients with stage IV renal cancer\r\n* Patients in the initial cohort receiving CT-011 alone are not required to have tumor resection as a part of protocol participation\r\n* Patients in the second cohort are eligible if they are undergo therapeutic debulking nephrectomy for independent clinical indications OR patients with other sites of accessible disease as defined by peripheral lung nodules approachable by thoracoscopy, malignant effusions, or cutaneous, subcutaneous or superficial lymph node involvement; patients should have an independent diagnostic or therapeutic indication for this purpose; tumor tissue should be at least 1.0 cm in longest dimension to provide an adequate source of tumor cells for vaccine generationXx_NEWLINE_xXBiopsy proven ER/PR positive tumorXx_NEWLINE_xXTumor that lacks both estrogen and progesterone receptorsXx_NEWLINE_xXPatients with solid tumor other than CRC.Xx_NEWLINE_xXPathologic proven diagnosis of solid tumor malignancyXx_NEWLINE_xXRadiosensitive or non-solid (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologiesXx_NEWLINE_xXBiopsy accessible tumor (may be waived under certain circumstances)Xx_NEWLINE_xXFor NSCLC, an ALK translocation must be detected by FISH in ? 15% of tumor cells.Xx_NEWLINE_xXMeasurable disease demonstrating intratumoral arterial enhancement by contrast enhanced computerized tomography (CT), with use of multislice scanners, or contrast enhanced dynamic magnetic resonance imaging (MRI), with at least 1 tumor lesion that meets the following criteria: located in the liver; can be accurately measured in at least 1 dimension; well delineated area of viable, hypervascular (contrast enhancement in the arterial phase) tumor that is >2 centimeter (cm) in the axial plane; suitable for repeat measurement; OR not previously treated with locoregional or systemic treatment unless the lesion shows a well-delineated area of viable (contrast enhancement in the arterial phase) tumor that is >2 cm in the axial plane. (If the lesion is poorly demarcated or exhibits atypical enhancement as a result of the previous intervention, then it cannot be selected as a target lesion)Xx_NEWLINE_xXSubjects must have a pathologically documented, definitively diagnosed, advanced solid tumorXx_NEWLINE_xXPresence of at least one measureable tumor lesion is requiredXx_NEWLINE_xXfor intratumoral cohorts, injection of tumor would require violation of ventricular systemXx_NEWLINE_xXHave at least one BCC tumor (greater than 4mm in diameter) at any skin location, which needs to be biopsied and surgically removedXx_NEWLINE_xXBRAF mutation positive melanoma or colorectal cancer; other BRAF mutation positive tumor types may be considered.Xx_NEWLINE_xXTumor size =< 5 cm in greatest dimension \r\n- For NSCLC lesions, staging studies must identify the lesion as T1 N0 M0, or T2 (=< 5 cm) N0 M0, or T3 (=< 5 cm) N0 M0Xx_NEWLINE_xXTumor size > 5 cmXx_NEWLINE_xXAll patients must have histological evidence of a solid malignant tumor (hematological malignancies are excluded) with convincing clinical, radiographic or isotopic evidence of cancer, for which no effective proven treatment exists. CNS associated tumors are preferred, but not required. Patients must sign an informed consent that complies with the investigator/DEKK-TEC policies and approved by a Human Investigation Review Committee.Xx_NEWLINE_xXDiagnosis:\r\n* Rhabdomyosarcoma: embryonal or alveolar\r\n* Ewing’s sarcoma family of tumors (ESFT), which include: classical, atypical, and extraosseous ESFT, peripheral primitive neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma\r\n* Neuroblastoma: may be diagnosed via histology or the standard clinical evidence for increased catecholamines in the urine plus tumor cells in the bone marrow\r\n* Undifferentiated or embryonal sarcoma\r\n* Desmoplastic small round cell tumor\r\n* Synovial cell sarcomaXx_NEWLINE_xXPatients must have adequate tumor bulk accessible to biopsy in order to generate the tumor lysate (at least 2 cm diameter); procedures employed to acquire biopsies for tumor lysates will be limited to percutaneous biopsies or open biopsies of readily accessible lesions; patients should not undergo biopsies, which will later compromise the ability to render function preserving local therapy (e.g. limb salvage therapy); to prevent this, all bone biopsies should be performed in consultation with the orthopedic consultant on the case; for patients with bone marrow involvement, bone marrow aspirates may be used as a source of tumor for tumor lysates; patients are not eligible if, in the opinion of the principal and associate investigators, tumor biopsy would entail extensive surgery such as thoracotomy or laparotomy, or if the tumor site places the patient a substantial risk from the biopsy procedure; National Cancer Institute (NCI) laboratory of pathology will review all tumor specimens for diagnosisXx_NEWLINE_xXConditions related to tumor, which require emergency treatment (airway compression, spinal cord compression) since enrollment would delay initiation of such therapyXx_NEWLINE_xXCorticosteroids initiated at the time of tumor diagnosis or recurrence for treatment of nerve compression or other symptoms is permitted during this phase of the trial, but will not be permitted during the immunotherapy phase, with the exception of a self-limited course of steroidsXx_NEWLINE_xXSymptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at restXx_NEWLINE_xXlarge tumor mass (bulky disease)Xx_NEWLINE_xXTumor thickness must be clinically indicated for hyperthermia therapy, as measured by clinical exam or imaging studies (CT or MRI). The target local tumor lesion(s) must be able to be covered within two hyperthermia fields of treatment.Xx_NEWLINE_xXAll patients must have had prior pathologic confirmation of tumor histology, anaplastic glioma (AG) or glioblastoma (GBM) and have supratentorial gliomasXx_NEWLINE_xXPatients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:\r\n* They are > 2 weeks from surgery\r\n* They have recovered from the effects of surgery\r\n* Evaluable or measurable disease following resection of recurrent tumor is mandated for eligibility into the study\r\n* To best assess the extent of residual disease post-operatively, an enhanced CT/MRI should be done no later than 96 hours after surgery or it will need to be done 4-6 weeks post-operatively; if the 96 hour scan is more than 2 weeks from registration, the scan needs to be repeatedXx_NEWLINE_xXPatients must have unequivocal evidence for tumor recurrence or progression by histology as determined by review of pathology by an attending neuro-pathologist at UCSFXx_NEWLINE_xXPatients must have evidence for tumor recurrence or progression by MRI as determined by radiographic review of images by an attending neuro-oncologist or neuro-radiologist at UCSFXx_NEWLINE_xXThe participant must have a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, measurable by elevated tumor markers (eg, 24-hour urine 5-HIAA, chromogranin A, adrenocorticotropin hormone (ACTH), gastrin, or other tumor specific biochemical markers), or bothXx_NEWLINE_xXThe participant's tumor has Ki-67 expression ? 20%Xx_NEWLINE_xXDisruption of the lung pleura by tumor.Xx_NEWLINE_xXEvidence of ascites, cirrhosis, portal hypertension, main portal or venous tumor involvement or thrombosis as determined by clinical or radiologic assessment.Xx_NEWLINE_xXPathologically confirmed giant cell tumor of bone within 1 year before study enrollmentXx_NEWLINE_xXKnown or suspected current diagnosis of brown cell tumor of bone or Paget's diseaseXx_NEWLINE_xXTumor must be accessible for injection and must not be located in the brainstem, midbrain, contained within the ventricular system, or located in an infratentorial location.Xx_NEWLINE_xXMay not receive other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from AdV-tk injection until tumor progression).Xx_NEWLINE_xXWilm's tumor and clear cell sarcoma\r\n * Patients with Wilm’s tumor or clear cell sarcoma will be eligible if relapse occurs following an autologous transplant or if the patient relapses following initial treatment, but is not eligible for an autologous transplant; patients who do not achieve a CR with initial therapy will also be eligible provided they can be rendered free of bulky disease as defined aboveXx_NEWLINE_xXProgression of solid tumors/lymphomas: Patients demonstrating clear tumor progression 4 weeks after receiving DLI will not be eligible to receive additional DLIXx_NEWLINE_xXKidney tumor has been removedXx_NEWLINE_xXGreater than 50% tumor burden in the liver by imagingXx_NEWLINE_xXPatients with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period of greater than 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term nonchemotherapy treatment, e.g., hormonal therapy, are eligible.Xx_NEWLINE_xXMajor surgery (requiring the use of a general anesthetic) within 4 weeks of study enrollment with the exception of transurethral resection of bladder tumor (TURBT)Xx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXPresence of a muscle invasive bladder tumor(s) (T2), specific for transitional cell carcinoma on pre-operative histology (i.e. biopsy or transurethral resection of bladder tumor [TURBT]).Xx_NEWLINE_xXPresence of a single bladder tumor lesionXx_NEWLINE_xXPatients with 1 focus of HCC will be eligible if their tumor is 3.5 cm or less in greatest diameter; patients with 2 foci of HCC will be eligible if each lesion is 3.5 cm in diameter or less and the combined diameter of both lesions is 5 cm or lessXx_NEWLINE_xXPrimary tumor deemed unresectable by hepatobiliary surgeonXx_NEWLINE_xXPatient is after surgical resection of the tumor where tumor was removed completely with surgical specimen microscopic margins free from tumor and with available archival tumor tissue from the surgical specimenXx_NEWLINE_xXPrior embolization, chemoembolization, or radiofrequency ablation permitted if >= 4 weeks from registration and evidence of new tumor growth is presentXx_NEWLINE_xXTumor expression of NY-ESO-1 by immunohistochemistry (IHC) and/or real-time polymerase chain reaction (RTPCR)Xx_NEWLINE_xXAll patients must consent to provide archival tumor samples; non-availability of evaluable tumor samples does not exclude patient from the studyXx_NEWLINE_xXPhase II: The initial 20 patients must have evaluable baseline tumor samples; evaluable samples are defined as those obtained by core biopsy or surgical resection and amendable to histological analysis; samples obtained by fine needle aspiration biopsy are not considered evaluable; patients who do not have evaluable archival tumor samples must consent to a tumor core biopsy prior to starting study treatment and, patients who consent to the baseline tumor biopsy will be eligible to receive study treatment irrespective of whether the samples obtained are evaluableXx_NEWLINE_xXPhase II: Have at least 1 metastatic lesion other than the primary pancreatic tumor that is evaluable per RECIST 1.1 criteria; lesions previously irradiated are not considered evaluableXx_NEWLINE_xXTumors with a depth of not greater than 3.0 cm from a laparoscopically accessible surface-meaning no part of the tumor should be deeper than 3.0 cm from the surfaceXx_NEWLINE_xXSubjects having had prior ablation therapy on the same tumorXx_NEWLINE_xXConsent to allowing his/her archival tumor tissues to be requested and analyzed; however, the non-availability or inadequate amount samples for analysis will not exclude the patientXx_NEWLINE_xXMaximum tumor dimension =< 5 cmXx_NEWLINE_xXTumor verified by a thoracic surgeon to be in a location that will permit a sublobar resectionXx_NEWLINE_xXTumor thickness is 4 mm or less (in the judgment of the physician)Xx_NEWLINE_xXTumor accessible for unrestricted illumination for photodynamic therapy (PDT) (accessibility as determined by the physician)Xx_NEWLINE_xXHistologic diagnosis of a well- to moderately differentiated PNET (low-intermediate grade); NOTE: pathology report should state one of the following: low-grade, intermediate grade, moderately- or well-differentiated NET, pancreatic NET (or neuroendocrine carcinoma of the pancreas); patients who have tumors with a Ki67 of 20 % - 30 % are eligible if the pathologist determines the tumor has the appearance of a well- to moderately differentiated neuroendocrine tumorXx_NEWLINE_xXThe contrast-enhancing intraparenchymal brain tumor must be well circumscribed and must have a maximum diameter of =< 4.0 cm in any direction on the enhanced scan; if multiple lesions are present and one lesion is at the maximum diameter, the other(s) must not exceed 3.0 cm in maximum diameterXx_NEWLINE_xXHas histological diagnosis of a primary solid tumor malignancy that meets study criteriaXx_NEWLINE_xXNo known presence of known EGFR or EML4-ALK driver mutations in the tumorXx_NEWLINE_xXNo evidence of recent hemorrhage at pre-registration MRI of the brain, however the following are permitted: presence of hemosiderin, resolving hemorrhagic changes related to surgery, and presence of punctate hemorrhage in the tumorXx_NEWLINE_xXPatients with stage IB1 with tumor size (maximum visible or palpable) > 2 cmXx_NEWLINE_xXPatient must be newly diagnosed or relapsed/progressed with a brain tumor that has not previously been treated with CRT\r\n* Note: COG therapeutic study participation is not required for ACCL10P1 enrollmentXx_NEWLINE_xXPatients scheduled for amputations as local control of their tumorXx_NEWLINE_xXRadiographic evidence of cavitary or necrotic tumor and local invasion of major blood vesselsXx_NEWLINE_xXMust meet criteria for initiation of treatment, consisting of:\r\n* Aggressive histology, or \r\n* Indolent histology with one of the following markers of large tumor burden:\r\n** Any nodal or extranodal tumor mass >= 7 cm in greatest dimension\r\n** >= 3 nodal masses that are each >= 3 cm in greatest dimension\r\n** Systemic symptoms\r\n** Cytopenias (leukocytes < 1 x 10^9/L and/or platelets, 100 x 10^9/L)\r\n** Substantial splenomegaly\r\n** Serous effusion (pleural effusion or peritoneal ascites)\r\n** Orbital or epidural involvement\r\n** Ureteral compression\r\n** Leukemic phase (malignant cells >= 5 x 10^9/L)Xx_NEWLINE_xXAdults with a primary diagnosis of any advanced solid tumor cancer within the last 3 yearsXx_NEWLINE_xXTargeted bone/tumor interface (most painful lesion) size up to 55 cm2 in surface areaXx_NEWLINE_xXTargeted (treated) tumor is in the skullXx_NEWLINE_xXTarget (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.Xx_NEWLINE_xXTargeted (most painful) tumor Not accessible to ExAblateXx_NEWLINE_xXRadiologic suspicion of lung involvement (primary or metastatic), lymphangitic carcinomatosis, or airway involvement secondary to tumor infiltration.Xx_NEWLINE_xXPathologically proven solid tumor malignancy (except for small cell lung cancer [SCLC], germ cell tumor)Xx_NEWLINE_xXSolid tumor survivors with no evidence of diseaseXx_NEWLINE_xXSolid tumor cancer diagnosisXx_NEWLINE_xXEnrollment within 6 weeks of tumor board reviewXx_NEWLINE_xXable to provide adequate tumor tissue from at least 1 accessible tumor siteXx_NEWLINE_xX(Part 2 only) Current evidence/diagnosis of alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor, dermatofibrosarcoma (unless transformed to fibrosarcoma), Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, or clear cell sarcomas.Xx_NEWLINE_xXMixed histology of the tumor or evidence of tumor histology other than serous carcinoma or endometrioid type of endometrial carcinoma;Xx_NEWLINE_xXSubject's tumor (either the most recent archival specimen or a fresh biopsy) shows positive NY-ESO-1 expression defined as ?30% of cells that are 2+ or 3+ by immunohistochemistry. All samples must have been pathologically reviewed by an Adaptimmune designated central laboratory.Xx_NEWLINE_xXUse of an anti-cancer vaccine within 2 months in the absence of tumor response, or the subject should be excluded if their disease is responding to an experimental vaccine given within 6 months.Xx_NEWLINE_xXBiopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula; recurrent laryngeal or phrenic nerve paralysisXx_NEWLINE_xXUncontrolled tumor in the brainXx_NEWLINE_xXFailure on bevacizumab (either as a monotherapy or a combination) as most recent regimen confirmed by tumor recurrence on MRI.Xx_NEWLINE_xXInfra-tentorial tumor.Xx_NEWLINE_xXMust have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screeningXx_NEWLINE_xXAll subjects must have a fresh tumor biopsyXx_NEWLINE_xXHistological or cytological documentation of an invasive malignancy that was diagnosed as locally advanced/metastatic or relapsed/refractory and is of one of the following tumor types:: bladder; cervical; colorectal (includes appendix); esophagus, squamous cell; head and neck; melanoma; malignant pleural mesothelioma (MPM); non-small-cell lung cancer (NSCLC), prostate; Microsatellite Instability-High/deficient mismatch repair (MSI-H/dMMR) tumor (Part 1B and Part 2B) and Human Papilloma Virus (HPV)-positive or Epstein-Barr (EBV)-positive tumor (Part 1B and Part 2B.Xx_NEWLINE_xXDocumented HPV/ EBV-positive tumor as determined by a local laboratory for Part 1B and Part 2B pembrolizumab combination viral-positive expansion cohorts onlyXx_NEWLINE_xXAny tumor gradeXx_NEWLINE_xXPathologically-confirmed solid tumor or hematologic malignancy with symptomatic bone metastasesXx_NEWLINE_xXAny patient with a past medical history for a chronic disease (such as sickle cell disease), cancer (solid tumor, lymphoma, brain tumor) and have a current diagnosis which includes pain for which they are being treated, or currently undergoing bone marrow transplant – currently admitted to the hospitalXx_NEWLINE_xXBiopsy-proven neuroendocrine tumor with tumor burden dominant in the liverXx_NEWLINE_xXLiver tumor burden less than or equal to 70%Xx_NEWLINE_xXSymptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in the liver OR baseline tumor burden > 25% of the liver volumeXx_NEWLINE_xXNewly diagnosed solid tumor or lymphoma with histological verificationXx_NEWLINE_xXShow no current evidence of disease (NED) for solid-tumor cancers.Xx_NEWLINE_xX>= 10 core prostate biopsy completed prior to randomization with at least 2 mm of tumor and Gleason sum =< 6 with no pattern 4 or Gleason 3+4 in < 34% of all cores; AND residual tumor tissue from such biopsy is obtainable and donated for the researchXx_NEWLINE_xXAll patients must have histologic proof of solid tumor malignancy and radiographic evidence of spine metastasisXx_NEWLINE_xXPatients who have had prior surgery at the spine level to be treated to include prior cement augmentation, laminectomy, vertebrectomy, tumor debulking, instrumentationXx_NEWLINE_xXTreatment for solid tumor cancersXx_NEWLINE_xXPosterior fossa tumor/approach for tumor resection requiring the prone positionXx_NEWLINE_xXSUBJECT: Children diagnosed with brain tumor in childhood.Xx_NEWLINE_xXExtremity or central axis (including craniofacial) primary tumor; localized or metastaticXx_NEWLINE_xXIncurable solid tumor malignancyXx_NEWLINE_xXPatients must have limited disease SCLC after clinical staging evaluation: clinical tumor, lymph nodes, metastasis (TNM) stages I-IIIB (i.e., confined to one hemithorax, but excluding T4 tumor based on malignant pleural effusion and N3 disease based on contralateral hilar or contralateral supraclavicular involvement) according to American Joint Committee on Cancer (AJCC) 1997 staging manual to be consistent with Radiation Therapy Oncology Group (RTOG) 0212Xx_NEWLINE_xXSubjects with histological diagnosis of incurable cancer (solid tumor)Xx_NEWLINE_xXDiagnosis of a primary brain tumor treated with at least one of the following:\r\n* Neurosurgical resection of the brain tumor\r\n* Cranial irradiation\r\n* Any chemotherapy to treat the brain tumorXx_NEWLINE_xXPatients must have had radiation therapy for a histologically confirmed CNS tumor including, but not restricted to glioma, astrocytoma, medulloblastoma or other embryonal tumors; patients with diffuse intrinsic pontine gliomas may be enrolled without pathologic confirmationXx_NEWLINE_xXHuman papilloma virus (HPV) status in tumor has been documented using tumor immunohistochemistry for HPV-p16 or other accepted testXx_NEWLINE_xXTumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, or salivary glandsXx_NEWLINE_xXNewly (within 1 month) diagnosed with a primary malignant brain tumor (PMBT) (tumor verified via pathology report to be a glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, medulloblastoma, or anaplastic ependymoma)Xx_NEWLINE_xXPatients with stable metastatic disease which is defined as (metastatic tumor demonstrates no increase in volume, tumor size or diameter and no evidence of new lesions, have been identified during last assessment by medical oncologist/radiologist or surgeons)Xx_NEWLINE_xXIndividuals with progressive metastatic disease in which the tumor has increased in size, volume and diameter or evidence of new lesions, as noted by medical oncologists, radiologists and surgeonsXx_NEWLINE_xXSubjects must have or have had at initial diagnosis, histologic proof of their malignancy; additionally they must have radiographic, nuclear image, or biopsy proof that they have had a recurrence of their disease within four weeks prior to study entry; subjects must have failed or relapsed from standard first-line chemotherapy for their tumor; young children with primary embryonal brain tumor treated according to Head Start protocol are eligible as well; subjects with bone marrow involvement are NOT eligible for studyXx_NEWLINE_xXA personal history of cancer, tumor, or a related illnessXx_NEWLINE_xXPatient in the Sarcoma, Solid Tumor Gastrointestinal (ST GI), or Thoracic Medicine service at Memorial Sloan Kettering Cancer Center (MSK)Xx_NEWLINE_xXDiagnosis of a metastatic or incurable solid tumorXx_NEWLINE_xXPatients enrolled on phase 1 of the study are eligible (and/or if recruited from tumor registry or clinic follow-up schedules)Xx_NEWLINE_xXBorderline resectable pancreatic ductal adenocarcinoma (BR-PDAC): defined as localized PDAC with 1 or more of the following features: a) an interface between the primary tumor and superior mesenteric vein (SMV)-portal vein (PV) measuring 180 degrees or greater of the circumference of the vein wall, and/or b) short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction and/or c) short-segment interface of any degree between tumor and hepatic artery with normal artery proximal and distal to the interface that is amenable to resection and arterial reconstruction and/or d) an interface between the tumor and SMA or celiac trunk measuring less than 180 degrees of the circumference of the artery wallXx_NEWLINE_xXIn Arm 1, subjects must have residual visible tumor following TURBT. In Arm 2, subjects must be fully resected (i.e., no visible tumor or as little tumor as possible) after restaging TURBT 2-6 weeks prior to Study Day 0.Xx_NEWLINE_xXHistory of MPNST (malignant peripheral nerve sheath tumor) or any malignancy other than asymptomatic and stable optic nerve gliomaXx_NEWLINE_xXUncontrolled tumor-related painXx_NEWLINE_xXMetastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses of large volume. HCC participants (Arm A and F) with vascular invasion of the portal or hepatic veins may be enrolledXx_NEWLINE_xXTumor with known or expected RAS/RAF/MEK/ERK pathway involvement. Diagnosis must be one of the following tumor types: Central nervous system gliomas, including high- and low-grade gliomas, and diffuse intrinsic pontine glioma (DIPG) Embryonal rhabdomyosarcoma and other non-rhabdomyosarcoma soft tissue sarcomas Neuroblastoma Melanoma Malignant peripheral nerve sheath tumor Rhabdoid tumors, including atypical teratoid/rhabdoid tumor (ATRT) NF1-associated tumor (including plexiform neurofibroma), schwannoma, or RASopathy-associated tumor that in the judgment of the investigator is life threatening, results in severe symptoms (including severe pain), or is in close proximity to vital structuresXx_NEWLINE_xXMust have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and during therapy on the study.Xx_NEWLINE_xXFolate receptor alpha positive tumor expression as defined in the protocolXx_NEWLINE_xXWilling to undergo tumor biopsyXx_NEWLINE_xXDisease-related criteria for Part 1 and Part 2: 1) Histologically or cytologically documented non-small cell lung cancer (NSCLC) - adenocarcinoma; 2) Stage III b or IV disease; 3) Tested for presence of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement; 4) Received at least 2 prior lines of Food and Drug Administration (FDA)-approved systemic therapy, of which one therapy has to be a platinum-containing regimen OR failed or completed a first-line platinum-containing regimen and refused a second-line regimen despite being informed about the different therapeutic options and their specific clinical benefit by the investigator; the content of this informed consent discussion including the therapeutic options reviewed by the investigator needs to be documented and the subject needs to sign a specific consent form; Disease-related criteria for Cohort 2B only: 1) Mesothelin protein overexpression, defined by immunohistochemistry (IHC) as detection of the protein by greater than or equal (>=) 50 percent (%) of tumor cells on archived tumor material; 2) Primary tumor or metastatic lesion(s) amenable to tumor core biopsiesXx_NEWLINE_xXSubjects must consent to allow for the acquisition of tumor sample prior to starting treatment on study (in most cases patients will require a tumor biopsy); this biopsy site may be the only site of measurable disease if the site is > 2 cm; the biopsy site must, in the opinion of the investigator, be likely to yield acceptable tumor sample for core biopsies; it is also acceptable if tumor sample is obtained by excision biopsy or during surgery (i.e. if procedure was previously planned), provided the tumor sample can be processed; in the case that a patient had a tumor sample acquired prior to consenting to the study and this tumor sample is acceptable for processing (i.e. frozen sample stored) and the tumor sample was acquired within 60 days of starting treatment, this is acceptable and a new biopsy will not be requiredXx_NEWLINE_xXThe greatest dimension of the tumor is less than 4 cm before surgeryXx_NEWLINE_xXThe volume of the tumor bed (TB) clinical target volume (CTV) is less than 25% of the whole breast planning target volume (PTV) which is a criteria used for partial breast alone trialsXx_NEWLINE_xXPatients with proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by at least 4 cm)Xx_NEWLINE_xXTumor bed is less than 5 mm from the skin surfaceXx_NEWLINE_xXPatients with skin involvement, regardless of tumor sizeXx_NEWLINE_xXA diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics.Xx_NEWLINE_xXFor Cohort 2, Cohort 3, and the Randomized Phase, tumor must be shown to have an FGFR3 mutation or gene fusion.Xx_NEWLINE_xXPeripheral neuropathy caused by tumor infiltration or compression of spinal nerves or surgical traumaXx_NEWLINE_xXHistological confirmation of tumor of the oral cavity, oropharynx, supraglottic larynx, or nasopharynxXx_NEWLINE_xXKnown malignant primary brain tumorXx_NEWLINE_xXClinical or radiologic history of lung/pleural involvement (primary or metastatic), lymphangitic carcinomatosis or airway involvement secondary to tumor infiltrationXx_NEWLINE_xXPatients with =< 10 cc largest tumor volume, and =< 15 cc total tumor volumeXx_NEWLINE_xXPrimary or secondary tumor in the oral cavityXx_NEWLINE_xXDiagnosed with one or more metastatic brain tumor(s)Xx_NEWLINE_xXThe patient has a clinical negative node status at the time of study entry (i.e. T0-4, M0, tumor staging criteria)Xx_NEWLINE_xXTumor resection candidatesXx_NEWLINE_xXTumor extends beyond kidney into major veins, perinephric tissues, or adrenal glandXx_NEWLINE_xXHas tumor(s) of the lips, sinuses, salivary glands, nasopharynx, glottic larynx, subglottic larynx or unknown primary tumorXx_NEWLINE_xXSubjects undergoing definitive mucosal head and neck tumor resection including oral cavity, oropharynx, larynx, and hypopharynxXx_NEWLINE_xX?1 cm of tumor-free lung parenchyma between target tumor and pleura or fissure.Xx_NEWLINE_xXTumor abutting main stem bronchus, main pulmonary artery branches, esophagus and/or trachea.Xx_NEWLINE_xXTumor with pleural contact.Xx_NEWLINE_xXPatients undergo recanalization procedure of tumor during bronchoscopyXx_NEWLINE_xXTumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, salivary glands or unknown primary tumorXx_NEWLINE_xXTumor involves a weight-bearing long bone of the lower extremity with the tumor causing > 50% loss of cortical boneXx_NEWLINE_xXHas undergone prior ablation treatment of the index tumorXx_NEWLINE_xXIndex tumor causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacementXx_NEWLINE_xXAnticipated treatment of the index tumor that would require iceball formation within 1.0 cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel such as the aorta or inferior vena cava, bowel, or bladderXx_NEWLINE_xXSurgery at the tumor site or surgery involving the cryoablation-treated tumor (index tumor)Xx_NEWLINE_xXIndex tumor involves the skull (treatment of other painful tumors in subjects with skull tumors is not excluded)Xx_NEWLINE_xXNewly diagnosed with a primary invasive colorectal adenocarcinoma (all stages) and have a resection at any hospital in Ohio between 1/1/2013 and 12/31/2015\r\n* For individuals who have neoadjuvant treatment and show a complete response at resection, the tumor screening will be attempted on their original biopsy (even if it occurred in 2012) as long as their resection occurred between 1/1/2013 and 12/31/2015\r\n* Many individuals with stage IV CRC will not have a resection; therefore, the tumor screening will be attempted on their original biopsy as long as their primary diagnosis occurred between 1/1/2013 and 12/31/2015; if only metastatic CRC is available on a biopsy, tumor screening will be attempted on the metastatic tissueXx_NEWLINE_xXPre-enrollment tumor survey: Prior to enrollment on this study, a determination of mandatory disease staging must be performed:Xx_NEWLINE_xXTumor imaging studies includingXx_NEWLINE_xXCo-medications that may interact with rolapitant (e.g. metoprolol/beta blocker, codeine, pimozide thioridazine) as reviewed by Duke Preston Robert Tisch Brain Tumor investigator pharmacistXx_NEWLINE_xXTumor in a location where enlargement could cause airway obstructionXx_NEWLINE_xXMalignancy or mass that is non-gynecologic in origin (mass/tumor of origin other than reproductive organ such as rectal, abdominal, breast)Xx_NEWLINE_xXPatients with gross tumor involvement of the oral cavity or oral mucosaXx_NEWLINE_xXTreatment with intravesical BCG or chemotherapy for a patient’s current < T2 tumor during the 12 months prior to the current diagnosisXx_NEWLINE_xXThe clinical or radiologic primary tumor size is at least 1.5 cm diameterXx_NEWLINE_xXPrimary tumor sample was collected before NACT began and was evaluated for genomic testing (integral biomarker)Xx_NEWLINE_xXPatients must be eligible for surgical resection according to the following criteria:\r\n* Part 1 Patients: Expectation that the surgeon is able to resect at least 350 mg of tumor from enhancing tumor and at least 350 mg from non-enhancing tumor with low risk of inducing neurological injury\r\n* Part 2 Patients: Expectation that the surgeon is able to resect at least 1000 mg from enhancing tumor and at least 350 mg from non-enhancing tumor with low risk of inducing neurological injuryXx_NEWLINE_xXProvision of written informed consent for tumor resection, stereotactic surgery, tumor biopsy, samples collection and treatment with investigational products prior to undergoing any study proceduresXx_NEWLINE_xXDetermined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or gastrointestinal oncology Tumor BoardXx_NEWLINE_xXPatients with tumors of two different subtypes will be eligible provided that the triple negative tumor otherwise meets eligibility requirements, and the non-triple negative tumor is < 1.0 cm in sizeXx_NEWLINE_xXIn the event that a tumor is in contact with the capsule, the length of the contact should be ? 5 mm, on axial images.Xx_NEWLINE_xXTumor distance, including tumor free margins, should not be more than 40mm from the rectal wall.Xx_NEWLINE_xXSubject's tumor(s) must be < 3.0 cm in greatest diameter by pre-operative assessmentXx_NEWLINE_xXSubject's tumor(s) must meet AJCC Tumor Classification: Tis, T1 or T2 (< 3 cm), N0, M0Xx_NEWLINE_xXEligible patients in the dose escalation phases of the trial must agree to biopsies of normal skin, unless they undergo optional tumor biopsies; the mandatory biopsy requirement can be waived at the discretion of principal investigator in the event of any medical contraindication (e.g. lidocaine allergy); patients enrolled to the expanded cohorts must agree to tumor sampling; patients on anticoagulation must be able to hold warfarin or low molecular weight heparin for a sufficient amount of time to make skin and tumor biopsies safe to perform; PT/INR and PTT should be =< 1.5 times the institutional upper limit of normal prior to performance of skin or tumor biopsies, with values re-checked after the eligibility screen as medically indicatedXx_NEWLINE_xXPatients must have proven positive tumor sample for NY-ESO-1 as follows:Xx_NEWLINE_xXPatients with tumor-induced seizures must be well controlled on a stable anti-epileptic treatmentXx_NEWLINE_xXHistologically proven diagnosis of solid tumor malignancy and Magnetic Resonance (MR) imaging documenting brain lesions.Xx_NEWLINE_xXNot eligible for Stereotactic Radiosurgery (SRS) treatment of brain tumor.Xx_NEWLINE_xXOther completely resected stage 1 solid tumor with low risk for recurrenceXx_NEWLINE_xXProgression of disease assessed by local site using Revised Assessment in Neuro-Oncology (RANO) criteria, with plan to administer bevacizumab, either as single therapy or in conjunction with other chemotherapeutic regimens, in order to treat tumor progression/recurrence per the treating physician; patients receiving bevacizumab primarily for reduction of edema (i.e. alleviation of symptoms) rather than for tumor treatment are excludedXx_NEWLINE_xXHistologic diagnosis of solid malignancy (excluding brain tumors and lymphoma) that meets at least one of the following criteria:\r\n* Refractory, defined as tumor progression after initiation of standard first line therapy without having achieved a prior partial or complete remission OR biopsy proven residual disease at the completion of planned standard initial front-line therapy\r\n* Recurrent, defined as tumor progression after achieving a prior partial or complete remission\r\n* Newly diagnosed high risk disease, defined as having an expected event free survival of < 50% at 2 years\r\n* Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group)\r\n** Examples include (eligibility not limited to these examples): \r\n*** Histology typically associated with a fusion in which fusion is not detected \r\n*** Ewing-like sarcoma \r\n*** Undifferentiated sarcoma\r\n*** Inflammatory myofibroblastic tumor without ALK fusion\r\n*** Infantile fibrosarcoma without NTRK fusionXx_NEWLINE_xXSufficient tumor specimen thought to be available to meet the minimum requirements for profiling from diagnosis or progression/recurrence; ORXx_NEWLINE_xXWillingness to undergo tumor biopsy prior to initiation of treatmentXx_NEWLINE_xXSubjects may be enrolled at one of three time points in the clinical course of disease:\r\n* Study 1 (New Diagnosis): \r\n** Pediatric patients with newly diagnosed primary central nervous system tumors undergoing surgical resection/biopsy within 21 days or who, within the prior 21 days, have undergone resection/biopsy with substantial residual (greater than half as assessed by the surgeon) tumor\r\n* Study 2 (Possible Tumor Recurrence): \r\n** Pediatric patients with a history of treated primary central nervous system tumor, in whom standard imaging has raised concern for tumor recurrence; tumor tissue for histological analysis must be available from a biopsy/resection planned within the next 21 days or from a prior resection/biopsy if no current biopsy material is available\r\n* Study 3 (Response to Therapy): \r\n** Pediatric patients with a primary central nervous system tumor who will be starting a new regimen (standard or experimental) of chemotherapy within 21 days, have not received radiation therapy during the past six months, and who will not be receiving radiation therapy during the first two cycles of chemotherapyXx_NEWLINE_xXDiagnosis of pathologically confirmed lung cancer by tumor biopsy and/or fine-needle aspirationXx_NEWLINE_xXPre-operative spirometry that suggests the patient cannot undergo resection of the primary tumor by segmentectomy, lobectomy, bilobectomy, or pneumonectomyXx_NEWLINE_xXConventional chest abdomen and pelvis CT images demonstrating recurrent tumor must be submitted within 21 days from acquisition to the American College of Radiology (ACR) Core LabXx_NEWLINE_xXChildren with a diagnosis of a brain tumor and who do not require sedation for MR imagingXx_NEWLINE_xXSufficient archived tumor material available (equivalent to 2 core biopsies or greater); if insufficient archived tumor material available new tumor biopsy is mandatoryXx_NEWLINE_xXHas had all urothelial cell carcinoma tumor resected within the past 12 monthsXx_NEWLINE_xXFor patients who undergo optional metastatic tumor biopsy following completion of gallium citrate PET:\r\n* Presence of one or more metastases by standard radiographic scans including cross-sectional imaging of the chest/abdomen/pelvis and whole body bone scan that is safely accessible to tumor biopsy in the judgment of treating clinician and/or interventional radiology\r\n* No history of radiation therapy to the target metastatic lesion selected for tumor biopsy\r\n* No contra-indication to biopsy including uncontrolled bleeding diathesis\r\n* Platelets > 75,000/ul\r\n* Prothrombin time (PT) or international normalized ratio (INR) and a partial thromboplastin time (PTT) =< 1.5 times the institutional upper limit of normal (ULN) within 14 days prior to biopsyXx_NEWLINE_xXReferral from an internist, oncologist, or surgeon for liver tumor ablation consultationXx_NEWLINE_xXLiver tumor ablation judged to be appropriate based on clinical assessment in the Brigham and Women’s Hospital (BWH) Tumor Ablation Clinic by the tumor ablation interventional radiologist, per standard clinical practiceXx_NEWLINE_xXThe tumor must be >= 1 cm and =< 6 cmXx_NEWLINE_xXPrimary tumor size > 6 cmXx_NEWLINE_xXDiagnosis of a proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumorXx_NEWLINE_xX(Part 2, intracranial tumor patients ONLY): Radiographical or pathological evidence of an intracranial tumorXx_NEWLINE_xX(Part 2, intracranial tumor patients ONLY): Other chemotherapy (besides what is being used to treat the intracranial tumor)Xx_NEWLINE_xXSubjects not deemed to be appropriate candidates for optimal resection of tumor based on location, involvement of eloquent brain, satellite lesions, or other factors not specifically listed hereXx_NEWLINE_xXActive metastatic cancer in addition to malignant primary brain tumorXx_NEWLINE_xXPatient is a candidate for cerebral tumor resection with lesion suspected to be or previously biopsy proven to be a primary brain tumor.Xx_NEWLINE_xXDiagnosis of histologically proven node-positive lung cancer (n=20) OR base of skull or brain tumor (n=20)Xx_NEWLINE_xXTumor(s) must be located near air cavitiesXx_NEWLINE_xXResults of CXCR4 immunohistochemistry or slides from biopsy of primary tumor or metastatic lesions available for study analysisXx_NEWLINE_xXParticipation in the Iowa Neuroendocrine Tumor RegistryXx_NEWLINE_xXPatients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial chemoembolization [TACE])Xx_NEWLINE_xXPatients must have evidence of disease either through elevation of tumor markers or radiologic evidence of diseaseXx_NEWLINE_xXTwo adult patient groups will be eligible for inclusion in this study: \r\n* Group A: Patients where there is compelling evidence, based on the MRI and/or CT imaging, that a high-grade primary brain tumor is present; pathologic confirmation will occur with biopsy or surgery; patients whose tumor is felt to be inoperable and a biopsy is performed but no surgery; patients with a newly diagnosed primary malignant brain tumor (World Health Organization [WHO] grade III or IV) who will be receiving chemoradiation and who either did not undergo surgical resection or underwent incomplete resection with residual tumor >= 1.0 cm in greatest diameter by contrast MRI postoperatively\r\n* Group B: Patients with pathologically proven malignant brain tumor (WHO grade III or IV glial-based tumors) who have undergone chemoradiation and have MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiationXx_NEWLINE_xXSubjects with a presumed diagnosis of brain tumor (based on imaging) or a confirmed brain tumor (based on pathology) before or after any oncologic treatment (surgery/chemotherapy/radiation)Xx_NEWLINE_xXPatients with histopathologic diagnosis of a solid tumor. All solid tumors will be considered, but patients with breast, pancreas, and colorectal masses will be prioritized.Xx_NEWLINE_xXA patient who has not received systemic or loco-regional treatment of the tumor within the last month.Xx_NEWLINE_xXPatient is referred for 90Y SIRT radioembolization of liver tumor(s)Xx_NEWLINE_xXPatients with measurable colorectal liver metastases on prior imaging, with at least one tumor greater than 2.0 cm in axial maximal diameterXx_NEWLINE_xXBiopsy or resection of the primary tumor within 14 days the first injection of [18F]F-AraGXx_NEWLINE_xXConfirmed or suspected head and neck tumor (benign or malignant)Xx_NEWLINE_xXNewly diagnosed primary brain tumor of any location and any histology (Cohort 1)Xx_NEWLINE_xXPrevious diagnosis of a brain tumor; patients who are either undergoing active treatment for a brain tumor or who have completed treatment will be eligible for study enrollment (Cohort 2)Xx_NEWLINE_xXPresence of at least one target lesion amenable to percutaneous tumor biopsy in the judgment of interventional radiologyXx_NEWLINE_xXPatients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsyXx_NEWLINE_xXFor patients undergoing optional tumor biopsy:\r\n* No history of bleeding diathesis\r\n* Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsyXx_NEWLINE_xXPatients with an extracoelomic solid tumor requiring SLN biopsyXx_NEWLINE_xXNo known endobronchial tumorXx_NEWLINE_xXTumor located anywhere in parenchymal tissue >1 cm from pleura and accessible bronchoscopically through a POE.Xx_NEWLINE_xXInoperable tumor/noduleXx_NEWLINE_xXMetastatic or primary malignant tumor involving spinal column, with or without extension into the epidural spaceXx_NEWLINE_xXIntradural extension of the tumorXx_NEWLINE_xXPatients undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed primary or metastatic brain tumor located in or adjacent to motor brain areasXx_NEWLINE_xXPatients presenting with a CNS tumor presumed to be resectable and are at risk for local recurrence on pre-operative assessmentXx_NEWLINE_xXHistopathologic or imaging and clinical features of tumor(s) diagnostic for hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and Data System (LI-RADS) 4 or greaterXx_NEWLINE_xXTumor amenable to transcatheter arterial embolizationXx_NEWLINE_xXHistologically diagnosed or suspected (pediatric only) neuroendocrine tumor or other tumor with probable somatostatin receptors subtype 2Xx_NEWLINE_xXAt least part of the tumor must be visible as observed in a diagnostic or planning CTXx_NEWLINE_xXSubject has a tumor that will undergo upfront resectionXx_NEWLINE_xXSubject has undergone primary tumor resection prior to arrival at St. JudeXx_NEWLINE_xXWilling to provide existing relapse-confirmatory DLBCL tumor sampleXx_NEWLINE_xXAdult patients seen in the Head and Neck Tumor Clinic who will require laryngoscopy in the operating room for diagnosis and staging of known or suspected tumors of the upper aerodigestive tract (UADT)Xx_NEWLINE_xXNo anti-estrogen therapy for desmoid tumor within the past 6 monthsXx_NEWLINE_xXMeasurable disease on MRI defined as tumor measuring at least 1 cm in two perpendicular dimensionsXx_NEWLINE_xXPatients with solid tumors with diagnoses OTHER than neuroblastoma or those listed above will be eligible if they meet both of the following criteria:\r\n* Immunohistochemical demonstration of GD2 expression on cell surface (tumor assessment by immunohistochemistry is required for this group of patients)\r\n* Have refractory or relapsed disease or metastatic diseaseXx_NEWLINE_xXTumor judged to be suitable for open cranial resection based on preoperative imaging studiesXx_NEWLINE_xXGROUPS 1, 2, AND 3: Must be consented for the Oregon Pancreatic Tumor Registry (OPTR)Xx_NEWLINE_xXTumor must measure >= 2 cm on CTXx_NEWLINE_xXNew or increased enhancing brain lesion(s) OR nonenhancing brain lesion(s) if receiving anti-angiogenic therapy, which is considered indeterminate for tumor progression versus (vs) radiation injury by the neuroradiologist or clinicianXx_NEWLINE_xXLess than 5 mm distance of the tumor margin from a major vessel (> 7 mm in diameter)\r\n* This will not be considered exclusion when irreversible electroporation (IRE) is usedXx_NEWLINE_xXNewly-diagnosed or recurrent (local, regional, metastatic) metastatic melanoma or malignant brain tumor patients with:\r\n* Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas, or malignant brain tumor\r\n* Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n* Newly diagnosed patients with previous excisional biopsyXx_NEWLINE_xXThe patient must have a newly diagnosed primary malignant brain tumors (World Health Organization [WHO] grade III or IV glial-based tumors) and not have had a complete surgical resection and by contrast MRI (obtained for clinical purposes within 28 days prior to FMISO study) have residual tumor >= 1.0 cm in greatest diameter and will be receiving radiotherapy or newly diagnosed brain metastasis (>= 1.0 cm in greatest diameter or dimension) and will be receiving radiotherapy; an anatomic imaging study (clinical MRI of the brain) must be current and have been obtained within 28 days prior to the research PET imaging sessions; in patients with a primary brain tumor the patient may be studied after biopsy or after surgery if an incomplete surgical resection has occurred and >= 1.0 cm of enhancing tumor is present; only patients intended to receive radiation therapy will be eligibleXx_NEWLINE_xXArchived tumor blocks must be provided for all subjects for correlative analysis before or during treatment with pazopanibXx_NEWLINE_xXSuspected or histopathologically proven diagnosis of high or low grade glioma, or a tumor suspected to harbor an isocitrate dehydrogenase (IDH) mutationXx_NEWLINE_xXPatients must have a malignant brain tumor histologically confirmed as: glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma, either at initial diagnosis or at the time of tumor relapse (patients treated at relapse do not require re-confirmation of histopathology that was determined at initial diagnosis); or patients must have typical clinical and radiological (MRI) characteristics of a malignant glioma of the brain stemXx_NEWLINE_xXBreast cancer from ER+ primary that is seen on other imaging tests; tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent diseaseXx_NEWLINE_xXTumor is accessible for local injection of the sentinel node tracer (for example oral cavity disease)Xx_NEWLINE_xXPathologically confirmed, locally advanced, malignancy of the rectum; based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatmentXx_NEWLINE_xXMinimum tumor dimension >= 1 cm (preferably >= 2 cm)Xx_NEWLINE_xXPathologically confirmed, locally advanced, malignancy of the esophagus; the cancer may involve the stomach up to 5 cm; based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatmentXx_NEWLINE_xXSubjects with cervical or Siewert 3 esophageal carcinoma, that are recommended by the multi-disciplinary tumor board to have treatment other than tri-modality chemo-radiation therapy (RT) followed by esophagectomyXx_NEWLINE_xXSubjects with at least 1 lesion of tumor of the breastXx_NEWLINE_xXHistory of mental retardation unrelated to brain tumorXx_NEWLINE_xXBiopsy proven neuroendocrine tumor, neuroblastoma, medulloblastoma, or other somatostatin receptor positive tumorXx_NEWLINE_xXPatients in whom the tumor might not be accessible for peritumoral injection of indocyanine green, e.g. small, central tumorsXx_NEWLINE_xXEither the primary tumor or at least one of the metastatic lesions must be >= 2 cmXx_NEWLINE_xXPrimary tumor 2.0 cm or greater, and/or clinical evidence of axillary disease (palpable N1 or N2 or biopsy proven)Xx_NEWLINE_xXLiver tumor diagnosed histologically as HCC or suspected of being HCC in association with serum alpha-fetoprotein level > 200 or tumor mass with characteristics of malignancy on diagnostic imagingXx_NEWLINE_xXParticipant must have either radiological (presumptive) or established (proven) histological diagnosis of a brain tumor or lesionXx_NEWLINE_xXKnown or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; pheochromocytoma; supporting evidence may include MRI, CT, biochemical markers, and or pathology reportXx_NEWLINE_xXPatients unlikely to be optimally debulked at surgery (tumor implants in difficult to reach places [i.e. falciform ligament or porta hepatitis], suprarenal retroperitoneal lymphadenopathy)Xx_NEWLINE_xXThe tumor will be evaluated by both mammography and ultrasoundXx_NEWLINE_xXHas any evidence of small cell histology, or combined small cell and non-small cell histology, in original tumor biopsy or in Screening biopsy performed after progressionXx_NEWLINE_xXHuman papilloma virus (HPV) negative tumor for patients with oropharyngeal cancers.Xx_NEWLINE_xXc-MET overexpression, ? 50% tumor cells with immunohistochemistry Grade 3+Xx_NEWLINE_xXCohort C: cholangiocarcinoma, esophageal, nasopharyngeal or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.Xx_NEWLINE_xXArchival tumor specimen according to protocol-defined criteria.Xx_NEWLINE_xXMAGE-A3/A6 positive tumorXx_NEWLINE_xXSubject's tumor has AFP expression of ?2+ in ?40% tumor cells by immunohistochemistry and their non-cancerous liver tissue has ?5% cells stained for AFP by immunohistochemistry.Xx_NEWLINE_xXHistologically proven: neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma/ primitive neuroectodermal tumor, Wilms tumor, desmoplastic small round cell tumor or malignant solid tumors of any other histology that test positive for B7-H3 .Xx_NEWLINE_xXMust have malignant solid tumors that demonstrate B7-H3 expression at 2+ or greater levels on the membranous surface of at least 10% of tumor cells or ? 25% of tumor vasculature by IHC.Xx_NEWLINE_xXThe primary tumor must originate in the esophagus; tumors that involve the gastroesophageal (GE) junction must meet Sievert type 1 criteria: “adenocarcinoma of the distal oesophagus which usually arises from an area with specialized intestinal metaplasia of the oesophagus (i.e. Barrett’s oesophagus) and which may infiltrate the esophagogastric junction from above;” for the purposes of this protocol, this will be interpreted as: greater than 50% of the tumor must be above the GE junction or, alternatively, the tumor must involve the GE junction and arise in the setting of biopsy-documented Barrett’s esophagus (specialized intestinal metaplasia)Xx_NEWLINE_xXThe first 15 patients with adenocarcinoma will be offered an optional tumor biopsy (typically EGD biopsy) at 8 weeks; starting with adenocarcinoma patient #16, patients must have an accessible tumor and must agree to tumor biopsy at 8 weeks; this will continue to be mandatory until a total of 20 patients have undergone biopsy at 8 weeksXx_NEWLINE_xXDocumentation of IDH1 or IDH2 mutation in any tumor specimenXx_NEWLINE_xXPrimary brainstem or spinal cord tumorXx_NEWLINE_xXRecurrent infratentorial tumorXx_NEWLINE_xXPrior re-irradiation or stereotactic radiosurgery for recurrent disease at the same tumor location intended for HFRT in this studyXx_NEWLINE_xXMaximal tumor diameter > 4 cmXx_NEWLINE_xXSomatostatin receptor 2 positive tumor as assessed at pre-screening or within 180 d of first drug administration using indium SPECT or gallium PET Patients in Phase 1 must have a histologically or cytologically-confirmed solid tumor in 1 of the following categories:Xx_NEWLINE_xXHistologically confirmed high grade endometrial cancer including grade 3 endometroid, serous, clear cell, malignant mixed Mullerian tumor (MMMT) or any mixed tumor containing one of these cell typesXx_NEWLINE_xXKnown or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; medulloblastoma; pheochromocytoma; supporting evidence may include magnetic resonance imaging (MRI), CT, biochemical markers, and/or pathology reportXx_NEWLINE_xXTumors beyond Milan criteria; this trial does not enroll patients with tumors beyond Milan criteria even from region(s) where transplant listing might still be permissible due to a special regional arrangement; any of the following will exclude the patient from the trial:\r\n* Evidence of extrahepatic tumor\r\n* Unifocal HCC > 5 cm in diameter\r\n* Multifocal HCCs, 4 or more in number\r\n* Multiple (2 or more) HCCs with at least one tumor >= 3 cmXx_NEWLINE_xXPost treatment subjects will have radiographic abnormalities that may or may not be recurrent tumorXx_NEWLINE_xXSubjects not deemed to be appropriate candidates for optimal resection of tumor based on location, involvement of eloquent brain, satellite lesions, or other factors not specifically listed hereXx_NEWLINE_xXHave a diagnosis or suspected diagnoses of brain tumor (primary, recurrent, or metastatic) by standard clinical diagnosis such as pathology or imagingXx_NEWLINE_xX-  15 years of age or older\n\n          -  Patients with metastatic sarcoma who have had no more than one prior systemic\n             treatment for metastatic disease\n\n          -  Patients with recurrent sarcoma at relapse\n\n          -  Patients with confirmed histological diagnosis of sarcoma or suspected diagnosis of\n             sarcoma. Some specific subtypes of sarcoma are NOT eligible (Gastrointestinal Stromal\n             Tumor (GIST), carcinosarcoma, sarcomatoid mesothelioma, and metastatic phyllodes\n             tumor)\n\n          -  If initial suspected diagnosis of sarcoma, must have sarcoma diagnosis confirmed prior\n             to proceeding with PDX drug sensitivity testing\n\n          -  Must have measureable disease for computed tomography (CT) scan or magnetic resonance\n             imaging (MRI) evaluation following biopsy or surgery to obtain tissue for PDX\n             development.\n\n          -  No plan for concurrent chemoradiation, for target lesions that will be used for drug\n             treatment correlation with PDX\n\n          -  Fresh tumor tissue available for PDX development\n\n          -  Eastern Cooperative Oncology Group performance status of 0-1\n\n          -  Life expectancy exceeds 6 months\n\n          -  Plan to receive systemic therapy\n\n          -  Informed consentXx_NEWLINE_xXAt least 5 mm of tumor on biopsy (can have multiple cores to comprise 5 mm)Xx_NEWLINE_xXPART B: Advanced solid tumor malignancy and the presence of at least one liver metastasis measuring > 1.5 cm in longest diameter in axial dimension on standard anatomic imagingXx_NEWLINE_xXERUS tumor state of T1Xx_NEWLINE_xXA biopsy-proven histological diagnosis of locally advanced, recurrent or metastatic melanoma of any stage that is surgically resectable and be scheduled for clinically indicated surgical removal of one or more melanoma tumors; additionally, patients must have a resectable tumor nodule >= 1 cm^3 (i.e., either a spherical tumor at least 1.0 cm in diameter or a tumor measuring at least 1 x 1 x 1 cm)Xx_NEWLINE_xX1. Patients with bladder cancer in follow-up for tumor recurrence (Note: Patients must be\n             included only at the first surveillance cystoscopy after a histologically confirmed\n             tumor. The histologically confirmed tumor could either be from a TURB or from a\n             surveillance cystoscopy where a biopsy was taken and a tumor was confirmed by\n             histology)\n\n          2. History of one or more of the following:\n\n               -  Multiple tumors\n\n               -  Recurrent tumors\n\n               -  High grade tumor(s)\n\n        Exclusion Criteria:\n\n          1. Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed\n             resulting in significant amounts of blood in the urine, which may visually limit\n             cystoscopy. Where the haematuria is light, the patient should not be excluded, if in\n             the investigator's opinion, rinsing and/or electro-cautery during cystoscopy will\n             alleviate the haematuria limitations to cystoscopy)\n\n          2. Patients who cannot undergo in-office or operating room cystoscopy (Note: Training\n             patients are eligible even if they cannot undergo operating room cystoscopy)\n\n          3. Patients who have received Bacillus Calmette-Guérin (BCG) immunotherapy or\n             intravesical chemotherapy within the past 6 weeks prior to the procedure\n\n          4. Porphyria\n\n          5. Known allergy to hexaminolevulinate hydrochloride or a similar compound\n\n          6. Pregnancy or breast-feeding (all women of child-bearing potential must document a\n             negative urine pregnancy test before study inclusion and use adequate contraception\n             during the study\n\n          7. Participation in other clinical studies with investigational drugs either concurrently\n             or within the last 30 days\n\n          8. Patient is the investigator or any sub investigator, research assistant, pharmacist,\n             study coordinator, other staff or relative thereof directly involved in the conduct of\n             the protocol\n\n          9. Patients that the investigator believes are unlikely to comply with the protocol, e.g.\n             mental condition rendering the patient unable to understand the nature, scope, and\n             possible consequences of participating in the clinical study, uncooperative attitude\n             or unlikelihood of completing the studyXx_NEWLINE_xXPatient with rapidly evolving brain tumor that could change in appearance between the time of the two study MRI examinations.Xx_NEWLINE_xXHave a primary tumor measuring >= 1.0 cmXx_NEWLINE_xXFresh frozen tumor, and/or paraffin block of biopsy or resected tumor is recommended, but not required to determine expression of somatostatin receptors in tumor by immunohistochemistry and/or quantitative polymerase chain reaction (qPCR)Xx_NEWLINE_xXKnown diagnosis of neuroendocrine tumor (NET) or suspected somatostatin receptor (SSTR) positive tumorsXx_NEWLINE_xXThere are any other past medical, physiological or demographic concerns; this includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this techniqueXx_NEWLINE_xXPatients must have clinically documented primary brain tumor for which resection is clinically indicated; radiographic findings should be consistent with high grade gliomaXx_NEWLINE_xXLymphnode negative and a clinical tumor classification of T2 (?3.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level.Xx_NEWLINE_xXTumor sample shipped to Agendia with ? 30% tumor cells or that fails Quality Assurance or Quality Control criteria.Xx_NEWLINE_xXPatients should have at least one tumor deposit that is > 1.0 cm in diameter, and that is amenable to imagingXx_NEWLINE_xXA tumor that is known to have a v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-ras) mutationXx_NEWLINE_xXThe primary tumor is not visualized by mammogram or breast ultrasound at the time of diagnosisXx_NEWLINE_xXPatients with a new or recurrent, presumed or documented, diagnosis of primary or secondary brain tumor in or adjacent to eloquent brain areas (motor, supplementary motor area [SMA] and language) who are scheduled to undergo tumor resectionXx_NEWLINE_xXPatients with no previous therapy other than biopsy or surgical resection of the primary tumor; patients can have received pre-operative radiation to the primary tumor site, but cannot have received radiation directly to, or in close approximation of, the lymph node basinXx_NEWLINE_xXTumor tissue or blood collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing complete disease response (CR)Xx_NEWLINE_xXInvasive malignant solid tumor of thoracic origin (e.g., lung, esophageal, thymus, mesothelioma, chest wall, mediastinum, trachea, pleura) with the intent to treat or biopsy by surgery as standard of care. Tumor must be >= 2 cmXx_NEWLINE_xXAt least one suspected soft tissue sarcoma tumor that is considered by the investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm in shortest dimension for patients undergoing an excisional biopsy/tumor resection. Tumors should not be selected if the Investigator believes them to be necrotic or exhibit signs of radiation-induced fibrosis.Xx_NEWLINE_xXTumor judged to be suitable for open cranial resection based on preoperative imaging studiesXx_NEWLINE_xXA superficial tumor easily and safely accessible for a research biopsy or are being considered for resection or biopsy of their tumor as part of standard of care and have recent pathologyXx_NEWLINE_xXTumor accessible to biopsyXx_NEWLINE_xXPatients with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at Thomas Jefferson University Hospital (TJUH) are eligible to participateXx_NEWLINE_xXBRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumorXx_NEWLINE_xXAre willing to provide available pre-existing diagnostic or resected tumor samples. Providing fresh tumor biopsies are optional for all subjects in Dose Escalation cohorts. In the Dose Expansion cohort, up to 6 subjects may be requested to provide pre- and post-treatment tumor biopsies based on eligibility for the procedure. For those subjects who do not have an MMR status, inclusion in the Dose Escalation and Dose Expansion can be achieved by providing a fresh tumor biopsy for MMR testing.Xx_NEWLINE_xXWilling to undergo 1 baseline and 1 posttreatment tumor biopsy procedure.Xx_NEWLINE_xXHave a confirmed diagnosis of advanced, refractory solid tumors and tumor progression or treatment intolerance to at least 1 prior therapy.Xx_NEWLINE_xXPatients must have a potential germline mutation, as determined by the NCI-MATCH tumor profiling assayXx_NEWLINE_xXPatients must have malignant bowel obstruction due to an intra-abdominal primary cancer (i.e. gastrointestinal [GI], pancreas, ovarian, uterine, cervical, kidney, bladder, prostate, gastrointestinal stromal tumor [GIST] [all sites], and sarcoma); patients may still have primary tumor as long as it is not a primary large bowel obstruction from colorectal cancerXx_NEWLINE_xXNewly diagnosed breast tumor, female genital system tumor, colorectal tumor, and/or lymphoma/myelomaXx_NEWLINE_xXGross tumor volume (GTV) or resection cavity must be visible on CT such that it can be delineated as a target for radiotherapyXx_NEWLINE_xXDiagnosed with primary or metastatic tumor < 5 cm located in peripheral lungXx_NEWLINE_xXPrimary or metastatic lung tumor located in central lung or near vertebral bodyXx_NEWLINE_xXTumor invades a major blood vesselXx_NEWLINE_xXTumor treated with PDT within the last 3 monthsXx_NEWLINE_xXCriteria 5, Metastatic liver lesions for injection must be without necrosis (dead tissue )and must be be located where any tumor swelling will not lead to gall bladder tract obstruction or lead to bleeding riskXx_NEWLINE_xXGastrointestinal stromal tumor (GIST).Xx_NEWLINE_xXA tumor with direct extension to the chest wall and/or to the skin.Xx_NEWLINE_xXSolid Tumor analyzed by Caris Molecular Intelligence™ Service Profile(s) and/or Caris\n             Next-Generation SequencingXx_NEWLINE_xXSubject must be candidate for intralesional therapy administration defined as one or more of the following: i. at least 1 injectable cutaneous, subcutaneous, or nodal SCCHN tumor ? 10 mm in longest diameter ii. multiple injectable cutaneous, subcutaneous, or nodal SCCHN tumors that in aggregate have a longest diameter of ? 10 mm Note: Mucosal surfaces of tumor lesions and visceral metastases should not be injected.Xx_NEWLINE_xXSubject at risk of airway compromise in the event of postinjection tumor swelling/inflammation based on investigator judgment.Xx_NEWLINE_xXSubjects with tumor that directly contacts or encases a major blood vessel AND there is ulceration and/or fungation onto the skin surfaceXx_NEWLINE_xXFor TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab only: Had disease accessible for repeat nonsignificant risk biopsy (those occurring outside the brain, lung/mediastinum, and pancreas, or obtained with endoscopic procedures extending beyond the esophagus, stomach, or bowel) and willingness to undergo serial tumor biopsies.Xx_NEWLINE_xXScheduled for a lumpectomy of a breast tumor.Xx_NEWLINE_xXDiagnosed solid tumor scheduled for surgical excision. Subjects with recurrent disease will be eligible only if the duration between last tumor surgery and scheduled new surgery is ?3 months.Xx_NEWLINE_xXThe test to confirm ALK-positivity may be performed in archival tumor (obtained at or since the time of diagnosis), or in a newly obtained tumor sample taken prior to the first day of study drug. Results confirming ALK-positive status must be available before initiating treatment with ceritinib.Xx_NEWLINE_xXanti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative andXx_NEWLINE_xXSubject must consent to pretreatment and on treatment tumor biopsiesXx_NEWLINE_xXOther chemotherapy or anti-tumor treatment for brain tumor (other than therapies required by the inclusion criteria of this protocol)Xx_NEWLINE_xXSubjects must have a tumor lesion that is amenable to an image-guided core biopsy and willingness to undergo two biopsies (baseline and 6 weeks after first dose of study treatment).Xx_NEWLINE_xXTotal serum bilirubin ? 1.5 x ULN regardless of liver involvement secondary to tumor. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.Xx_NEWLINE_xXDLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment. Positive is defined as staining in ?75% of tumor cells.Xx_NEWLINE_xXPrior treatment with a tumor vaccine.Xx_NEWLINE_xXTumor must harbor an IDH1-R132X mutationXx_NEWLINE_xXTumor amenable to biopsy and willingness to undergo tumor biopsies before and after M6620 (VX-970) treatment during the expansion phase of the trial (biopsies optional during the escalation phase)Xx_NEWLINE_xXPatients in the expansion cohort undergoing tumor biopsies may not be on anticoagulantsXx_NEWLINE_xXDiagnosis of BRAF V600 mutant Low Grade glioma whose tumor is unresectable and who require treatmentXx_NEWLINE_xXConfirmed HER2 overexpression or gene-amplified tumorXx_NEWLINE_xXHistological or cytological documentation of an advanced solid tumorXx_NEWLINE_xXThe patient's tumor has been evaluated and prospectively identified as having FGFR 1, 2, 3, or 4 genetic alterations.Xx_NEWLINE_xX